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Streptococcus pneumoniae causes significant global morbidity and mortality 
and is responsible for many cases of septicaemia, meningitis and 
pneumonia. Protective antibodies against capsular polysaccharides (> 90 
serotypes) can be acquired naturally or induced by vaccination.  
In April 2010, a 7-valent conjugate vaccine (PCV7; serotypes 4, 6B, 9V, 14, 
18C, 19F and 23F) was replaced by a 13-valent conjugate vaccine (PCV13; 
PCV7 serotypes plus 1, 3, 5, 6A, 7F and 19A) in the United Kingdom 
immunisation schedule. Response to vaccine can be evaluated by 
determining serotype-specific immunoglobulin G (IgG) antibody 
concentrations.  The Vaccine Evaluation Unit of Public Health England 
currently use a multiplex fluorescent bead based assay to determine IgG 
concentrations for serotypes in PCV13 (excluding serotype 6A).  
In this thesis, this assay has been developed to include serotype 6A and 
successfully validated in terms of specificity, accuracy, reproducibility, 
linearity and stability. A seroprevalence study was conducted to test the 
assay, using sera from children aged < 4 years old in 2009 and 2012 (pre 
and post PCV13 introduction, respectively). Results showed no differences 
in antibody concentrations against serotypes present in both vaccines 
between 2009 and 2012.  Additional serotypes in PCV13 had significantly 
higher geometric mean concentrations of IgG in 2012 compared to 2009, 
except for serotype 3, and an increase in the proportion of individuals with a 
protective antibody concentration ≥ 0.35 µg/mL.  






The World Health Organization (WHO) describes Streptococcus 
pneumoniae (S. pneumoniae; pneumococcus) as a significant cause of 
morbidity and mortality worldwide, accounting for many cases of bacterial 
meningitis, especially in young children and infants (WHO, 2011). Vaccines 
against a limited number of serotypes of S. pneumoniae have reduced the 
threat caused by this bacterium, but not eliminated it (Musher, 2013). 
Higher valency conjugate vaccines are therefore required to further protect 
against disease caused by S. pneumoniae. Laboratory methods for the 
evaluation of vaccines against S. pneumoniae include enzyme linked 
immunosorbent assays (ELISA), opsonophagocytic killing assays (OPA), 
fluorescent polystyrene microsphere (bead) based immunoassays and 
electrochemiluminescent (ECL) immunoassays (Romero-Steiner et al., 
1997; Pickering et al., 2002; Wernette et al., 2003; Lal et al., 2005; 
Marchese et al., 2009). The aim of this project was to adapt the multiplexed 
microsphere assay used in the Vaccine Evaluation Unit (VEU) of Public 
Health England (PHE) by optimising and adding a 13th antigen, to validate 
the assay and to undertake a seroprevalence study for all 13 antigens in 
children from the United Kingdom (UK). 
1.1. Streptococcus pneumoniae 
1.1.1. Disease 
S. pneumoniae is implicated in a range of diseases from relatively 
innocuous conditions such as conjunctivitis, through more painful illnesses 
such as otitis media and sinusitis to serious diseases such septicaemia, 




S. pneumoniae is the most common cause of bacterial pneumonia and it is 
estimated that pneumonia accounts for 18% of all deaths worldwide in 
those under 5 years old (Andrews et al., 2003; WHO, 2010).  
S. pneumoniae are also implicated in a number of diseases that are 
grouped under the heading ‘invasive pneumococcal disease’ (IPD) which is 
defined by the WHO as “any condition in which Streptococcus pneumoniae 
is present in blood, cerebrospinal fluid or another normally sterile body site,” 
(WHO, 2008). Examples of IPD thus include meningitis and septicaemia.  
The early symptoms of meningitis include stiff neck, fever, disorientation, 
and sensitivity to light and patients may go on to suffer shock, seizures and 
coma (Rehm et al., 2009; de Jonge et al., 2010). It has been estimated that 
case fatality rates for pneumococcal meningitis in the United States of 
America (USA) are around 12.5 % (Tsai et al., 2008). 
In addition to the symptoms of meningitis, patients with septicaemia may 
also have joint pain and case fatality rates for septicaemia are estimated at 
15%-20% in adults, or higher in the elderly, despite appropriate treatment 
(WHO, 2008). 
The most common method for diagnosis of S. pneumoniae is by growth in 
culture media, although this is easiest in cases of IPD where bacteria can 
be isolated from normally sterile sites (WHO, 2008). It has also been 
suggested that agglutination, antigen detection and PCR methods are 
useful tools for case confirmation where culture methods have not been 
effective (Smith et al., 2009).  
Treatment for pneumococcal disease is normally in the form of a broad 
spectrum antibiotic, followed by more targeted antibiotic(s) once any 
susceptibility has been determined during typing. S. pneumoniae is, 
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however, known to be increasingly resistant to a number of antibiotics, 
including β-lactams (such as penicillin and cephalosporins) and macrolides 
(such as erythromycin and clarithromycin). 
Whilst most patients suffering from community acquired pneumonia can 
expect to make a full recovery after 6 months many patients with IPD have 
long term sequelae as a result of invasive infection by pneumococcus (El 
Moussaoui et al., 2006; de Jonge et al., 2010).  
1.1.2. The Organism 
S. pneumoniae is an encapsulated Gram-positive diplococcus and common 
commensal of the human upper respiratory tract (Obaro & Adegbola, 2002; 
WHO, 2008). Its surface structure briefly consists of a plasma membrane, 
cell wall and capsule; some, but not all, pneumococci also express a pilus. 
A schematic representation of the structure of pneumococci is shown in 
Figure 1.1. The cell wall is highly conserved amongst all pneumococci, 
predominantly composed of teichoic acid and lipoteichoic acid; these are 
also known as cell wall polysaccharide, C-polysaccharide or C-Ps (Fischer, 
2000).  
In contrast, the pneumococcal capsule is highly variable, consisting of 
repeating units of a variety of sugars, which allows for serotyping of 
pneumococci according to which capsular polysaccharide is expressed. 
With the recent discoveries of serotypes 9D and 11E there are currently 94 
serotypes of pneumococci described (Yother, 2004; Bratcher et al., 2010; 
Calix & Nahm, 2010). 
1.1.3. Carriage, Virulence Factors and Pathogenesis 
S. pneumoniae is usually found within the nasopharynx of the human host, 
with colonisation occurring after host contact with droplet secretions 
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expelled during breathing, coughing or sneezing; pneumococci in the 
nasopharynx elicit no inflammatory immune response in the host  and may 
persist for a number of weeks (asymptomatic carriage) before being cleared 
by the host’s immune response (Tuomanen, 2000; O'Brien & Nohynek, 
2003). Carriage rates among children are high, with one in three children 
carrying at least one serotype of pneumococcus (Tuomanen, 2000).  
Acquisition of a new serotype, rather than persistence of carriage of a 
serotype, is associated with onset of pneumococcal disease, both in 
children and adults (Gray et al., 1980; Musher, 1992). 
 
 
Figure 1.1: S. pneumonia surface components 
 
This figure illustrates the pneumococcal cell membrane, wall and capsule and 
includes various virulence factors; image reproduced from Longo et al. (2011). 
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The capsule is essential to the organism’s ability to colonise the host, 
probably by protecting the pneumococcus on entry to the nasopharynx by 
reducing agglutination of the bacteria and clearance by mucus, allowing the 
organism to survive long enough to adhere (Magee & Yother, 2001; Nelson 
et al., 2007). Pneumococci can regulate the amount of capsule produced to 
adapt to different conditions, reducing the capsule in order to facilitate 
adherence to epithelial cells (Weiser et al., 1994; Cundell, Weiser, et al., 
1995; Kim & Weiser, 1998; Fischer, 2000; Hammerschmidt et al., 2005). 
Once colonisation has occured a number of attributes contribute to the 
ability of the pneumococcus to convert from a commensal to a pathogen, 
many of these virulence factors are shown in Figure 1.1. Absence of 
virulence factors may prevent the organism from becoming pathogenic, as 
in the case of the capsule, or reduce the pathogenicity of the organism, as 
in the case of the pilus (Magee & Yother, 2001; Aguiar et al., 2008). The 
virulence factors of pneumococci have a number of roles, from facilitating 
adherence and internalisation to protecting the bacterium from the host 
defences (Cundell, Gerard, et al., 1995; Schneider et al., 1999; Yoshimura 
et al., 1999; Braun et al., 2002; Hoffmann et al., 2007; McCullers et al., 
2008; Orihuela et al., 2009; Thornton et al., 2010). 
1.1.4. Immunology  
Upon invasion of the host by S. pneumoniae the primary immune response 
is mediated by the complement cascade (Winkelstein, 1981). Both the 
classical and alternative complement pathways, but not the mannose-
binding lectin (MBL) pathway, are involved in this response although it may 
be that the alternative pathway is more important (Winkelstein, 1981; Brown 
et al., 2002; Jarva et al., 2003).  
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Evidence showing that pneumococcal serotypes differ in their ability to 
protect against complement mediated phagocytosis suggests that an 
important role of the capsule may be in masking, reducing or inhibiting the 
deposition of complement on the bacterial surface (Winkelstein, 1981; Melin 
et al., 2010; Hyams et al., 2010). It has been demonstrated that the capsule 
of S. pneumoniae inhibits the deposition of C3b/iC3b from both the classical 
and alternative pathways through a number of mechanisms and that other 
pneumococcal structures, including pneumococcal surface protein (Psp) A, 
Psp C binding of Factor H and C-Ps recruitment of C-reactive protein, are 
also involved in defence against complement opsonisation (Jarva et al., 
2003; Hyams et al., 2010).  
It is known that antibodies produced against pneumococcal capsular 
polysaccharides during infection or after vaccination are able to protect 
against reoccurrence of diseases caused by the bacterium (Austrian, 1977; 
Black et al., 2000; Siber et al., 2007). Similarly, it has been shown that 
antibodies against capsular polysaccharides, and other pneumococcal 
virulence factors, are induced as a result of carriage of the organism in the 
nasopharynx (Goldblatt et al., 2005; Weinberger et al., 2008). This has led 
to the assumption that the primary mechanism of acquired immunity against 
pneumococci is the generation of anti-capsular antibodies (Malley, 2010). 
However, there is some evidence that an acquired immunity begins to 
cause a decrease in the incidence of carriage and diseases caused by 
pneumococci prior to there being a detectable anti-capsular antibody 
presence in vaccine naive children  and so there remain some questions as 
to the mechanisms of immunological protection (Lipsitch et al., 2005). Work 
to determine the mechanism of this acquired immunity has led to the 
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hypothesis that CD4+ Interleukin 17A producing T (CD4+ TH17) cells that 
recognise pneumococcal antigens and recruit phagocytes are implicated in 
the reduction of acquisition of carriage and therefore disease. As a result it 
has been proposed that acquired immunity to the pneumococcus has two 
components, the earlier CD4+ TH17 cell component followed by the anti-
capsular antibody component (Malley, 2010). 
All currently licensed vaccines against pneumococci aim to elicit an immune 
response against capsular polysaccharides. Polysaccharides are T-cell 
independent antigens, and the immune response to them is both 
complement and B-cell dependent (Breukels et al., 2005). The CD21 
receptor on B cells appears to be key in this immune response and the 
CD21 receptor is found in greater quantity on B cells in the splenic marginal 
zone but is not expressed as highly in neonates and infants which may 
explain the observation that these patients do not respond well to plain 
polysaccharide vaccines (Breukels et al., 2005; Timens et al., 1989). 
Polysaccharide vaccines have also been associated with hypo-
responsiveness, an attenuated response by the patient to repeated doses 
of vaccine especially when the doses are given within a short space of time, 
in older age groups (Jackson & Janoff, 2008; Poolman & Borrow, 2011).  
While both young children and the elderly are at increased risk of 
pneumococcal disease, no vaccine was available prior to 2000 that was 
effective in the younger age group (especially those under 2 years of age) 
(WHO, 2011). After the success in infants of other conjugate vaccines, such 
as the Haemophilus influenzae (Hi) type B and meningococcal serogroup C 
conjugate vaccines, efforts were made to formulate a pneumococcal 
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conjugate vaccine (Peeters et al., 1991; Vella et al., 1992; Kelly et al., 2004; 
Campbell et al., 2009). 
In contrast to plain polysaccharide vaccines, conjugate vaccines induce an 
immune response in infants as they elicit both a B and T cell response. The 
conjugation of the polysaccharide to the protein carrier allows antigen 
presenting B cells to recruit CD4+ T helper cells, inducing both 
immunogenicity in infants and immunological memory (Poolman & Borrow, 
2011). 
Interestingly, the issue of hypo-responsiveness has not been completely 
resolved by the use of conjugate pneumococcal vaccines. There is 
increasing evidence that the administration of vaccine while the recipient is 
carrying a vaccine serotype leads to a blunted immune response to the 
carried serotype, although not to the non-carried types (Dagan et al., 2010; 
Vakevainen et al., 2010). This phenomenon puts patients at risk of 
contracting IPD despite receiving a full course, or even additional doses, of 
vaccine (Borrow et al., 2008; Stanford et al., 2012).  
The mechanism for this blunted response is hypothesised to be most likely 
associated with B-cell fatigue, where the circulating capsular polysaccharide 
from the carried serotype causes a reduction in responsiveness by the B-
cell pool to the normally immunogenic conjugate vaccine (Dagan et al., 
2010). 
1.1.5. Pneumococcal Vaccines 
A 14-valent polysaccharide vaccine was licensed in the 1970s after 
effectiveness data showed that polysaccharide vaccines protected South 
African miners from pneumococcal diseases (Smit et al., 1977; Hilleman et 
al., 1978). This vaccine was replaced by a 23-valent polysaccharide vaccine 
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(PPV23) which has been available for use since 1983 (Robbins et al., 
1983). The formulation of PPV23 contains pneumococcal capsular 
serotypes (Pn) 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 
18C, 19F, 19A, 20, 22F, 23F and 33F (Merck and Co., 2011).  
As PPV23 is ineffective in infants under 2 years a 7-valent conjugate 
vaccine (PCV7) containing Pn 4, 6B, 9V, 14, 18C, 19F and 23F conjugated 
to CRM197, a non-toxic variant of the diphtheria toxin, was developed and 
licensed in 2000 in the United States of America  and subsequently in many 
other countries worldwide (ACIP, 2000; Pfizer, 2009). 
Licensure of PCV7 was based on efficacy data generated in vaccine naive 
populations (Black et al., 2000; ACIP, 2000). As it would not be ethical, or 
even possible, to perform similar studies with newer formulations of vaccine 
recommendations were made to facilitate licensure of new vaccines based 
on non-inferiority to the current vaccines as demonstrated by IgG 
concentration measured by ELISA, with a correlate of protection suggested 
of ≥ 0.35 µg/mL; as a secondary, supporting, end-point the 
recommendations were that functional antibody should be determined by 
OPA and that immunological memory should be demonstrated (WHO, 
2005).  
These recommendations were used to inform the licensure of conjugate 
vaccines which protect against increased numbers of serotypes. A 10-
valent (PCV10) and 13-valent (PCV13) conjugate vaccine have both been 
licensed (Hausdorff et al., 2009; ACIP, 2010). 
The formulation of PCV10 contains Pn 1, 4, 5, 6B, 7F, 9V, 14, 19F and 23F 
conjugated to Protein D, a protein derived from non-typeable Hi, Pn 18C 
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conjugated to Tetanus Toxoid and Pn 19F conjugated to Diphtheria Toxoid 
(GlaxoSmithKline, 2011). 
PCV13 contains Pn 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F 
conjugated to CRM197 (Pfizer, 2011). 
Following licensure of these vaccines the UK childhood vaccine schedule 
was amended in April 2010 so that PCV13 was used instead of PCV7 
(PHE, 2013c) 
1.1.6. Incidence and Epidemiology 
Whilst the epidemiology of IPD varies according to geography, age and by 
disease manifestation, it is well known that the very young (less than 5 
years and especially less than 2 years of age) and the elderly (over 65 
years of age) are most at risk of serious IPD, and this was certainly the 
case prior to the introduction of PCV7 in England and Wales (Kaye et al., 
2009). It has been estimated that serious pneumococcal disease accounts 
for 11% of all deaths globally in children less than 5 years old (O'Brien et 
al., 2009).  
A review reported that PCV7 has had a significant impact on the recent 
epidemiology of pneumococcal serotypes and disease; this effect has been 
twofold, firstly in the target patient group (those less than two years old) 
where there has been a highly significant reduction in disease caused by 
vaccine serotypes, and secondly with an originally unanticipated reduction 
in disease caused by vaccine serotypes across all age groups. The data 
demonstrating this in the studies cited in the review disagree on the effects 
of PCV7 on the older age groups (Weinberger et al., 2011). Data from 
England and Wales, and the USA have shown evidence of this effect 
(ACIP, 2005; Kaye et al., 2009; Miller et al., 2011a).  
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This reduction in disease caused by vaccine serotypes outside the 
vaccinated population is due to ‘herd protection’; a phenomenon whereby 
vaccination of the target group prevents carriage of the vaccine serotypes 
and so the serotypes are prevented from spreading from the target group to 
other age groups, providing an indirect protection. While this herd protection 
is mostly a positive benefit of vaccination there are concerns about serotype 
replacement, where serotypes that previously caused little disease replace 
the eliminated serotypes, causing disease which cannot be prevented by 
the vaccine in use. There is evidence to show that this phenomenon has 
occurred in the UK, Europe and the USA with Pn 7F, 19A and 22F all 
observed as potential replacement serotypes (Kaye et al., 2009; Hanage et 
al., 2010; Miller et al., 2011a; Weinberger et al., 2011). 
The licensure of PCV10 and PCV13 is expected to further reduce the 
incidence of IPD and will reduce the concerns raised by serotype 
replacement as some replacement serotypes are contained within these 
new formulations (GlaxoSmithKline, 2011; ACIP, 2010). 
Data available from the UK shows that introduction of PCV13 has reduced 
the incidence of disease from the additional 6 serotypes significantly in both 
vaccinees and in older children and adults (PHE, 2013b). 
Changes to the intranasal flora of children affected by otitis media have 
been attributed the introduction of PCV7 and it has been shown that the 
main cause of otitis media has shifted from pneumococci to Hi since the 
introduction of the vaccine (Brunton, 2006). The inclusion of a component to 
induce immunity to non-typeable Hi in a 10-valent pneumococcal conjugate 
vaccine is anticipated to further reduce the incidence of otitis media 
(Schuerman et al., 2009). 
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1.2. Pneumococcal Assays 
A number of assays have been developed to assist in the evaluation of 
vaccines against pneumococci. These can assay for functional antibody 
(OPA) or for concentration of an immunoglobulin class (ELISA, bead based 
and electrochemiluminescence assays) 
1.2.1. Detection of functional antibodies 
Different forms of opsonophagocytic assays (OPA), including viability/killing, 
up-take and multiplexed assays, have been described (Romero-Steiner et 
al., 1997; Martinez et al., 1999; Nahm et al., 2000; Martinez et al., 2006). 
A workshop on OPA standardisation in 2007 came to the consensus that 
the preferred ‘gold standard’ OPA should be a viability assay and the 
importance of OPA as a correlate of protection in vaccine evaluation was 
later highlighted, although a protective threshold is not yet identified due to 
standardisation issues (WHO, 2007; WHO, 2009).  
1.2.2. Determination of immunoglobulin concentration 
1.2.2.1. ELISA 
As early as 1978 an ELISA for detection of anti-capsular antibodies was 
described, although it was later observed that antigen preparations used for 
serotype-specific ELISA were contaminated with C-Ps leading to false 
positives (Berntsson et al., 1978; Koskela, 1987).  
A method was later described which incorporated a C-Ps adsorption step to 
remove this nonspecific binding (Quataert et al., 1995). Efforts were made 
to standardise this methodology to allow data generated from multiple sites 
to be used in the licensure of vaccines. To facilitate this, a standard 
reference serum was produced, 89-SF, and weight based antibody 
concentrations determined, a panel of 12 sera identified to be used to 
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calibrate the assay between laboratories and 2 reference laboratories set 
up (Quataert et al., 1995; Wernette et al., 2003; Quataert et al., 2004). A set 
of guidelines and recommendations has been suggested so that 
laboratories can demonstrate that their ELISA matches the operating 
characteristics of the laboratories used in a multicentre study (Plikaytis et 
al., 2000). 
Another modification of the method was subsequently made to further 
enhance the specificity of the ELISA by adding a different pneumococcal 
capsular polysaccharide, different methods for providing this extra 
adsorption have been developed using either serotype 22F polysaccharide, 
serotypes 25 and 72 polysaccharides or an extra C-Ps purified from 22F 
(Concepcion & Frasch, 2001; Marchese et al., 2006; Skovsted et al., 2007). 
The current WHO accepted protocol uses 22F as the extra adsorption 
component (WHO, 2000). 
In brief the WHO ELISA is performed using pneumococcal capsular 
polysaccharide bound to the wells, serially diluted 89-SF as the standard 
curve (pre-adsorbed with C-Ps alone), QC and test sera (pre-adsorbed with 
C-Ps and Pn22F Ps) are added to the wells, followed by an enzyme linked 
anti-human antibody, and finally a substrate. Colour development is 
measured in a spectrophotometer with an increased colour corresponding 
to a greater anti-capsular antibody present in the sample (WHO, 2000). 
Currently, the ELISA is the primary correlate of protection used in vaccine 
evaluation (WHO, 2009), with a threshold of ≥ 0.20 to ≥ 0.35 µg/mL used as 
the threshold concentration demonstrating protection. 
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Concerns that have been raised about the ELISA are that it is time 
consuming, laborious and utilises a large serum volume (Pickering et al., 
2002; Lal et al., 2005). 
Due to depletion of stocks of the 89-SF reference standard efforts were 
made to develop and characterise an alternative, resulting in the publication 
of data validating a new reference serum, 007sp, for use in the 
pneumococcal ELISA with adsorption using both C-Ps and 22F 
polysaccharide (Goldblatt, Plikaytis, et al., 2011). 
1.2.2.2. Bead based assays 
As an alternative to the ELISA a multiplexed bead based assay was 
described allowing multiple (14) serotypes to be assayed in the same well 
simultaneously by utilising beads, instead of the plastic plate surface, as the 
base on which to conjugate antigen (Pickering et al., 2002).. 
A fluorescent dye is used as the reporter which allows an adapted flow 
cytometer (Luminex or Bio-Plex) to quantify the amount of antibody bound 
to the beads by comparing to a reference standard (Pickering et al., 2002). 
A similar 9-plex bead assay used in the Vaccine Evaluation Unit (VEU) of 
Public Health England (PHE) has previously been published (Lal et al., 
2005) and comprises capsular polysaccharides from Pn 1, 4, 5, 6B, 9V, 14, 
18C, 19F and 23F coupled to fluorescent microspheres. Since publication 
the assay has been expanded to include capsular polysaccharides from 
serotypes 3, 7F and 19A to make a total of 12 serotypes (Yaro et al., 2013). 
1.2.2.3. ECL assay 
In 2009 a new mulitiplex method for detecting antibodies against 
pneumococcal serotypes was described which uses ECL as the detection 
method (Marchese et al., 2009). ECL uses a chemical reaction that is 
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initiated by an electrical current to generate light (Meso Scale Discovery, 
2012). Antigen is attached to specific spots within a well of a plate, with up 
to 10 spots per well. When reporter is added and electrical current passed 
through the plate the magnitude of light generated, relative to the reference 
standard, is used to quantify the antibody concentration in the sample 
(Marchese et al., 2009). 
This methodology has been compared to the WHO ELISA with the 
conclusion that although the new methodology produced higher results in 
some cases it was generally in agreement with the WHO ELISA (Goldblatt, 
Ashton, et al., 2011). 
1.3. Aims 
This thesis aims to demonstrate the adaptation of the PHE multiplex bead 
assay by optimising Pn6A PS for inclusion in the assay as the 13th serotype 
included in PCV13. Validation parameters including specificity, accuracy, 
reproducibility, linearity and stability will be tested to show the assay is fit for 
use. Finally, a seroprevalence study on 1.00 to 3.99 year old infants from 
the UK in 2009 and 2012 will be performed for al 13 serotypes in to 
determine the effect of introduction of PCV13 in 2010 on antibody levels in 





2.1. Conjugation of pneumococcal polysaccharides to 
poly-l-lysine 
Pn 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F polysaccharides (PS) 
(LGC Standards, Middlesex, UK) were covalently linked to poly-l-lysine 
(PLL) as described by Lal et al., with minor modifications (Lal et al., 2005). 
Reconstituted PS was added to alkalising buffer (0.01 % weight/volume 
[w/v] sodium hydroxide [Sigma-Aldrich Co. LLC, Gillingham, UK] containing 
0.001 % w/v phenolphthalein [Sigma]) as summarised in Table 2.1. This 
was added to 12.5 milligrams (mg) cyanuric chloride (Sigma) and vortex 
mixed until transparent, followed by the addition of 50 microlitres (µL) of 250 
µg/mL PLL (Sigma), vortex mixing and incubation at 2 to 8 ⁰C for 16 to 20 
hours (hrs). 
A PD-10 Sephadex column (GE Healthcare, Buckinghamshire, UK) was 
primed with 25 millilitres (mL) of filter sterilised, using a 0.2 micrometre (µm) 
filter (Nalgene, Rochester, USA), phosphate buffered saline (PBS; 0.14 
Molar [M] sodium chloride, 0.021 M monobasic potassium phosphate, 0.013 
M dibasic sodium phosphate, 0.0021 M potassium chloride pH 7.3 [all 
Sigma]). 
Following this, PS/PLL was passed through the column and eluted using 
3.5 mL of PBS. The eluent was collected and aliquots prepared which were 
stored at -20 ⁰C (-15 to -30 ⁰C) until needed. 
2.2. Conjugation of PS/PLL to beads 
Unconjugated carboxylated beads (500 µL) 1.25x107 beads/mL (Luminex 
Corporation, Austin, Texas, USA) were washed by centrifugation at 16,060 
gravitational force (xg) for 2 minutes (mins), supernatant removed and 
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beads re-suspended by vortex mixing in 200 µL PBS. This procedure was 
repeated. Beads were then centrifuged as above,  supernatant removed 
and beads re-suspended by vortex mixing in a final volume of 500 µL of 
bead activation buffer containing 5 µg/mL 1-ethyl-3-(-3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC; Pierce Protein 
Research Products, Perbio Science UK Ltd., Northumberland, UK) and 5 
µg/mL N-hydroxysulphosuccinimide (NHS; Perbio Science UK Ltd.) and 
incubated on an orbital shaker (Polymax 1040; Heidolph UK, Essex, UK) at 
50 revolutions per minute (rpm) for 20 mins in the dark. 
Beads were then washed by centrifugation as previously, but re-suspended 
in a final volume of 100 µL of PS/PLL  and incubated in the dark for 1.25 to 
3 hrs depending on the pneumococcal serotype being conjugated (Table 
2.1) at room temperature (RT). A different ‘region’ of beads was used for 
each different serotype. 
Following this incubation beads were washed by centrifugation as 
previously, but after the final supernatant was removed the beads were re-
suspended in 200 µL PBS and centrifuged at 16060 xg for 30 seconds (s) 
counted from the point the centrifuge reached the required xg), the 
supernatant was removed and the beads re-suspended in 1 mL of bead 
storage buffer (PBS containing 0.1% w/v bovine serum albumin and 0.05% 
w/v sodium azide [both Sigma], filter sterilised [0.22 µm filter; milipore]), 
vortex mixed and enumerated using a FastRead counting chamber 
(Immune Systems Ltd., Devon, UK) under a Labophot 2 upright microscope 




2.3. A multiplexed bead based assay for the detection of 
IgG to pneumococcal serotypes. 
2.3.1. Preparation of the standard reference serum, lot 89-SF, quality 
control (QC) and sample sera for use in the multiplex assay 
The standard serum used in the assay was the pneumococcal reference 
serum, lot 89-SF (89-SF; Food and Drug Administration, Maryland, USA). A 
7 point serially diluted standard curve was prepared (starting dilution 1/20, 
dilution factor 1/4). Serum was diluted in adsorbent buffer (PBS containing 
0.05 % volume/volume [v/v] Tween-20 [Sigma], 1 % v/v newborn bovine 
serum [NBBS; Labtech International Ltd, East Sussex, UK] and 4 µg/mL C-
Ps [Statens Serum Institut, Copenhagen, Denmark]) to give final dilutions at 




Table 2.1: Conditions for bead preparation 
This table shows the concentration and volume of reconstituted Pn PS used in PS/PLL 
















time of beads 
with  PS/PLL 
(mins) 
1 2 1.75 1.25 90 
3 3 1.25 1.25 90 
4 2 1.25 1.25 90 
5 2 1.25 1.25 90 
6B 2 1.5 1.25 180 
7F 2 1.25 1.25 90 
9V 2 1.25 1.25 90 
14 2 1.25 1.25 75 
18C 2 1.5 1.25 120 
19A 2 1.25 1.25 90 
19F 2 1.75 1.25 180 
23F 2 1.25 1.25 180 
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Three QC sera were used QCHigh, at a final dilution of 1/1000, and 
 QCMed (both Pfizer Ltd., Kent, UK) and IgG deficient serum (IgG-; Sigma), 
at a final dilution 1/100. QC sera were diluted in adsorbent buffer containing 
5 µg/mL Pn 22F PS (ads+22F).  
Test serum samples were also diluted in ads+22F, at 1/100; if necessary 
higher dilutions were prepared at 1/500, 1/1000, 1/5000 or 1/10000. 
2.3.2. Assay procedure 
2.3.2.1. Dilution of beads prior to use in the assay. 
Stock beads for each serotype required were sonicated for 30 s, vortex 
mixed for 30 s and then the volume containing 5000 beads per well for each 
serotype was pooled together to create a ‘bead cocktail’ of all the required 
serotypes. The bead cocktail was centrifuged at 16060 xg for 2 mins, 
supernatant removed and beads re-suspended in 200 µL PBS, followed by 
brief vortex mixing to re-suspend the beads. Centrifugation was repeated as 
above and supernatant removed after which the beads were re-suspended 
in the total volume of PBS required. 
2.3.2.2. Addition of sample to filter plates and addition of beads to 
the sample 
A 96 well MultiScreen HTS filter plate (Millipore UK Ltd., Watford, UK) was 
prepared by adding 50 µL per well of PBS containing 0.05% v/v Tween-20 
(PBS-T) followed by gentle vacuum filtration (pressure  ≤ 5 mm/Hg) using a 
MultiScreen HTS Vacuum Manifold (Millipore). 
Adsorbent buffer (used as a blank), 89-SF dilutions, QC sera and test 
samples were prepared as previously described (section 2.3.1) and 
assayed in duplicate by adding 25 µL per well. An example plate layout is 






. Following this, 25 µL of bead cocktail was added to each well. The plate 
was then incubated on a plate shaker at 500 rpm in the dark for 20 mins. 
2.3.2.3. Filter Plate Wash 
Plate washing was as follows: Liquid was removed from wells by vacuum 
filtration as described previously. Well contents were re-suspended in 100 
µL PBS-T. Vacuum filtration and re-suspension were repeated followed by a 
final vacuum filtration. 
2.3.2.4. Addition of R-Phycoerythrin conjugated anti-human goat 
Immunoglobulin G (conjugate) 
Conjugate (Stratech Scientific Ltd., Suffolk, UK) was diluted 1/200 with PBS 
and 100 µL added to each well. The plate was incubated on a plate shaker 




Figure 2.1: Example plate layout. 
 













































































































































































This figure shows an example of the layout of and plate for an assay run with the 
position of duplicate wells for the blank, 89-S, QC and teast sample dilutions. 
 
2.3.2.5. Re-suspension of beads for acquisition 
Following this the plate was washed as previously described (section 
2.3.2.3). The contents of the wells were re-suspended in 125 µL PBS-T and 
incubated in the dark as above for a minimum of 5 mins. 
2.3.2.6. Data Acquisition 
The plate was read using a Bio-Plex 100 or 200 plate reader (Bio-Plex; Bio-
Rad Laboratories, Inc, Hertfordshire, UK) using Bio-Plex Manager version 
4.1.1 software (Bio-Rad).  
2.3.2.7. Data Analysis 
The standard curve was generated using a four parameter logistic (4PL) by 
Bio-Plex Manager on the median FI (MFI) data for the duplicate standard 
points minus the MFI of the blank. Alternative data analysis  
software were assessed, but none were found to be superior to Bio-Plex 
Manager 4.1.1, the currently used software. 
For all serotypes except Pn14 the most dilute standard curve dilution 
(1/81920) were masked as standard. The limit of detection, based on the 
lowest available curve point, varied by serotype from 0.01 µg/mL for Pn3 to 
0.09 µg/mL for Pn19A. The lower limit of quantitation (LLQ) was set at 0.1 
µg/mL for all serotypes. The ½ LLQ for all serotypes, assigned to any result 
below the LLQ, was 0.05 µg/mL. Further blank, standard curve and QC 
result rejection criteria were applied as applicable (Table 2.2). 
The sample results were accepted provided the %CV between duplicates 



























fell outside the linear phase of the curve were repeated at dilution factors 
more dilute or more concentrated as applicable (section 2.3.1). Samples at 
a 1/100 dilution which were below the lower limit of the curve or samples 
which produced a result below the LLQ were assigned the ½ LLQ value 
(0.05 µg/mL).  
2.4. Optimisation of conditions for inclusion of Pn6A 
capsular polysaccharide conjugated beads in the 
multiplex assay 
2.4.1. Optimisation of Pn6A PS used in bead preparation. 
Pneumococcal serotype 6A polysaccharide lots CPS6A-2, CPS6A-5 (both 
SSI) and 59508355 (LGC) were reconstituted and diluted to 0.01, 0.1, 0.25, 
0.5, 1, 2, 3 or 6 mg/mL and used to prepare beads as described previously 
(sections 2 and 2.2) with a 1.5 hr incubation of beads with PS/PLL. 
Beads were run in monoplex with 89-SF and QC serum only as previously 
described (section 2.3). 
 
Table 2.2: Assay rejection criteria.  
Rejection criteria for standard curve points and QC 
results 
Action taken on rejection 
Blank value > 200 MFI Serotype failed 
Standard Curve Point %CV ≥ 30 % Curve point masked 
Standard Curve Point Obs/Exp < 80 % Curve point masked 
Standard Curve Point Obs/Exp > 120 % Curve point masked 
< 5 Standard Curve Points Serotype failed 
Either QCHigh or QCMed %CV ≤ 25 % Serotype failed 





This table shows the rejection criteria applied to assays during data analysis 
and the action taken on rejection.  
 
For CPS6AM-1 bead preparations (2 to 5 per concentration) were produced 
at 0.25, 0.5, 1, 2, 3 and 6 µg/mL PS with up to 3 replicates (Day 1, 20 to 23 
or 43 post conjugation) generated per bead preparation. 
For CPS6AM-5 bead preparations (1 to 3 per concentration) were produced 
at 0.01, 0.1, 1, 2 and 3 µg/mL PS with up to 2 replicates (Day 1, 23 or 77 
post conjugation) generated per bead preparation. 
For 59508355 bead preparations (1 to 3 per concentration) were produced 
at 0.01, 0.1, 1, 2 and 3 µg/mL PS with up to 3 replicates (Day 1, 23 or 77 
post conjugation) generated per bead preparation. 
2.4.1.1. Final preparation method for beads prepared using Pn6A PS 
The method for producing Pn6A beads was as described previously 
(sections 2 and 2.2) using a 1 mg/mL concentration of Pn6A PS to prepare 
PS/PLL and a 1.5 hr incubation of beads with PS/PLL. 
2.4.2. Assessment of specificity of beads prepared using different PS 
using inhibition analyses 
The impact of mixing beads prepared using different serotypes was 
assessed by running beads for each serotype in a monoplex and a duplex 
with beads of each other serotype. These tests were performed using 
surplus volume from anonymised test samples sourced from the 
pneumococcal serology service provided by the laboratory. An ethical 
opinion was sought on 05/12/2011 from Professor Simon Mitchell, chair of 
the Northwest 7 Research Ethics Committee – Greater Manchester Central, 
IgG- > LLQ Serotype failed 
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who replied to inform that formal ethical review was not required for use of 
these samples to validate the assay.  
Three test samples with known high positive results and with sufficient 
volume for multiple tests was sourced and prepared at a 1/100 dilution as 
described previously (section 2.3). The mean percentage recovery (% Rec) 
for the three samples was calculated for each of the duplex combinations. 
Secondly, beads of each serotype were run in monoplex with or without 
inhibition with PS from each of the 13 pneumococcal serotypes from the 
assay giving homologous and heterologous inhibition. A test sample with 
known high positive results and with sufficient volume for multiple tests was 
sourced and incubated 1/1 with water for injections (uninhibited result) or 
1/1 with 100 µg/mL of pneumococcal PS for 1 hour. Each mixture was 
diluted to 1/100 final dilution of test sample serum in ads+22F before 
assaying as described previously (section 2.3.2). Two data points were 
generated for each combination and the mean % Rec calculated for each of 
the inhibitions. A further replicate from each of 11 different test samples 
using beads prepared with serotypes 4, 18C, 19A and 19F PS inhibited with 
Pn5 PS were generated and the results incorporated into the mean % Rec 
data. 
2.4.3. Separation of the 13-plex assay into two panels 
In order to limit potential cross reactivity, serotypes were separated into 2 
panels as follows: Panel A contained Pn4, Pn6B, Pn9V, Pn14, Pn19A and 
Pn23F and panel B contained Pn1, Pn3, Pn5, Pn6A, Pn7F, Pn18C and 
Pn19F. The panels were run as separate plates, with no mixing of 
serotypes between panels (i.e. no panel A serotype to be run with any panel 
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B serotype), but within a panel any mixture of serotypes was permitted (e.g. 
serotypes could be run as monoplex or up to hexaplex in panel A). 
 
2.4.4. Modifications to assay method 
Once panels were defined, bead cocktails were prepared as previously 
described (section 2.3.2.1) but only using beads from within each panel 
(section 2.4.3). In order to test a sample for all thirteen serotypes two 
identical filter plates were prepared (section 2.3.2.2) and a bead cocktail 
(panel A or B) was added, each to a different plate and incubated as 
described in section 2.3.2.2 from which point the plates were treated as per 
section section 2.3.2.3 onwards.  
2.5. Validation of the 13 plex assay 
2.5.1. Sample selection 
Initial investigation of 603 anonymised test samples sourced from the 
clinical pneumococcal serology service provided by the laboratory resulted 
in 74 samples being selected for use in the assay validation. Samples were 
tested using the assay as described previously (section 2.4.4) and 
compared to previous data (except for Pn6A). Samples with > 50 % CV 
and/or a greater than 4-fold difference in concentration between results 
were excluded. Investigation of a further 3818 samples found 43 potential 
negative samples of which only 5 had no detectable antibody for all 13 
serotypes. A total of 79 samples were available for the validation. 
2.5.2. Bead preparation 
Except where specifically mentioned different operators (myself, Helen 
Flynn, Jake Mills, Sarah Frankland, Sarah Martin, Ros Warrington and 
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Michael Norman) were involved in preparing beads, using all 13 serotypes, 




Positive and low positive samples (5 of each) were identified for each 
serotype and inhibited by addition of homologous and heterologous 
inhibitor. The heterologous inhibitors used were the other 12 Pn PS used in 
the assay and Neisseria meningitidis group A and C PS. 
Aliquots of the sample were incubated 1:1 with either water for injections 
(without inhibition) or with a 100 µg/mL solution of pneumococcal or 
meningococcal PS for 60 mins at RT with vortex mixing every 15 mins. 
Each mixture was diluted 1/50 in ads+22F, to give a final test sample 
dilution of 1/100, before being assayed as described previously (section 
2.4.4) using either Panel A or Panel B beads.  
Results from each serotype were generated, by 1 operator, for each of the 
uninhibited and inhibited test samples with results required from the same 
assay. 
The criteria for passing the inhibition analysis were that ≥ 80 % of the 
samples had more than 70 % Rec for the heterologous inhibitors and less 
than 50 % Rec for the homologous inhibitor. 
2.5.4. Spiking 
Five negative test samples and one positive test sample were selected for 
each serotype. The negative test samples were spiked with the positive 
sample at dilutions of 1/2, 1/4 and 1/8. The negative test sample, the three 
spiked dilutions and the undiluted positive test sample were prepared as 
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described previously (section 2.3.1) and the assay performed as described 
previously (section 2.4.4) with all five preparations run on the same assay.  
Results from each serotype were generated for each of the positive test 
sample, the three dilutions and the negative test sample from the same 
assay. 
The acceptance criteria for the spiking analysis were that for ≥ 80% of the 
test sample results the negative (un-spiked) sample produced a negative 
result and the spiked test samples produced values within ± 30 % of the 
positive test sample once adjusted for the dilution factor. 
2.5.5. Accuracy 
Accuracy is normally determined by running test samples with known 
concentrations to demonstrate that the assay produces the correct result. 
No such test samples are available for all 13 serotypes using 89-SF as the 
standard serum. As such the accuracy of the assay was assessed using a 
replicate spiking assay which was performed as described previously 
(section 2.5.4) except that five replicates from separate assays were 
produced for each serotype. 
The acceptance criteria were as described previously (2.5.4)  with the 
addition that ≥ 80 % of the results for each of the spiked test samples fell 
within ± 30 % of the median value for that dilution.  
2.5.6. Reproducibility 
For all the reproducibility parameters, except the low end reproducibility, 15 
positive test samples across the whole range of the standard curve and 5 
negative test samples were selected for each serotype. Where possible the 




For the low end reproducibility the criteria were for 15 samples from the 
bottom 20 % of the standard curve of each serotype and five negative sera 
for each serotype. 
The results generated from negative sera were excluded from the 
acceptance criteria for each parameter. 
2.5.6.1. Inter assay reproducibility 
The test samples were prepared and assay performed described previously 
(section 2.4.4). 
Results from each serotype were generated for each test sample with 5 
results each generated from a different assay required. 
The acceptance criteria were that for ≥ 80 % of the samples the % CV 
between the replicate results was ≤ 25 %. 
2.5.6.2. Intra assay reproducibility 
The test samples were prepared and assay performed as described 
previously (section 2.4.4). 
Results from each serotype were generated for each test sample with 5 
results all generated from the same assay required. 
The acceptance criteria were that for ≥ 80 % of the samples the % CV 
between the replicate results was ≤ 25 %. 
2.5.6.3. Inter operator reproducibility 
The samples were prepared and assay performed as described previously 
(section 2.4.4).  
Results from each serotype were generated, by 3 different operators 
(myself, Sarah Frankland and Katy Gray), for each test sample with 2 
results from each operator generated from a different assay required. 
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The acceptance criteria were that for ≥ 80 % of the samples the % CV 
between the replicate results was ≤ 25 %. 
2.5.6.4. Inter operator analyte reproducibility 
The samples were prepared and assay performed as described previously 
(section 2.4.4) using 3 different bead preparations each prepared by the 
same operator (Helen Flynn) as described previously in sections 2.2 and 
2.4.1.1. 
In order to limit the variability of the assay, as much as possible, to the 
different beads the assay was performed across up to 6 plates (3 plates 
each for panel A and panel B) with the plates sourced from the same bag to 
reduce variability due to transport and storage. Sufficient volumes of 89-SF, 
QC and sample serum were prepared to plate the same preparation across 
the 6 plates. 
Results from each serotype were generated for each test sample with 1 
result from each bead preparation (3 results per serotype) required from the 
same assay except for beads prepared using Pn19A PS for which results 
were generated from 2 assays.  
The acceptance criteria were that for ≥ 80 % of the samples the % CV 
between the replicate results was ≤ 25 %. 
2.5.6.5. Intra operator analyte reproducibility 
The samples were prepared and assay performed as described previously 
(section 2.4.4) using 4 different bead preparations each prepared by a 
different operator as described previously in sections 2.2, 2.4.1.1 and 2.5.2. 
In order to limit the variability of the assay as much as possible to the 
different beads the assay was initially performed across up to eight plates 
(four plates each for panel A and panel B) with the plates sourced from the 
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same bag to reduce variability due to transport and storage. Sufficient 
volumes of 89-SF, QC and sample serum were prepared to plate the same 
preparation across the 8 plates.  
Results from each serotype were generated for each test sample with 1 
result from each bead preparation (4 results per serotype) required from the 
same assay except for beads prepared using Pn23F, Pn3 and Pn5 PS for 
which results were generated from 2 assays.  
The acceptance criteria were that for ≥ 80 % of the samples the % CV 
between the replicate results was ≤ 25 %. 
2.5.6.6. Low end reproducibility 
The samples were prepared and assay performed as described previously 
(section 2.4.4). 
Results from each serotype were generated for each test sample with 5 
results each generated from a different assay required. 
The acceptance criteria were that for ≥ 80 % of the samples the % CV 
between the replicate results was ≤ 25 %. 
2.5.7. Linearity 
For each serotype ten positive samples were selected and prepared in a 
similar manner to section 2.5.4 except that only 1/4 and 1/8 dilutions were 
prepared and the dilutions were prepared using a commercially available 
IgG deficient (IgG-) serum (Sigma).  
Results from each serotype were generated for each of the positive test 
sample, 1/4 and 1/8 dilutions from the same assay. 
The acceptance criteria were that for ≥ 80 % of sample results the diluted 
samples produced values within ± 30 % of the positive sample once 




For the stability parameters 15 positive test samples that covered the range 
of the standard curve and 5 negative test samples for each serotype were 
selected. The test samples were pre-aliquoted on selection into 2 µL 
aliquots. 
The results generated from negative test samples were excluded from the 
acceptance criteria for each parameter. 
2.5.8.1. Freeze/thaw stability 
Aliquots for each sample were thawed at RT until fully thawed and re-frozen 
for a minimum of twelve hours at – 80 ⁰C (-65 to -95 ⁰C) until there were 
aliquots available that had been freeze-thawed 1 (the original aliquoting), 5, 
10 and 15 times. 
The samples were prepared and assay performed as described previously 
(section 2.4.4).  
Results from each serotype were generated for each test sample from all 4 
different freeze/thaw cycle points from the same assay. 
The acceptance criteria were that for ≥ 80 % of sample the % CV between 
the four freeze/thaw cycle levels was ≤ 25 % 
2.5.8.2. Short term temperature stability 
An aliquot of each test sample was thawed at RT for a minimum of 5 hrs. 
This was then prepared as described previously (section 2.4.4) alongside 
another aliquot that had been thawed for less than 1 hr. 
Results from each serotype were generated for each test sample with 
results for both incubation periods required from the same assay. 
The acceptance criteria were that for ≥ 80 % of samples the % CV between 
the results from the time points was less ≤ 25 %.  
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2.5.8.3. Post preparative stability 
An aliquot of each test sample was thawed and prepared as described 
previously (section 2.4.4), the prepared test sample was incubated at RT for 
6 hours. A second aliquot of each test sample was thawed and prepared in 
the same manner but not allowed to stand at RT for greater than 1 hr. Both 
samples were assayed together as described previously (section 2.4.4).  
Results from each serotype were generated for each test sample at with 
results for both incubation periods required from the same assay. 
The acceptance criteria were that for ≥ 80% of the samples the % CV 
between the two preparations was ≤ 25 %. 
 
2.6. Seroprevalence of antibodies against 13 serotypes in 
UK infants in 2009 and 2012 aged between 1.00 to 3.99 
years. 
2.6.1. Samples 
Serum samples provided by the Sero-Epidemiology Unit (SEU) of PHE from 
2009 (n= 200) and 2012 (n = 203) were selected for testing from children 
aged between 1.00 and 3.99 years of age. Sample testing was covered by 
SEU ethics as part of testing for a larger seroprevalence survey being 
undertaken (Appendix I). 
2.6.2. Assay 
Except where specifically mentioned different operators (myself, Helen 
Flynn, Katy Gray and Michael Norman) were involved in preparing beads, 
using all 13 serotypes, for use in all testing the seroprevalence samples. 
All 403 samples were tested (by myself, Helen Flynn, Katy Gray, Joanna 
Gregson, Ruksana Isaji, Ros Warrington, Sarah Frankland or Sarah Martin) 
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as described previously (section 2.4.4), or using an assay similar to that 
described previously (section 2.3) but using 007sp as the standard serum, 
until 1 result for each sample from all 13 serotypes was acquired. 
2.6.3. Data Analysis 
Geometric mean concentrations (GMC) and 95 % confidence intervals (CI) 
were calculated for results within 1 year age bands (i.e. 1.00 to 1.99, 2.00 to 
2.99 and 3.00 to 3.99 years of age). In addition the percentage of samples 
with an antibody concentration ≥ 0.35 µg/mL was calculated for each 
serotype in each age band by year of collection. Independent t-tests were 
performed between the results for each year of collection in each age band 
to determine any significant differences with a p value of ≤ 0.05 considered 
as significant. 
Additional analyses were performed on 2 sub-sets within this data. The first 
sub-set was for those samples from the 2012 collection for which the known 
date-of-birth of the patient was after 01/05/2010 and who were at least 1.25 
years of age at the time of sample collection, the second sub-set was 
samples from the 2012 collection for which the known date of birth of the 
patient was between 01/04/2009 and 30/11/2009. In both cases samples of 
corresponding age were selected from the 2009 collection for comparison 




3.1. Optimisation of conditions for inclusion of 
pneumococcal serotype 6A polysaccharide in the 
multiplex assay. 
3.1.1. Optimisation of concentration of pneumococcal serotype 6A PS 
used to prepare beads 
Beads were prepared from three Pn6A PS lots (CPS6AM-1, 509508355, 
CPS6AM-5) using different concentrations as previously described (section 
2.4.1). Blanks, standard curves and QC sera were assayed in monoplex as 
described previously (section 2.4.4) from 2 to 12 times depending on lot and 
coating concentration as specified previously (section 2.4.1). Statistical 
analysis was performed using an independent t-test to compare data from 
each coating concentration with p < 0.05 considered as significant. Data 
from CPS6AM-1, for which the lowest PS concentration used was 0.25 
µg/mL, showed no significant difference between blank values, the standard 
curves or QC results by reduction of PS concentration (data not shown).  
The other 2 PS lots were prepared at lower PS concentrations (0.1 µg/mL 
and 0.01 µg/mL) to determine if there was an effect of reducing PS 
concentration further. Data including the values and means of the blanks 
(Figure 3.1) and a representative standard curve from each of the 5 coating 
concentrations (Figure 3.2) are shown for beads prepared using lot 
59508355.  
The means of the QC sera results for each coating concentration are shown 
for PS lot 509508355 (Figure 3.3). Different numbers of results were 
obtained for this lot at the different coating concentrations of 0.01 (n = 3), 
0.1 (n = 5), 1 (n = 5), 2 (n = 4) and 3 µg/mL (n = 2).  
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No significant difference was noted between the blank values obtained 
using beads conjugated with any concentration of Pn6A PS (Figure 3.1), 
although possible increased variability was noted in the lower coating 
concentrations. An increase in MFI values for all standard curve dilutions 
was observed from a coating concentration of 0.01 mg/mL to 0.1 mg/mL, 
but no further increase was seen at higher coating concentrations for both 
lot 509508355 (Figure 3.2) and CPS6AM-5 (data not shown) demonstrating 
that using at 0.01 mg/mL the beads had not been optimally coated. 
Significant differences were found between results obtained from both QC 
sera for a coating concentration of 0.01 mg/mL compared to 0.1, 1 and 2 
mg/mL, suggesting that at this concentration results obtained are not 
optimal. Additionally a significant difference between beads coated at 0.1 
mg/mL and 1 mg/mL was noted for QcMedium for lot 509508355 (Figure 
3.3). The statistical differences observed for this lot were not seen at any 
concentration in lot CPS6AM-5, although it should be noted that the number 
of results available for analysis in this lot was reduced by 1 for each 
concentration.  
The concentration which produced the most optimal results was 1 mg/mL 
and so this concentration was selected for preparation of PS/PLL and used 





































Concentration of 6A PS Used to Prepare Beads (µg/mL) 
0.01                0.1                 1                2           3 




The blank values generated (x), the mean values of the blanks (–) and ± 1 
standard deviation (SD) are plotted for beads prepared using lot 59508355. 
Different numbers of results were obtained at the different coating 
concentrations: 0.01 (n = 3), 0.1 (n = 5), 1 (n = 5), 2 (n = 4) and 3 µg/mL (n 
= 2). No significant difference in blank values was noted at any of the 
coating concentrations.  
This figure shows that blank values at all coating concentrations are low 
and appears to show a reduction in blank values and variability as coating 
concentration increases.  
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One representative standard curve for each coating concentration using 
beads prepared with Pn6A PS lot 59508355 are plotted and show an 
increase in MFI at all curve points from beads prepared using Pn6A PS at 
0.01 mg/mL to 0.1 mg/mL but no further increase in MFI with any further PS 
concentration increase.  
This figure shows that the optimal standard curve is achieved using a 
coating concentration of 0.1 mg/mL or higher. 
  

































Dilution of 89-SF 
































Concentration of 6A Ps Used to Prepare Beads 
B 
p = 0.0040 
p = 0.0003 
p = 0.0098 
p = 0.0266 
Figure 3.3: Mean QC serum concentrations generated at different 
coating concentrations 
 
The mean values ± 1 SD for all results at the different coating 
concentrations for QcHigh (A) and QcMedium (B) from beads prepared 
using PS lot 59508355 are plotted. Different numbers of results were 
obtained at the different coating concentrations: 0.01 (n = 3), 0.1 (n = 5), 1 
(n = 5), 2 (n = 4) and 3 µg/mL (n = 2). A significant difference between the 
mean results at 0.01 µg/mL and 0.1, 1 and 2 µg/mL was observed for 
QcHigh (p < 0.05) and QcMedium (p < 0.01). Additionally, a significant 
difference was observed between the 0.01 and 1 µg/mL results for 
QcMedium (p < 0.05).  
This figure shows that the optimal QC results are obtained using a coating 






























Concentration of 6A PS Used to Prepare Beads 
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p = 0.0408 
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3.1.2. Consistency of beads preparations produced using the same PS 
lot 
Results were obtained from 5 different bead preparations prepared using 
Pn6A PS lot CPA6AM-1 as described previously (section 2.4.1.1) and were 
used to analyse consistency of bead preparations as the most bead 
preparations were produced for this PS lot. All 5 bead preparations were 
tested the day after preparation as described previously (section 2.4.4).  
The highest MFI observed for blank values for the 5 preparations was 54.3 
MFI, below the maximum of 200 MFI. Standard curves generated by the 5 
preparations are shown in Figure 3.4 and % CV was calculated between the 
replicates at each dilution with results less than 25 % for all curve dilutions 
except the 1/81920 dilution (25.02 %). QC sera results showed good 
consistency between bead batches with % CV between QcHigh and Qc 
Medium results for all 5 batches of 15.1 % and 12.6 %, respectively. These 
results demonstrated that the coating concentration of 1 mg/mL produced 
blank values in the expected range, consistent MFI values for all standard 
curve dilutions and consistent concentration results for QC sera across 










Curves from all 5 bead preparations using PS lot CPS6AM-1, and tested 
the day following preparation, are shown. The % CV between the points 
were all below 25 % except at the 1/81920 dilution where the % CV was 
25.02 %.  
This figure demonstrates that curves generated by different bead 
preparations give have consistent MFI values. 
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Batch 1 Batch 2 Batch 3 Batch 4 Batch 5 
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3.1.3. Stability of beads up to 77 days post conjugation 
Bead preparations were produced for all PS lots and assayed on three 
occasions up to 43 to 77 days post conjugation as described previously 
(section 2.4.1). Standard curve MFI values from 1 representative bead 
preparation from lot CPS6AM-1, which was tested on day 1, 20 and 43 
post-preparation, are shown in Figure 3.5.  
The highest MFI value for the blank wells from beads prepared using any of 
the PS lots was 66.3, well below the maximum 200 MFI threshold (Figure 
3.6). The average % CV between standard curve dilutions across the 3 time 
points was 18.8 % and between QcHigh and QcMedium results was 16.3 % 
and 12.8 % respectively. Similar results were observed in other bead 
preparations (data not shown).  
These results demonstrated that the coating concentration of 1 mg/mL 
produced beads, for any lot of PS, which showed consistent results for 
blank, standard curve MFI and QC sera in the first 77 days post-preparation 




Figure 3.5: Standard curves generated up to 43 days post preparation 
 
 
Curves from 1 representative bead preparation produced using PS lot 
CPS6AM-1 and assayed 1, 20 and 43 days after preparation are shown. 
The % CV between the 3 time points from most dilute to most concentrated 
curve point are 14.1, 30.6, 17.9, 16.3, 13.6, 10.9 and 4.8 %, respectively.  
This figure demonstrates that there is little variation between standard curve 
MFI values produced over time suggesting that bead preparations are 
stable post-preparation. 
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3.1.4. Different lots of 6A PS from different suppliers produce similar 
blank, standard curve and QC results 
Results from beads prepared using different lots of Pn6A Ps, CPS6AM-1 
and CPS6AM-5 from SSI and 59508355 from LGC, and assayed as 
described previously (section 2.4.1) were compared. Statistical analysis 
was performed using an independent t-test to compare data from each 
coating concentration with p < 0.05 considered as significant. 
The maximum blank value for any PS lot was 66.3 MFI as reported 
previously (Figure 3.6). The means of all curves generated for each lot are 
shown (Figure 3.7) and the % CV between the means was low (a maximum 
of 20.0 %). Mean results for each QC sera are shown in Figure 3.8 with only 
one comparison between the lots showing a significant difference, namely 
the mean concentration for 59508355 was significantly lower than that for 
CPS6AM-1 (p = 0.010). No other significant differences were seen. 
As such, no clear advantage could be seen to using any one supplier, 
however, the variation in results for lot 59508355 appeared to be slightly 
less, at least for the blanks and QcMedium, and so this lot was chosen for 
use in the assay during validation. 
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Figure 3.6: Blank values generated using lots of Pn6A PS  
 
 
The blank values generated (x), the mean values of the blanks (–) and the 
standard deviation (I) are plotted for PS lots from LGC (59508355) and SSI 
(CPS6AM-1 and CPS6AM-5). The maximum observed blank value was 
66.3 MFI, below the maximum acceptable value of 200 MFI. Lots 59508355 
and CPS6AM-5 showed less variation ion results, but had fewer results, 
than CPS6AM-1.   
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Figure 3.7: Mean values of standard curves generated using different 
Pn6A PS lots 
 
 
The mean values of all curves generated for each PS lot from LGC 
(59508355) and SSI (CPS6AM-1 and CPS6AM-5) are plotted. The % CV 
between the mean values for the 3 PS lots from most dilute to most 
concentrated curve point are 20.0, 17.0, 15.5, 13.0, 11.3, 9.1 and 2.9 %, 
respectively.  
This figure shows that there is little variation between standard curve MFI 
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Figure 3.8: Mean concentrations generated for QcHigh and QcMedium 




This figure shows the mean values ± 1 SD for all results the different PS 
lots from LGC (59508355) and SSI (CPS6AM-1 and CPS6AM-5) for QcHigh 
(A) and QcMedium (B). Different numbers of results were obtained for each 
lot: 59508355 (n = 5), CPS6AM-1 (12) and CPS6AM-5 (4). Following 
calculation of the independent t-test statistic, no significant difference was 
observed between the results for QcHigh for any lot. For QcMedium a 
significant difference was found between lots 59508355 and CPS6AM-1 
(p=0.010) but not between any other combination of lots.  
This figure shows that for 1 lot of LGC PS, but not the other, there was a 
significant difference in results generated in the assay compared to the 
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3.2. Inclusion of beads prepared with Pn6A PS with beads 
prepared using other Pn PS. 
A total of 14 test samples were selected from samples submitted for clinical 
testing as required for the following parts of the optimisation. Samples were 
chosen that were positive for the 12 serotypes tested in the original assay 
(section 2.3.2) in order to show a clear inhibition if any were observed. 
3.2.1. Comparison of beads assayed as monoplex or as duplex with 
beads prepared using any other serotype. 
Results from 3 test samples generated for beads from each serotype run in 
monoplex or duplex with each other serotype as described previously 
(section 2.4.2) were compared to provide a mean percentage recovery (% 
Rec) for each serotype. A change in % Rec of ± 20 % was used as the 
threshold for a change as a result of combining the beads. 
No impact of running a bead preparation from any serotype with and other 
bead preparation was observed except combining beads prepared with 
Pn23F and Pn3 together saw an increase in the mean % Rec of 21.42 % 
over the monoplex result for the results for Pn23F, but no impact was 
observed the result for beads prepared using Pn3 when run with beads 
prepared using Pn23F (Table 3.1). Of the other duplex combinations 
148/156 results, including serotypes expected to cross react, had a % Rec 
within ± 10 %. 
These results suggest that there is no impact on the specificity of the assay 




Table 3.1: Mean % Rec of beads assayed in duplex combinations 
 
    Duplex bead preparation (serotype) 




























Pn1   105.35% 107.93% 104.68% 108.92% 106.43% 106.42% 105.02% 98.37% 103.68% 104.39% 103.95% 100.88% 
Pn3 99.10% 
 
96.46% 96.87% 96.48% 92.39% 94.54% 93.41% 94.18% 88.11% 94.66% 87.70% 93.99% 
Pn4 108.57% 98.09%   95.75% 101.05% 96.03% 104.91% 97.79% 97.28% 95.67% 99.97% 96.93% 101.50% 
Pn5 103.23% 104.43% 98.31% 
 
104.43% 106.47% 101.90% 101.18% 96.62% 99.04% 99.12% 99.22% 87.39% 
Pn6A 105.09% 105.81% 104.22% 109.81%   94.99% 97.52% 95.73% 94.89% 97.10% 97.49% 95.36% 95.56% 
Pn6B 100.66% 97.03% 100.81% 110.83% 98.73% 
 
99.29% 100.87% 101.82% 93.91% 97.51% 98.57% 95.30% 
Pn7F 101.63% 98.29% 99.74% 102.62% 99.57% 98.53%   98.06% 98.43% 95.60% 96.14% 97.51% 97.20% 
Pn9V 98.17% 95.47% 96.15% 103.34% 99.42% 100.74% 98.84% 
 
99.50% 96.64% 97.39% 97.15% 99.81% 
Pn14 99.43% 108.05% 104.01% 98.25% 96.72% 101.95% 98.66% 98.58%   96.29% 91.94% 96.26% 97.17% 
Pn18C 100.11% 94.81% 98.65% 101.12% 101.29% 97.36% 99.76% 100.05% 99.63% 
 
98.81% 98.19% 98.37% 
Pn19A 93.30% 97.15% 93.97% 101.59% 98.45% 97.64% 98.29% 97.80% 96.04% 99.95%   99.98% 94.44% 
Pn19F 99.22% 90.71% 97.43% 106.66% 102.66% 102.36% 103.33% 101.68% 103.48% 98.60% 101.45% 
 
86.15% 
Pn23F 115.13% 121.42% 119.32% 102.88% 104.62% 102.95% 107.84% 105.68% 106.63% 102.48% 97.88% 91.29%   
  
Three samples were tested and mean % Rec calculated between beads preparations in monoplex or as a duplex for all serotype 
combinations.  One duplex combination (Pn3 with Pn23F) had a % Rec greater than ± 20 %.  
This table shows that there does not appear to be an impact on results as a result of combining beads prepared with one serotype 
with beads prepared with another. 
61 
 
3.2.2. Inhibition of beads prepared using all serotypes with 
homologous and heterologous inhibitors  
Inhibition of beads in monoplex was performed using polysaccharides as 
homologous and heterologous inhibitors and assayed as described 
previously (section 2.4.2). The results for un-inhibited and inhibited samples 
were combined to give a mean % Rec for each bead preparation inhibited 
with each PS (Table 3.2). 
Inhibition using homologous PS showed a maximum % Rec of 6.04 and so 
homologous inhibition occurred as expected. 
Inhibition revealed cross reactivity between beads prepared using Pn6A PS 
with Pn6B PS and vice versa and beads prepared using Pn19A PS with 
Pn19F PS and vice versa. Inhibition of beads prepared using Pn18C PS by 
Pn19A Ps and beads prepared using Pn18C and Pn19A Ps by Pn5 PS was 
also noted. 
These result showed that there was some cross reactivity between 
serotype. Of concern following these results was the requirement of the 
assay to pass the specificity validation parameter, measured using this type 
of inhibition analysis, and so the assay was split into 2 panels as previously 





Table 3.2: Mean % Rec of beads inhibited with homologous or heterologous polysaccharides 
 
 
This table highlights results for which a mean % Rec of less than 80 % was achieved (light blue). Homologous inhibition occurred as 
expected (highlighted in grey). Of particular note are the inhibition of the beads prepared using Pn18C PS by Pn19A Ps, the cross 
reactivity between Pn6A PS and Pn6B PS and between Pn19A PS and Pn19F PS and the inhibition by Pn5 PS of beads prepared 
using Pn18C and Pn19A PS.  
This table demonstrates that specificity between related, and some unrelated, serotypes is not sufficient to pass validation and 
formed the basis for splitting the assay into 2 panels 
 
 
Bead preparation (serotype) 










Pn1 1.61% 100.51% 103.74% 101.05% 100.41% 100.80% 103.24% 98.52% 103.31% 107.92% 98.57% 100.71% 111.00% 
Pn3 96.21% 2.52% 80.05% 97.44% 105.52% 99.28% 103.76% 99.67% 104.91% 106.52% 96.46% 98.33% 121.40% 
Pn4 96.83% 99.71% 2.25% 99.87% 103.78% 101.16% 102.72% 101.18% 102.93% 108.29% 98.80% 100.88% 119.50% 
Pn5 98.19% 94.77% 88.08% 0.55% 105.14% 104.53% 103.20% 99.94% 107.96% 74.58% 73.53% 101.35% 116.52% 
Pn6A 94.25% 94.44% 93.88% 45.06% 2.56% 41.18% 100.47% 96.14% 102.46% 102.39% 93.06% 88.39% 112.76% 
Pn6B 94.92% 94.75% 96.21% 92.41% 11.17% 1.87% 99.88% 97.34% 102.77% 104.04% 96.94% 96.96% 80.28% 
Pn7F 94.24% 91.20% 96.51% 96.51% 102.09% 99.01% 6.04% 97.45% 78.93% 99.62% 93.02% 102.13% 115.95% 
Pn9V 94.45% 89.03% 98.94% 97.86% 101.38% 101.33% 98.09% 5.02% 102.42% 82.32% 96.13% 95.71% 116.60% 
Pn14 93.81% 89.83% 89.75% 101.26% 65.40% 73.71% 99.64% 91.80% 2.73% 99.20% 84.14% 99.25% 115.99% 
Pn18C 95.97% 100.11% 96.06% 97.36% 66.44% 69.76% 101.59% 94.51% 98.57% 2.76% 95.29% 99.48% 112.24% 
Pn19A 88.87% 74.18% 84.11% 94.46% 64.04% 70.00% 97.01% 91.52% 92.59% 2.52% 2.52% 65.52% 105.35% 
Pn19F 96.68% 101.55% 102.48% 105.69% 97.19% 98.68% 98.59% 94.53% 103.42% 90.21% 78.24% 1.41% 98.21% 
Pn23F 95.35% 104.61% 98.62% 105.34% 93.06% 90.38% 98.57% 93.22% 104.83% 108.55% 98.98% 108.25% 2.24% 
63 
 
3.2.3. Summary of assay optimisation 
Beads prepared using different lots Pn6A PS were investigated to 
determine the optimal coating concentration. The outcome of the 
investigations was that a concentration of 1 mg/mL was found to be optimal 
(section 3.1.1) giving good consistency of blank, standard curve and QC 
values between bead preparations (section 3.1.2) and over time (section 
3.1.3). No lot to lot variation was observed (section 3.1.4). 
Investigation of the performance of the beads in multiplex identified a 
number of serotypes that showed evidence of cross reactivity (section 
3.2.2), as a result the assay was split into 2 panels (panel A contained 
beads prepared using Pn 4, 6B, 9V, 14, 19A and 23F and panel B 





3.3. Validation of the 13-plex Assay 
Seventy nine test samples were selected from samples submitted to the 
VEU for clinical testing as previously described (section 2.5.1). Samples 
were selected to cover the range of the standard curve for all serotypes 
and, where possible, to be used across multiple serotypes; in addition 
samples that were completely negative for all serotypes were selected for 
the spiking analyses. At least 80 % of results within each serotype were 
required to meet or exceed the pre-determined acceptance criteria of that 
parameter in order for the parameter to be considered as validated for that 
serotype. 
3.3.1. Specificity 
The specificity parameter comprised both inhibition and spiking tests.  
3.3.1.1. Inhibition 
Ten samples (5 low positive and 5 positive) were prepared with or without 
homologous and heterologous inhibitors as described previously (section 
2.5.3). Inhibited results were compared to uninhibited results to give % Rec 
for each serotype (Appendix II). 
 A summary of the inhibition results show that a minimum of 80 % of 
samples met or exceeded the pre-determined criteria of % Rec < 50 % for 
homologous inhibition and % Rec > 70 % for heterologous inhibition (Table 
3.3). 
These result demonstrated that the serotypes, when tested within the 
assigned panels, showed cross reactivity within permitted boundaries and 
so the cross reactivity seen in the assay previously in section 3.2.2 had 





A sample with a high concentration was spiked into each of 5 negative 
samples previously described (section 2.5.4). Negative samples produced 
negative results for 100 % of the results analysed (Appendix II). Spiked 
results, adjusted for dilution factor, were compared to see if they fell within ± 
30 % of the un-spiked test sample result (Appendix II). 
A summary of the results of the spiking tests show that a minimum of 86.67 
% of results met or exceeded the pre-determined criteria (Table 3.3). 
The results of both the inhibition and spiking analyses show that the 









Heterologous Inhibition Spiking 
  % Rec < 50 (%) % Rec > 70 (%) 
Results within ± 30 % of 
un-spiked result (%) 
Pn4 100.0 90.0 to 100.0 86.67 
Pn6B 100.0 100.0 93.33 
Pn9V 90.0  100.0 100.00 
Pn14 100.0 100.0 86.67 
Pn19A 100.0 90.0 to 100.0 86.67 
Pn23F 100.0 80.0 to 100.0 100.00 
  
     
Pn1 80.0 90.0 to 100.0 100.00 
Pn3 100.0 100.0 100.00 
Pn5 90.0 90.0 to 100.0 100.00 
Pn6A 90.0 90.0 to 100.0 100.00 
Pn7F 80.0 100.0 93.33 
Pn18C 90.0 80.0 to 100.0 100.00 
Pn19F 90.0 80.0 to 100.0 100.00 
 
A summary of the results obtained for the specificity parameter of the assay 
validation is shown. The percentage of samples meeting or exceeding the 
acceptance criteria of each test are shown, with at least 80 % of samples 
required in order for the parameter to pass.  
This table shows that the specificity parameter was passed for beads 





A sample with a high concentration was spiked into each of 5 negative 
samples as previously described (section 2.5.5). For each serotype 5 
replicated results were generated. Spiked results, adjusted for dilution 
factor, were compared to see if they fell within ± 30 % of the un-spiked test 
sample result from the same run and the results from each dilution factor 
were compared to see if they fell within ± 30 % of the median result for that 
dilution factor (Appendix III). 
A summary of the results for all serotypes show that for Pn 4, 6B, 9V, 14, 
23F, 1, 3, 5, 6A, 18C and 19F show that the accuracy parameter met or 
exceeded the pre-determined criteria (Table 3.4). For Pn7F the parameter 
exceeded the pre-determined criteria for percentage of results within ± 30 % 
of the median (98.67 %) but did not meet the pre-determined criteria for 
results within ± 30 % of the positive sample (76.00 %) and for Pn19A the 
results did not meet the pre-determined criteria for both criteria (77.33 and 




Table 3.4: Summary of results for the accuracy parameter 
 
Serotype Results within ± 30 % of un-
spiked result (%) 
Results within ± 30 % of 
median result (%) 
Pn4 89.33 94.67 
Pn6B 86.67 90.67 
Pn9V 89.04 97.26 
Pn14 91.76 94.52 
Pn19A 54.67 77.33 
Pn23F 94.67 96.00 
   
Pn1 89.33 90.67 
Pn3 81.33 89.33 
Pn5 85.33 97.33 
Pn6A 94.67 93.33 
Pn7F 76.00 98.67 
Pn18C 94.67 96.00 
Pn19F 85.33 94.67 
 
A summary of the results obtained for the accuracy parameter of the assay 
validation is shown. The percentage of results meeting or exceeding the 
acceptance criteria of each test are shown, with at least 80 % required in 
both tests for the parameter to pass.  
 
This table shows that the pre-determined criteria were met or exceeded for 
the accuracy parameter using beads prepared with Pn 4, 6B, 9V, 14, 23F, 




For each serotype 15 positive and 5 negative test samples were selected 
using historical data to provide a spread across the whole standard curve 
range for all reproducibility tests except for the low end reproducibility where 
the 15 positive test samples were selected to be in the bottom 20 % of the 
range of the standard curve. On testing in the reproducibility analysis some 
samples that were selected to be positive gave negative results and, rarely, 
test samples that were expected to be negative gave positive results. Only 
positive results from test samples were included in the analyses of the tests. 
Raw data for each of the reproducibility tests can be found in Appendix IV. 
3.3.3.1. Inter assay 
The test samples were assayed to give 5 results each from a different 
assay as described previously (section 2.5.6.1). A summary of results for 
this test show that beads prepared using all serotypes except Pn19A and 
Pn3 (both 66.67 %) met or exceeded the pre-determined criteria (Table 
3.5). 
3.3.3.2. Intra assay 
The test samples were assayed to give 5 results from the within the same 
assay as previously described (section 2.5.6.2). A summary of results for 
this test show that beads prepared using all serotypes met or exceeded the 
pre-determined criteria (Table 3.5). 
3.3.3.3. Inter operator 
The test samples were assayed by 3 operators to give 2 results from each 
operator as described previously (section 2.5.6.3). A summary of results for 
this test show that beads prepared using all serotypes except Pn23F (78.57 
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%) and Pn3 (73.33 %) met or exceeded the pre-determined criteria (Table 
3.5) 
3.3.3.4. Inter operator analyte 
The test samples were assayed using 3 bead preparations each produced 
by the same operator as described previously (section 2.5.6.4). A summary 
of results for this test show that beads prepared using all serotypes except 
Pn1 (78.57 %) met or exceeded the pre-determined criteria (Table 3.5) 
3.3.3.5. Intra operator analyte 
The test samples were assayed using 4 bead preparations each produced 
by a different operator as previously described (section 2.5.6.5). A summary 
of results for this test show that beads prepared using all serotypes met or 
exceeded the pre-determined criteria (Table 3.5) 
3.3.3.6. Low end 
The test samples were assayed to give 5 results each from a different 
assay as described previously (section 2.5.6.6). A summary of results for 
this test shown that beads prepared using all serotypes met or exceeded 
the pre-determined criteria except Pn 19A and 3 which had only 71.43 and 













































Pn4 93.75 93.33 100.00 86.67 100.00 92.86 
Pn6B 93.33 100.00 93.33 100.00 100.00 93.33 
Pn9V 100.00 93.33 100.00 86.67 100.00 100.00 
Pn14 93.33 100.00 80.00 100.00 93.33 80.00 
Pn19A 66.67 92.86 100.00 86.67 93.33 71.43 
Pn23F 100.00 100.00 78.57 85.71  100.00 100.00 
  
      
Pn1 85.71 85.71 87.50 78.57 87.50 84.62 
Pn3 66.67 86.67 73.33 92.86 66.67 60.00 
Pn5 100.00 100.00 94.12 100.00  93.75 100.00 
Pn6A 93.33 100.00 100.00 100.00 100.00 93.33 
Pn7F 100.00 100.00 80.00 100.00 87.50 93.33 
Pn18C 93.33 93.33 100.00 100.00 100.00 100.00 
Pn19F 100.00 100.00 93.33 100.00 93.33 86.67 
 
A summary of the results obtained for the reproducibility parameter of the 
assay validation is shown. The percentage of results meeting or exceeding 
the acceptance criteria of each test are shown, with at least 80 % required 
in all tests for the parameter to pass.  
This table shows that the reproducibility results met or exceeded the pre-
determined criteria beads prepared using Pn4, Pn6B, Pn9V, Pn14, Pn5, 
Pn6A, Pn7F, Pn18C and Pn19F, but not for beads prepared using Pn19A, 





For the linearity parameter 10 test samples were spiked into commercial 
IgG- sera at a dilution of 1/4 and 1/8 as described previously (section 2.5.7). 
For beads prepared using each serotype 1 result for the un-spiked positive 
sample and the 2 dilutions was generated from the same assay. Spiked 
results, adjusted for dilution factor, were compared to see if they fell within ± 
30 % of the un-spiked test sample result, results from test samples that 
were negative or which fell below the limit of detection (LOD) of the curve 
were excluded from the analysis (Appendix V). 
A summary of the results shows that > 80 % of results met or exceeded the 
pre-determined acceptance criteria for beads prepared using all serotypes 




Table 3.6: Summary of results for the linearity parameter 
 
Serotype 
Results within ± 30 % of 
















A summary of the results obtained for the linearity parameter of the assay 
validation is shown. The percentage of results meeting or exceeding the 
acceptance criteria of each test are shown, with at least 80 % required in all 
tests for the parameter to pass.  
This table shows that the linearity results met or exceeded the pre-







For the stability parameter sub-aliquots of test samples were prepared in 
advance. For each serotype 15 positive test samples from across the range 
of the standard curve and 5 negative samples were selected. Only positive 
results from the test samples were included in the analyses of the tests. 
Raw data for the stability tests can be found in 0. 
3.3.5.1. Freeze/thaw 
Test samples were thawed and re-frozen up to 15 times as described 
previously (section 2.5.8.1). Results for each test sample were obtained for 
1, 5, 10 and 15 freeze/thaw cycles from the same assay and the % CV 
between the 4 time points calculated. A summary of the results for this test 
shows that the pre-determined criteria were met or exceeded for beads 
prepared using all serotypes except Pn6A (78.57 %; Table 3.7). 
3.3.5.2. Short term temperature 
Test samples were thawed and incubated at RT <1 hr or 5 hr as described 
previously (section 2.5.8.2). Both aliquots of the test samples were assayed 
together and the % CV between results at the two time points was 
calculated.  A summary of the results for this test shows that the pre-
determined criteria were met or exceeded for beads prepared using all 
serotypes (Table 3.7). 
3.3.5.3. Post preparative 
Test samples were thawed and diluted in ads+22F before incubation at RT 
<1 hr for or 6 hr as described previously (section 2.5.8.3). Both aliquots of 
the test samples were assayed together and the % CV between results at 
the two time points was calculated. A summary of the results for this test 
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shows that the pre-determined criteria were met or exceeded for beads 




Table 3.7: Summary of results for the stability parameter 
 
  Freeze/ Thaw Short Term Post Preparative 
  
% CV between 
replicates ≤ 25.00 
(%) 
% CV between 
replicates ≤ 25.00 
(%) 
% CV between 
replicates ≤ 25.00 
(%) 
Pn4 100.00 93.33 92.86 
Pn6B 92.86 93.33 100.00 
Pn9V 100.00 100.00 100.00 
Pn14 93.33 100.00 93.33 
Pn19A 93.75 86.67 93.33 
Pn23F 93.33 100.00 93.75 
  
   
Pn1 84.62 100.00 91.67 
Pn3 86.67 86.67 73.33 
Pn5 81.25 86.67 93.33 
Pn6A 78.57 93.33 93.33 
Pn7F 87.50 87.50 93.75 
Pn18C 86.67 100.00 100.00 
Pn19F 81.25 100.00 93.75 
 
 A summary of the results obtained for the linearity parameter of the assay 
validation is shown. The percentage of results meeting or exceeding the 
acceptance criteria of each test are shown, with at least 80 % required in all 
tests for the parameter to pass.  
 
This table shows that of the stability results met or exceeded the pre-
determined criteria for beads prepared using all serotypes except Pn6A 
(freeze/thaw) and Pn3 (post preparative). 
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3.3.6. Summary of assay validation 
The performance of the assay was compared to pre-determined criteria for 
specificity, accuracy, reproducibility, linearity and stability in order to 
demonstrate validity of the results (sections 3.3.1, 3.3.2, 3.3.3, 3.3.4 and 
3.3.5). The pre-determined criteria were met or exceeded for all parameters 
for beads prepared using Pn 6B, 9V, 14, 5, 18C and 19F. For beads 
prepared using Pn 4, 23F 6A and 7F the pre-determined criteria were not 
met for results from only one test and for beads prepared using Pn 19A, 1 
and 3 the results from multiple tests did not meet the pre-determined 
criteria. 
The results of the validation are discussed further below (section 4) with the 




3.4. Seroprevalence of antibodies against 13 serotypes in 
UK infants 1.00 to 3.99 years of age. 
A total of 403 samples from patients aged 1 to < 4 years were selected for 
testing for the seroprevalence study of which 200 were from 2009 and 203 
were from 2012. Of these, 1 sample from 2009 was found to be insufficient 
which left 199 samples available to be tested for this year. 
Samples were tested as previously described (section 2.6.2) with the first 
accepted result for each serotype accepted as the correct result. 
3.4.1. Overall seroprevalence of antibodies 
Samples were grouped by year of sample collection and then by age at 
sample collection (i.e. 1.00 to 1.99, 2.00 to 2.99 and 3.00 to 3.99 years of 
age) and geometric mean concentrations (GMC), 95 % confidence interval 
(CI) calculated and the % of samples with concentration ≥ 0.35 µg/mL was 
calculated for all serotypes at each age band (Table 3.8). The independent 
t-test statistic was calculated between the years of collection for each 
serotype (Table 3.8). 
No statistical difference in GMC titres was observed between the years for 
any of the serotypes in PCV7 except for Pn4 in the age 1.00 to 1.99 year 
group and Pn18C in the age 2.00 to 2.99 year group. In both cases the 
2012 cohort had a lower GMC than 2009, however, the p values were only 
just significant (0.045 and 0.049, respectively) and 95 % CI overlap 
completely in both instances suggesting these results are due to natural 
variations in the data sets and are not genuine differences. Similarly % 




These results suggest that there has been no effect of the introduction of 
PCV13 on the serotypes that were present in both vaccines. 
For serotypes present in PCV13 but not PCV7 significant increases were 
observed from 2009 to 2012 for all serotypes except Pn3 in both the age 
1.00 to 1.99 and 2.00 to 2.99 year groups. Significant increases for 
serotypes Pn5 and Pn7F were also noted in the age 3.00 to 3.99 year 
group. Very few children aged > 3 in 2012 are likely to have received a dose 
of PCV13 as they were born and vaccinated prior to introduction of PCV13, 
as such it is likely that these increases are due to individual samples in the 
cohorts with antibodies obtained naturally by contact with those serotypes. 
The samples with concentrations ≥ 0.35 µg/mL greatly increased for non-
PCV7 serotypes samples from those aged 1.00 to 2.99 years regardless of 
serotype, and there was a slight increase in all serotypes in those aged 3.00 
to 3.99 years.  
These results indicate that the introduction of PCV13 has significantly 
increased the antibody concentrations in infants for serotypes that were not 
present in PCV7, and that these increases in antibody concentration result 







Table 3.8: Seroprevalence of antibodies in 2009 and 2012 
 
GMC, 95% CI and % samples with concentration ≥ 0.35 µg/mL for 
each serotype at different age ranges in each of the 2009 and 2012 
cohorts are shown. The independent t-test statistic between 2009 
and 2012 is also shown (P < 0.05 in bold typeface).  
 
This table shows no effect of PCV13 introduction on PCV7 serotypes 
and significant increase in antibody concentrations for non PCV7 
serotypes, except Pn3, for infants aged 1.00 to 2.99, along with 
increases in the proportion of patient reaching at least 0.35 µg/mL in 













Pn4 1.99 (1.38,2.61) 85.00 1.55 (0.26,2.85) 81.43 0.045
Pn6B 1.12 (0.77,1.46) 67.50 0.64 (-0.55,1.83) 61.43 0.102
Pn9V 1.04 (0.72,1.37) 67.50 0.76 (-0.07,1.58) 71.43 0.212
Pn14 2.47 (1.71,3.24) 90.00 2.30 (0.55,4.05) 88.57 0.900
Pn18C 1.06 (0.73,1.39) 77.50 0.91 (-0.36,2.19) 78.57 0.702
Pn19F 1.57 (1.08,2.05) 87.50 2.13 (-1.52,5.77) 91.43 0.507
Pn23F 1.05 (0.73,1.38) 65.00 1.09 (-0.93,3.11) 72.86 0.881
Pn1 0.09 (0.06,0.12) 10.00 0.78 (-0.78,2.34) 67.14 0.019
Pn3 0.09 (0.06,0.12) 10.00 0.36 (0.00,0.72) 52.86 0.233
Pn5 0.06 (0.04,0.07) 2.50 0.60 (0.07,1.14) 65.71 < 0.001
Pn6A 0.20 (0.13,0.26) 27.50 1.90 (-2.47,6.27) 82.86 0.013
Pn7F 0.13 (0.09,0.17) 10.00 1.42 (0.08,2.77) 90.00 0.002
Pn19A 0.20 (0.14,0.27) 40.00 1.00 (-1.67,3.67) 64.29 0.026
Pn4 1.41 (1.05,1.77) 83.05 0.75 (-0.77,2.27) 73.00 0.818
Pn6B 0.98 (0.73,1.23) 79.66 0.63 (-1.53,2.79) 68.00 0.884
Pn9V 0.83 (0.62,1.05) 72.88 0.41 (-1.03,1.85) 53.00 0.709
Pn14 1.85 (1.38,2.32) 93.22 0.88 (-1.61,3.38) 76.00 0.583
Pn18C 0.90 (0.67,1.13) 74.58 0.48 (-0.03,0.99) 66.00 0.049
Pn19F 1.78 (1.33,2.24) 79.66 0.98 (-1.29,3.25) 79.00 0.058
Pn23F 1.24 (0.92,1.55) 83.05 0.82 (-1.37,3.01) 67.00 0.290
Pn1 0.09 (0.07,0.11) 6.78 0.42 (-0.33,1.17) 53.00 0.016
Pn3 0.09 (0.07,0.11) 11.86 0.27 (-0.40,0.95) 44.00 0.074
Pn5 0.06 (0.04,0.07) 1.69 0.39 (-0.56,1.35) 59.00 0.047
Pn6A 0.26 (0.19,0.33) 38.98 0.99 (-1.10,3.08) 78.00 0.030
Pn7F 0.10 (0.08,0.13) 13.56 0.88 (0.23,1.53) 80.00 < 0.001
Pn19A 0.23 (0.17,0.29) 33.90 0.62 (-5.58,6.82) 67.00 0.049
Pn4 0.50 (0.40,0.59) 66.00 0.53 (-0.75,1.82) 66.67 0.453
Pn6B 0.50 (0.40.0.60) 52.00 1.03 (-0.61,2.68) 84.85 0.673
Pn9V 0.39 (0.32,0.47) 50.00 0.38 (0.15,0.62) 57.58 0.356
Pn14 0.65 (0.52,0.77) 64.00 0.51 (-0.45,1.48) 60.61 0.445
Pn18C 0.55 (0.44,0.66) 60.00 0.39 (0.01,0.76) 54.55 0.129
Pn19F 1.06 (0.85,1.27) 64.00 0.80 (0.30,1.31) 78.79 0.108
Pn23F 0.54 (0.43,0.64) 54.00 1.26 (-5.36,7.91) 75.76 0.068
Pn1 0.11 (0.09,0.13) 11.00 0.15 (0.02,0.29) 21.21 0.508
Pn3 0.16 (0.13,0.19) 28.00 0.18 (-1.50,1.86) 30.30 0.484
Pn5 0.06 (0.04,0.07) 1.00 0.11 (-0.01,0.24) 18.18 < 0.001
Pn6A 0.31 (0.25,0.37) 39.00 0.45 (-0.28,1.17) 57.58 0.518
Pn7F 0.15 (0.12,0.18) 19.00 0.43 (-0.42,1.28) 51.52 0.003
Pn19A 0.29 (0.23,0.34) 42.00 0.24 (-0.36,0.84) 33.33 0.743
2009 2012
2.00 to 2.99 
(n = 59 [2009] 
and 100 
[2012])
1.00 to 1.99 
(n = 40 [2009] 
and 70 
[2012])
3.00 to 3.99 
(n = 100 





3.4.2. Comparison of 3 doses of PCV7 to 3 doses of PCV 13 
Results were selected out of the total data set for samples from the 2012 
cohort whose date of birth could be determined to be between 01/05/2010 
and who were at least 15 months old at the time the sample was collected 
which resulted in selection of 62 samples. These samples were expected to 
have received the full 3 dose course of PCV13. Samples (n = 46) from the 
2009 cohort with the same age profile at time of sample collection were also 
selected. GMCs, 95 % CI were calculated for the 2 years, and independent 
t-test calculations were performed on the results between the years, for 
each serotype. 
Significant increases in GMC were observed for all serotypes in PCV13 but 
not in PCV7, except for Pn3 and Pn19A (Figure 3.9). Although there was an 
apparent increase in GMC for both serotypes from 2009 to 2012 this was 
not significant (p = 0.215 [Pn3] and 0.060 [Pn19A]). The proportion of 
samples with antibody concentration ≥ 0.35 µg/mL increased for all 
serotypes not in PCV7 by 2 to 10 fold (Figure 3.9). 
No differences were observed for the serotypes present in PCV7 except 
that a significant decrease in GMC was noted for Pn4 and Pn6B from 2009 
to 2012 (p = 0.011 [Pn4] and 0.027 [Pn6B]; Figure 3.9) although no 
difference was seen in the proportion of samples with ≥ 0.35 µg/mL 
antibody concentration for any PCV7 serotypes (Figure 3.9). 
These results demonstrate that the full 3 dose course of PCV 13 produces 
robust increases in GMC for all the extra serotypes, including Pn3, without 






















































Figure 3.9: GMC and percentage ≥ 0.35 µg/mL from patients receiving 
3 doses of PCV7 (2009) or PCV13 (2012) 
 
The GMC (A) and percentage results ≥ 0.35 µg/mL (B) are shown for each 
serotype for patients who had received either 3 doses of PCV7 (2009) or 
PCV13 (2012). Significant differences in GMC are denoted by * (P < 0.05) 
and ** (P < 0.01).  
These figures show significant increases in GMC for serotypes not in PCV7 
except Pn3 and Pn19A, 2 to 10 fold increases in the proportion of non 
PCV7 serotype results ≥ 0.35 µg/mL, and no reduction in any PCV7 
serotype proportion ≥ 0.35 µg/mL despite significant reductions in Pn4 and 
Pn6B GMC.  
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3.4.3. Comparison of 3 doses of PCV7 with 2 doses of PCV7 followed 
by 1 dose of PCV13 
Results were also selected out of the total data set for samples from the 
2012 cohort were selected whose date of birth could be determined to be 
after 01/04/2009 and 30/11/2009 resulting in selection of 50 samples. 
These samples were expected to have received the 2 doses of PCV7 as 
they were born before introduction of PCV 13 but to have received the 
booster dose of PCV13 as they were 13 months old at least one month after 
introduction of PCV13. Samples from the 2009 cohort with the same date of 
birth range, but 3 years earlier, were also selected resulting in 56 samples 
being selected. GMCs, 95 % CI were calculated for the 2 years, and 
independent t-test calculations were performed on the results between the 
years, for each serotype. 
Increases in GMC were observed for all non PCV7 serotypes, although 
significance was only found for Pn1, Pn7F and Pn19A (Figure 3.10). 
Increases in the proportion of samples achieving ≥ 0.35 µg/mL of at least 
1.5 fold were seen in all non PCV7 serotypes (Figure 3.10).  
No significant difference was noted in GMC and the proportion of results ≥ 
0.35 µg/mL was similar for all serotypes present in PCV7 (Figure 3.10). 
These results demonstrate that increased protection for all extra serotypes 
in PCV13 was achieve with only 1 dose of PCV13 after 12 months of age, 




Figure 3.10: GMC and percentage ≥ 0.35 µg/mL from patients receiving 
3 doses of PCV7 (2009) or 2 doses of PCV7 plus 1 dose of PCV13 
(2012) 
 
The GMC (A) and percentage results ≥ 0.35 µg/mL (B) are shown for each 
serotype for patients who had received either 3 doses of PCV7 (2009) or 2 
doses of PCV7 followed by one dose of PCV13 (2012). Significant 
differences in concentrations are denoted by * (P < 0.05) and ** (P < 0.01).  
These figures show significant increases in GMC for serotypes Pn1, Pn7F 
and Pn19A, at least 1.5 fold increases in the proportion of non PCV7 
serotype results ≥ 0.35 µg/mL, and no adverse impact on any PCV7 






















































3.4.4. Comparison of 3 doses of PCV13 with 2 doses of PCV7 followed 
by 1 dose of PCV13 
In addition, independent t-tests were performed between the results from 
2012 of patients who were eligible to have received 2 doses of PCV7 and 1 
of PCV13 and those who were eligible to have received 3 doses of PCV13. 
No significant difference in concentration was seen for any serotype (data 
not shown), although in general a 10 % higher proportion of results ≥ 0.35 
µg/mL was seen across all serotypes (Figure 3.11). 
This result indicates that, although there is no apparent difference in 
concentrations, protection is more likely to be achieved after 3 doses of 




Figure 3.11: Percentage ≥ 0.35 µg/mL from patients receiving either 2 
doses of PCV7 plus 1 dose of PCV13 or 3 doses of PCV13. 
 
 
The percentage of results with concentration ≥ 0.35 µg/mL for patients 
receiving either 2 doses of PCV7 followed by a booster dose of PCV13 or a 
full 3 dose course of PCV13 are shown for each serotype.  
This figure shows that, in general, approximately 10 % more patients 



























2 doses PCV7, 1 doses PCV13 3 doses PCV13 
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3.4.5. Summary of seroprevalence study 
Comparison of results from 2012 with 2009 show that there has been a 
significant rise in IgG GMC against most of the serotypes present in PCV13 
but not in PCV7 (Pn 1, 5, 6A, 7F, and 19A but not 3) in the target age group 
following introduction of PCV13 in April 2010. In addition the proportion of 
patients with IgG concentrations ≥ 0.35 µg/mL substantially increased for all 
additional serotypes (sections 3.4.1 and 3.4.2). No impact was seen on the 
IgG GMC against serotypes in both vaccines or on the proportion of 
patients with ≥ 0.35 µg/mL (sections 3.4.1 and 3.4.2). 
Further, patients who were expected to have received only one dose of 
PCV13 showed good increases in both IgG GMC and proportion ≥ 0.35 
µg/mL (sections 3.4.3 and 3.4.4). 
These results showed that patients who were expected to receive at least 1 





Streptococcus pneumoniae continues to be a significant global cause of 
pneumonia, septicaemia, meningitis (WHO, 2008). Antibodies against S. 
pneumoniae serotype-specific capsular polysaccharides, acquired naturally 
or by vaccination with PPV23, PCV7, PCV10 or PCV13, protect patients 
from pneumococcal infection and disease (Austrian, 1977; Nielsen et al., 
1993; Black et al., 2000; Vesikari et al., 2009; Snape et al., 2010). Infants, 
young children and the elderly are at increased risk of pneumococcal 
disease but young children do not respond well to plain polysaccharide 
vaccines (Timens et al., 1989; Balmer et al., 2007a). 
Current vaccination strategies rely on eliciting a response to each capsular 
polysaccharide in order to provide protection; in order to increase coverage 
it is necessary to increase the number of PS contained in the vaccine (Kaye 
et al., 2009; Rodgers & Klugman, 2011). In order to circumvent this some 
groups have explored alternative vaccination strategies using surface 
expressed protein or whole cell vaccines with varying degrees of success 
(Miyaji et al., 2013). 
Following introduction of PCV7 a vaccine which is effective in infants, there 
has been a significant decrease in disease caused by vaccine serotypes in 
both the vaccinated age groups (0 to 2 years) and in all other age groups 
(Isaacman et al., 2010; Flasche et al., 2011; Miller et al., 2011a; Fitzwater et 
al., 2012). The mechanism for this broad effect is that the vaccine prevents 
acquisition of vaccine serotypes, preventing the capsular types from being 
transmitted within the infant age group and therefore more widely (Flasche 
et al., 2011). An increase in disease caused by capsular serotypes not 
included in the vaccine, especially Pn19A, has been noted; a phenomenon 
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termed ‘serotype replacement’ (Hanage et al., 2010; Miller et al., 2011a; 
Weinberger et al., 2011). It has, therefore, been necessary to increase the 
number of serotypes included in a paediatric conjugate vaccine to combat 
the serotype replacement (Gladstone et al., 2011). 
Measurement of IgG antibodies against pneumococcal capsular types for 
licensure of vaccines has been undertaken using an ELISA method; 
however, this is time and labour intensive, requires increasingly large 
volumes of sera as more serotypes are tested and is expensive, so 
multiplex bead based assays have been developed as alternatives to the 
ELISA (Wernette et al., 2003; Pickering et al., 2002; Lal et al., 2005; 
Marchese et al., 2009).  
A previously optimised assay in use in this laboratory which tested for 
antibodies against 9 (Lal et al., 2005), and later against 12 (Yaro et al., 
2013), pneumococcal capsular serotypes was optimised and validated to 
include Pn6A. The optimisation included examination of the coating 
concentration of Pn6A Ps, preliminary consistency and stability 
investigations and analysis of cross-reactivity between serotypes and 
resulted in a 2 panel assay testing for antibodies against all 13 capsular 
serotypes.  
The beads used in the assay were MicroPlex® beads. An alternative bead 
type, SeroMAP® beads, which are designed to reduce non-specific binding 
in serological assays (Luminex, 2006) showed no advantage in preliminary 
investigations (data not shown).  
Beads were washed by centrifugation and re-suspension, or by vacuum 
filtration and re-suspension, raising the possibility of bead loss during 
pipetting or of damage to filter plates resulting in leaking wells. An 
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alternative magnetic bead type (MagPlex®, Luminex) may circumvent these 
issues and improve the specificity and signal-to-noise ratio (Luminex, 2012). 
The assay in use in the VEU has not historically had issues with bead loss 
or leaking plates and the noise (background) of the assay is normally low. In 
addition, switching to magnetic beads would require additional equipment 
and assay optimisation and so was not investigated.  
In order to conjugate the PS to the beads a 2 step process is used, firstly 
binding of the PS to PLL then the binding of PLL to the beads (Gray, 1979; 
Pickering et al., 2002; Lal et al., 2005). This process means there is the 
potential for an insufficient amount of binding to take place at either step 
leaving some binding sites, either on the beads or on PLL, available for 
non-specific binding. The quantity of PLL used in the reaction has been 
shown previously to be sufficient to coat the beads and so it was decided 
not to investigate this step (Pickering et al., 2002; Lal et al., 2005).  
Attachment of PS/PLL to beads was performed using carbodiimide 
chemistry utilising EDC and NHS. This chemistry is well established 
although others have noted that it is a complex multistep process which can 
be circumvented by using an alternative linker molecule, 4-(4,6-
dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium (DMTMM), which may 
be simpler than the PLL/EDC/NHS method as it requires only one step 
(Staros et al., 1986; Schlottmann et al., 2006; Farkas et al., 2013). 
However, changing the chemistry of bead conjugation would be a major 
change to the current method in use in the VEU, requiring re-optimisation of 
the method for all serotypes, and as the remit of this project was to optimise 
Pn6A into the current assay method this was not investigated. 
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Measurements were made using Bioplex 100 or 200 devices. These are 
first generation devices which can identify up to 100 regions simultaneously 
(Luminex, 2013). A subsequent generation of equipment, the FlexMAP 3D, 
can measure up to 500 analytes simultaneously and has an increased 
dynamic range (Luminex, 2008). The additional benefits of using this next 
generation equipment would lie in the increased dynamic range, the 
additional capacity for analytes is not required, and this is limited as few of 
the serotypes saturate at the most concentrated curve points.  
In order to generate readings the Bioplex instrument samples each well of 
the plate in sequence, utilising the same needle for each sample. This 
raises the possibility of beads from the previous well(s) being carried over 
into subsequent readings. In order to limit this, the needle is flushed with an 
instrument buffer (sheath fluid, Bio-Rad) when the well contents are ejected. 
In preliminary tests, up to 20 beads, compared to up to 1000 beads 
recovered from the expected region, were carried over in up to 2 
subsequent wells following sampling (data not shown). This may affect the 
variability of results generated and is a disadvantage of this technology 
compared to both the ELISA and ECL assays as these do not involve 
physical sampling of the wells (Wernette et al., 2003; Hanley, 2008; 
Marchese et al., 2009). As part of the validation guidelines carryover is, 
however, anticipated and previous data from the VEU has shown that 
carryover does not have an significant impact on the data produced in the 
assay (data not shown), and so this issue was not of concern in the 
optimisation and validation of the assay (FDA, 2001; EMA, 2011). 
Software used for calculation of standard curve and sample results values 
was Bioplex Manager 4.1.1, the current version available from Bio-Rad is 
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Bioplex Manager 6.1. During the optimisation of the assay conditions this 
newer version of Bioplex Manager, along with xPonent (Luminex), 
Masterplex QT (Miraibio Group, CA) and Statlia (Brendan Technologies, 
Inc., CA) were assessed but none were sufficiently superior in terms of 
standard curve generation, and downstream result management, to warrant 
replacement of old version of Bioplex Manager.  
A Pn6A PS concentration of 1 mg/mL was found to be optimal for preparing 
beads; in contrast, the other PS used to prepare beads for use in the assay 
are prepared using 2 or 3 mg/mL. Other assays, using similar methodology, 
have used PS concentrations from 1 mg/mL to 5 mg/mL in the preparation 
of beads (Pickering et al., 2002; Schlottmann et al., 2006). No advantage 
was identified in using a PS concentration higher than 1 mg/mL for Pn6A in 
the work presented in this thesis, and it may be that optimisation of the 
concentrations used for the other serotypes identifies that they can be 
lowered without impact.  
For coating concentrations less than 1 mg/mL statistical differences were 
seen between QC samples. The 0.1 mg/mL result showed a significant 
difference against only a coating concentration of 2 mg/mL, which had very 
low variability in results, but not any other concentration and it may be that 
low numbers of results available in the different experiments made it difficult 
to properly determine significance (Witt & McGrain, 1985). The 0.01 mg/mL 
results in the same analysis are clear; there was a difference noted against 
all other concentrations except 3 mg/mL (which had a low n) giving 
confidence that the significance was true.  
Samples were selected, following a favourable ethical opinion, for both 
optimisation and validation from samples submitted for clinical testing. 
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Although these samples were anonymised samples are normally submitted 
to the clinical service to ensure determine the immunological status of older 
adults, although some infant sera are submitted, and so the samples used 
are most likely to be from adult samples with naturally acquired antibodies 
or antibodies produced in response to PPV23 vaccination. Naturally 
acquired antibodies are broad spectrum, lower avidity antibodies, whereas 
vaccinated individuals produce serotype-specific, high avidity antibodies 
(Baxendale et al., 2008; Ekstrom et al., 2013). Avidity is an important factor 
in pneumococcal immunity as there is an inverse relationship between 
avidity of antibodies and the concentration required for protection, however, 
antibody binding assays - such as ELISA, bead based and ECL assays – 
rely on avidity and results will give some indication of the strength of 
antibody binding (Usinger & Lucas, 1999; Sun et al., 2001; Ekstrom et al., 
2013). Within the validation it is impossible to identify samples with natural, 
low affinity antibodies or vaccine-related high avidity antibodies, or assess 
the impact on results of the 2 antibody types. 
89-SF was the serum used as the standard curve for assay optimisation 
and validation. This reference serum is well characterised and was the 
WHO approved international standard serum until stocks depleted. A new 
international standard reference serum, 007sp, has been produced and 
characterised (Goldblatt, Plikaytis, et al., 2011). 
89-SF was prepared by pooling serum from a large number of adults who 
had been vaccinated with PPV23 and weight based antibody levels against 
each serotype were determined using an ELISA based method (Quataert et 
al., 1995; Quataert et al., 2004; Goldblatt, Plikaytis, et al., 2011). An ELISA 
method for detection of pneumococcal antibodies has been used since at 
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least 1978, although the current WHO consensus method has undergone 
revisions over time as a significant degree of non specific binding was 
observed due to the presence of CPs in capsular polysaccharide 
preparations, pre-adsorption of sera with CPs alleviates this issue 
(Berntsson et al., 1978; Goldblatt et al., 1992; Wernette et al., 2003). It was 
noted, however, that some non-specific binding remained in the assay, and 
this was alleviated by pre-adsorption of sera with capsular polysaccharide 
from an un-assayed serotype, most commonly Pn22F although other 
capsular PS or CWPS2 – a product derived from the cell wall of a de-
capsulated Pn22F strain - have also been used (Soininen et al., 2000; 
Concepcion & Frasch, 2001; Marchese et al., 2006; Skovsted et al., 2007). 
Interestingly, pre-adsorption of 89-SF with 22F is not recommended in the 
WHO consensus ELISA method as the weight based antibody calculations 
were performed without this step (Quataert et al., 1995; Plikaytis et al., 
2000; Quataert et al., 2004; Poolman et al., 2010). It has been shown that a 
reduction in reported results occurs if 89-SF is pre-adsorbed (Henckaerts et 
al., 2006). 
The minimum test sample dilution used was 1/100, the minimum sample 
dilution accepted in the WHO consensus ELISA was 1/50 (Marchese et al., 
2006). At a 1/50 dilution the assay presented in this thesis would be more 
sensitive at the lower end. During the linearity assessment samples were 
diluted up to 1/800 without indication of any issues as a result of dilution. 
Higher dilutions were not assessed although the assay is used with a 
sample dilution of up to 1/10,000 as samples requiring dilutions at these 
higher factors are highly positive and not regularly required.  
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QC sera were sampled in each assay to give confidence in the assay 
performance in each run. In order for the assay to be acceptable for beads 
prepared using any given serotype the result for the QC sample is 
compared to, and must fall within ± 2 SD of, historical results. Ideally QC 
sera would fall on different points of the curve, giving confidence in the 
performance across the whole curve. In practice this not the case as results 
for beads prepared with some serotypes produce QC results on similar 
parts of the curve (data not shown).  
Both QC and test samples are determined using a single point, in contrast 
to the ELISA which determines results from a serial dilution of QC and 
samples (Wernette et al., 2003). In order for a single point determination to 
be used there must be confidence that the sample, on dilution, has a curve 
parallel to that of the standard sera (Plikaytis et al., 1994). In validating the 
assay both accuracy, in which 1 sample was spiked into different unknown 
sera, and linearity, in which multiple samples were spiked into known IgG 
negative sera, showed no evidence of non-parallelism giving confidence 
that a single point determination is acceptable in this format. 
The LLQ assigned to the assay was 0.1 µg/mL; this value is slightly above 
the concentration of the most dilute accepted standard curve point for the 
serotype with the highest antibody levels present in 89-SF (Pn19A; 
(Quataert et al., 1995; Quataert et al., 2004). It would be possible, with 
further analysis and optimisation, to assign LLQ values lower than this for 
many of the serotypes. The LLQ assigned is below the 0.2 to 0.35 µg/mL 
antibody concentrations that correlate to protection in adults (Henckaerts et 
al., 2006; WHO, 2009). 
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During the optimisation of the assay inhibition analyses observed that both 
serotypes 6A/6B and 19A/19B PS inhibited each other. This was not an 
unexpected result due to the similarities in the structure of these serotypes 
(Grant et al., 2013). In validating specificity of assays the required validation 
method is an inhibition analysis as this shows that the presence of a 
heterologous analyte does not impact on the result generated by the assay 
(FDA, 2001; EMA, 2011). The inhibition analysis performed in the 
optimisation showed that in a 13-plex assay the required level of specificity 
was unlikely to be met for 6A/6B and 19A/19F pairs and so the decision 
was made to split the assay into 2 panels. This decision allowed the 
specificity parameter to be passed for all analytes in the validation of the 
assay. 
Examination of the literature revealed only one other current assay using all 
13 serotypes present in the new vaccine, in which assay all 13 serotypes 
were performed on one plate (Elberse et al., 2010). This study reported that 
increased antibodies against Pn6A were reported after administration of 
PCV7 which they attributed to cross reactive Pn6B antibodies (others have 
noted that cross reactive antibodies may be of low avidity, but that 
antibodies against Pn6A induced by PCV7 are likely to be high avidity)  but 
did not comment on Pn19A/Pn19F cross reactivity nor on the impact of 
cross reactivity on the assay (Elberse et al., 2010; Grant et al., 2013; 
Licciardi et al., 2010). Whilst at high antibody concentrations cross reactivity 
is unlikely to be an issue at low concentrations, especially around the 
correlate of protection, antibodies which are cross reactive against multiple 
serotypes may make a difference between an un-protected or protected 
outcome. This issue will also be important for ECL assays as they are 
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validated, although cross reactive serotypes such as Pn6A/6B  and 
Pn19A/19F have not yet been assayed on the same plate using this method 
(Marchese et al., 2009).  
Further, this issue raises the concern that what is measured in these assays 
is not functional antibody. Although an IgG concentration of ≥ 0.35 µg/mL 
has been proposed as a correlate of protection previous observations have 
noted that naturally occurring high IgG concentrations occur in ageing 
populations alongside an increase in IPD (WHO, 2005; Balmer et al., 
2007b). As the mechanism of defence against pneumococci is 
opsononophagocytosis and ideal surrogate of protection would be 
measured by a standard OPA method able to determine functional antibody 
levels against pneumococcal strains, however this has proved difficult (Hu 
et al., 2005; Balmer et al., 2007b; Wang et al., 2008; Rose et al., 2011). 
Assay validation is required to ensure that the results obtained using an 
assay during a clinical trial can be interpreted in a way that gives confidence 
in the outcome of the trial (Shah et al., 2000; DoH, 2004). Prior to 
performing the validation criteria were assigned to each parameter to 
determine whether a parameter had met the requirements of validation. In 
determining these criteria reference was made to guidelines for validation of 
bioanalytical methods (FDA, 2001; EMA, 2011). In many cases, however, 
the criteria set for the validation of this assay were more stringent than the 
requirements in the guidelines. 
The criteria for all parameters were set so that a minimum 80 % of results 
were to pass the requirements of any given test in order to be validated. 
Within the guidelines it is suggested that a pass rate of 75 % is sufficient for 
validation. In many cases where the 80 % pre-determined criteria was not 
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met in the validation of this assay ≥ 75 % of results did meet the criteria. 
This was true for results from: 
 Accuracy for Pn 19A ± 30 % of median result (77.33 %) and 7F 
within ± 30 % of un-spiked result (76.00 %), 
 Inter operator reproducibility for Pn 23F (78.57 %), 
 Inter operator analyte reproducibility for Pn 1 (78.57 %), 
 Linearity for Pn 4 (78.54 %) and 1 (75.00 %) and 
 Freeze/Thaw stability for Pn 6A (78.54 %). 
For each of these results, although the pre-determined criteria were not 
met, the outcomes for the tests met the minimum requirements of the 
guidelines and were considered to be validated. 
The Pn19A accuracy results within ± 30 % of un-spiked result (54.67 %) did 
not meet the pre-determined criteria, nor were ≥ 75 %. The sample used for 
this test gave very high results, close to the upper limit of quantitation, for 
Pn 19A. The Pn 19A curve also saturates at the top end and as a result 
diluting the high sample produced highly variable results within each of the 
assays performed for the accuracy. This means that the outcome for Pn19A 
in this part of the accuracy validation is most likely due to the sample used 
and not a true reflection of the accuracy of beads prepared using Pn19A. 
The remaining results which did not meet the pre-determined criteria were 
all reproducibility results, except the Pn 3 post-preparative stability, and for 
all these tests the pre-determined criteria were that results from 15 samples 
(across the required range of the curve) should be gained. Within the 
guidelines the minimum requirement is that results should be gained from 3 
test samples (at different concentration levels) for the reproducibility and 
from 2 test samples (low and high) for the stability (FDA, 2001). A minimum 
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of 9 test samples gave results which passed the acceptance criteria for any 
these tests and so, although less than 75 % of results met the criteria, the 
minimum requirements to demonstrate validity were achieved. 
Of interest were the results for the reproducibility parameter for Pn 3 as 
these were unexpectedly variable. Examination of the results shows an 
interesting phenomenon as reproducibility tests for Pn 3 met the pre-
determined criteria when the assay took place on the same day using the 
same standard curve (for the intra assay and inter-operator analyte 
reproducibility) but for other reproducibility tests where data were required 
from multiple assays on different days the outcome was that beads 
prepared using Pn 3 did not meet the criteria. Also, in other parameters the 
results for Pn 3 were obtained from the same assay, except for the replicate 
spiking test where a different method of assessing the closeness of the 
results was used (a range around the median, not % CV).  
Variability for beads prepared using Pn 3 PS may well be due to the 
physical properties of the PS as beads prepared using Pn3 produce the 
lowest MFIs in the standard curve, typically 6,000 to 9,000 MFI at the 
highest standard concentration compared to > 18,000 MFI for beads 
prepared using all other serotypes. This means that for this serotype the 
curve stops well before the maximum point in the dynamic range of the 
instrument and before the curve has reached a plateau. As a result 
relatively small differences in the curve MFI could have a great impact on 
the slope of the curve and may have resulted in higher variability in the 
results from different assays. Also many of the samples with high % CV for 
beads prepared using Pn 3 had low concentration. These samples are likely 
to be from un-immunised patients with low levels of naturally acquired, 
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broad spectrum, low avidity antibody. Whilst this did not appear to be an 
issue for other serotypes it may be that this, coupled with the greater curve 
variability, added to the reduced reproducibility of the assay for this 
serotype. 
As the purpose of this project was to introduce beads prepared using Pn6A 
into the current assay, without assessing the other serotypes prior to 
validation, this was not observed until the validation was performed. It may 
be that this is an issue which cannot be easily solved as it will likely require 
alteration to the method for diluting the standard curve, require more 
standard serum (of which stocks are now depleted) and so require re-
optimisation of the curves for all serotypes. As beads prepared using Pn3 
met the minimum requirements of the guidelines and insufficient time was 
available to properly carry out this optimisation this investigation was not 
performed. 
Accuracy of low samples was not assessed as part of the accuracy 
parameter in validation of the assay, due mainly to the method employed to 
assess accuracy which would be best assessed using a panel of reference 
sera of known concentrations. Such a panel was not available for use in this 
validation as historical samples from a previous multicentre trial only had 
results for 7 of the capsular serotypes tested generated using the ELISA 
(Plikaytis et al., 2000). A new panel was available using 007sp as the 
standard sera with no data available for those samples using 89-SF as the 
standard sera, and again data were generated using the ELISA (Goldblatt, 
Plikaytis, et al., 2011). As a result it was unclear if the results generated as 
part of the validation would be able to match the results generated in these 
studies and so the decision was made to use the replicate spiking method 
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to assess accuracy. A spiking method using low samples would be at risk of 
diluting samples so results are below the curve and so high positive 
samples were used to assess accuracy. Some lower samples were used in 
the linearity validation, although all were above the 0.35 µg/mL threshold, 
and of these samples only Pn 1 results for 1 sample were, on spiking, were 
below 0.35 µg/mL when the un-spiked sample was above. Low end 
reproducibility was also assessed as part of the validation, using samples 
above and below the 0.35 µg/mL, and showed that this assay had good 
reproducibility at the low end indicating that the assay is likely to be 
accurate even around the protective threshold.  
The criteria determined for validating the assay were met or exceeded by 
the majority of serotypes for all, or all but 1, of the tests performed and so it 
is likely that this level of stringency was appropriate for the validation of the 
assay. For some tests, particularly the Pn3 reproducibility, it may be that a 
lower level of stringency, still meeting the minimum requirements of the 
guidelines, was more appropriate. Overall, the entire validation of the assay 
met, and often exceeded, the minimum requirements for validation as set 
out in published guidelines (FDA, 2001; EMA, 2011). 
In 2007 a study was published in which the 9-plex assay was used to 
assess the seroprevalence of antibodies against pneumococci prior to 
introduction of PCV7 (Lal et al., 2005; Balmer et al., 2007b). They observed 
that in general a small rise in GMC levels occurred at around age 1 followed 
by a second rise in GMC around age 20, probably coinciding with 
parenthood and exposure to pneumococci in infants (Balmer et al., 2007b). 
The study also observed that IPD in the elderly increased despite relatively 
high GMCs (Balmer et al., 2007b). 
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There is a great deal of evidence to show that introduction of PCV7 resulted 
in a reduction in disease caused by the vaccine serotypes in both the 
targeted age group (0 to 2 years) and in the wider population (Isaacman et 
al., 2010; Gladstone et al., 2011; Myint et al., 2013; PHE, 2013a). This 
protection of the wider population is a result of the vaccine preventing 
carriage of the vaccine serotype in immunised infants and so preventing the 
exposure of others to the pneumococci by contact with a colonised 
individual, this effect is termed ‘herd protection’ (Weinberger et al., 2008; 
Flasche et al., 2011; Rodrigo et al., 2013). 
In order to broaden coverage of pneumococcal vaccines to cover other 
serotypes in circulation and to combat serotype replacement PCV13 was 
introduced to the UK schedule in 2010. Results from the seroprevalence 
study undertaken here have shown that high GMC levels are maintained for 
the PCV7 serotypes with the introduction of the new vaccine, although 
some significantly lower values were noted (Pn4 and Pn18C) the 
percentage of vaccinees with ≥ 0.35 µg/mL was similar in both groups. This 
is in line with other immunogenicity data reported during the licensure and 
introduction of PCV13 (Kieninger et al., 2010; Weckx et al., 2012). 
Significant increases in GMC were noted for most of the non-PCV7 
serotypes in the 1.00 to 1.99 age group, with only Pn3 failing to make a 
significant response, and this significant increase was continued into the 
2.00 to 2.99 age group for all serotypes except Pn3 and Pn19A. Again 
these results are similar to previous observations (Nunes & Madhi, 2011; 
Miller et al., 2011b). Pn3 is known to be less immunogenic than the other 
serotypes; there is a good response to initial vaccination but failure to make 
a response to the booster dose in most patients, although it is unclear if this 
103 
 
has any clinical significance (Nunes & Madhi, 2011; Poolman & Borrow, 
2011; EMA, 2013).  
Epidemiology in the UK, and in Norway, has noted that the impact of 
PCV13 introduction on IPD caused by the new vaccine serotypes has been 
rapid, reducing in the vaccinated age groups within 1 year of introduction, 
and evidence of herd protection has also been noted 2 years after 
introduction (PHE, 2013a). This epidemiological data shows that the 
increases in GMC and % ≥ 0.35 µg/mL seen in this study have translated 
into reduced disease. 
In general, no difference was noted between the 3.00 to 3.99 age group 
between the 2 years, a significant increase in Pn 5 and 7F results is likely to 
be due to a difference in numbers of results between the groups (2009 had 
100 results and 2012 only 33 in this age group), this result was expected as 
those aged over 3 in 2012 are expected to have been vaccinated prior to 
introduction of PCV13. 
No advantage, in terms of GMC achieved, was noted in patients who 
receive a full three doses of PCV13 compared to those who only received 
PCV13 as a booster. It is known, however, that in infants the risk of IPD is 
higher amongst those aged < 1 year and reduces with age, and so it is likely 
that the doses received at 4 and 8 weeks of age will be important in 
protecting younger infants (Kaye et al., 2009; Ardanuy et al., 2009; Link-
Gelles et al., 2013). 
The seroprevalence study presented here is limited, only a few samples 
from a narrow age range were analysed. The samples were submitted to 
the SEU following consent after collection by clinicians in various regions of 
the UK, the reason for collection and patient history of the samples is 
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unknown, and so it has been assumed that these samples have undergone 
‘normal’ immunisation as per the UK schedule. Also, the number of samples 
in each age band varied considerably (33 to 100 samples), in comparison 
more than 100 samples was used in each of these age bands in previous 
work (Balmer et al., 2007b). Also, older populations are at increased risk of 
IPD and this study was unable to examine seroprevalence of antibodies in 
this group. 
5. Future work 
In order to confirm that the accuracy results for beads prepared using Pn 
19A did not meet the pre-determined validation criteria due to sample 
selection the replicate spiking assay will be repeated for these beads using 
a sample that is on the linear part of the curve, rather than at the extreme of 
the curve. 
Both long-term sample stability and analyte (bead) preparation stability 
experiments will be performed up to one year to demonstrate stability of 
these components after storage up to this point.  
Stocks of 89-SF are depleted, and so a new reference serum, 007sp, has 
been produced and characterised to replace 89-SF (Goldblatt, Plikaytis, et 
al., 2011). As the assay described in this thesis was optimised and 
validated using 89-SF the assay will need to be re-optimised to make the 
change to using 007sp as the reference serum. Further, a partial validation 
will be performed to ensure the new reference serum can be used without 
concern. 
Further work should be carried out to analyse the seroprevalence of 
antibodies in the UK population, Balmer, et al. (2007b) comment that it 
105 
 
would be interesting to follow an age group through life to see changes to 
seroprevalence over time, seroprevalence of samples from older ages may 
give some insight into this question. Also, duration of protection is a 
question that could be assessed for patients immunised with PCV7 using a 
seroprevalence study; how long do protective levels of antibodies last for? 
Data could be examined for vaccines up to 7 years post PCV7 introduction 
in the UK to increase knowledge in this area. 
6. Conclusion 
This thesis has presented the optimisation of beads prepared using Pn6A 
PS and the subsequent validation of a 13-plex assay for detection of 
antibodies to pneumococcal serotypes. While the pre-determined criteria 
were not met for all serotypes in some parameters, the minimum 
requirements as described in published guidelines were met and the assay 
deemed fit for purpose. 
Seroprevalence analysis showed that levels of protection remain similar for 
the PCV7 serotypes following the switch to PCV13 and that GMC levels 
increase significantly for 5/6 of the additional serotypes. Patients who only 
received 1 dose of PCV13 as a booster do not appear to be at a 
disadvantage to those who completed the whole course. 
The assay described in this thesis is a useful tool to examine the 
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Appendix II. Assay Validation: Specificity 
 




Pn4 Pn6B Pn9V Pn14 Pn19A Pn23F MnA MnC 
13-Plex 05 13.89% 155.56% 152.78% 147.22% 133.33% 158.33% 138.89% 133.33% 
13-Plex 08 2.73% 102.19% 98.36% 119.67% 106.01% 120.22% 119.13% 107.65% 
13-Plex 09 6.61% 85.96% 85.15% 113.46% 109.51% 124.94% 85.85% 108.58% 
13-Plex 12 10.42% 114.58% 97.92% 120.83% 93.75% 100.00% 95.83% 87.50% 
13-Plex 18 24.56% 115.79% 106.35% 110.53% 54.39% 100.00% 117.46% 122.81% 
13-Plex 19 2.42% 113.04% 106.76% 97.10% 97.10% 111.11% 113.04% 110.63% 
13-Plex 28 8.62% 70.69% 77.59% 93.10% 77.59% 94.83% 84.48% 100.00% 
13-Plex 39 39.30% 99.13% 112.23% 95.63% 98.25% 103.93% 117.90% 111.79% 
13-Plex 49 22.73% 95.45% 113.64% 104.55% 90.91% 90.91% 109.09% 118.18% 
13-Plex 54 2.48% 111.39% 106.44% 93.07% 95.05% 93.07% 90.10% 96.04% 
Total no. of results 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
10 - - - - - - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
100 - - - - - - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
- 10 10 10 9 10 10 10 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
- 100 100 100 90 100 100 100 
iii 
 






Pn4 Pn6B Pn9V Pn14 Pn19A Pn23F MnA MnC 
13-Plex 05 112.50% 12.50% 110.00% 107.50% 105.00% 100.00% 110.00% 112.50% 
13-Plex 08 106.55% 1.21% 100.24% 119.42% 95.87% 93.20% 108.25% 99.51% 
13-Plex 09 97.52% 1.80% 103.75% 115.92% 114.11% 119.89% 101.58% 107.73% 
13-Plex 19 99.56% 2.18% 124.02% 108.30% 107.42% 95.20% 106.99% 103.49% 
13-Plex 28 117.59% 4.63% 107.41% 114.81% 109.26% 117.59% 110.19% 111.11% 
13-Plex 39 86.49% 45.95% 112.16% 100.68% 104.05% 70.27% 117.57% 117.57% 
13-Plex 42 103.70% 18.52% 111.11% 107.41% 107.41% 88.89% 118.52% 114.81% 
13-Plex 46 115.22% 5.43% 110.87% 113.04% 113.04% 109.78% 114.13% 122.83% 
13-Plex 50 100.00% 3.40% 91.84% 76.19% 100.68% 74.15% 95.24% 95.24% 
13-Plex 54 114.23% 1.87% 105.62% 92.13% 96.25% 79.78% 93.63% 97.38% 
Total no. of results 10 10 10 10 10 10 10 10 
No. of results with 
<50% Recovery with 
homologous 
inhibition 
- 10 - - - - - - 
Percentage of 
sample results with 
<50% Recovery with 
homologous 
inhibition 
- 100 - - - - - - 
No. of results with 
>70% Recovery with 
heterologous 
inhibition 
10 - 10 10 10 10 10 10 
Percentage of 
sample results with 
>70% Recovery with 
heterologous 
inhibition 
100 - 100 100 100 100 100 100 
iv 
 





Pn4 Pn6B Pn9V Pn14 Pn19A Pn23F MnA MnC 
13-Plex 05 116.33% 113.27% 5.10% 106.12% 106.12% 105.10% 113.27% 113.27% 
13-Plex 08 110.11% 103.75% 1.87% 111.99% 95.51% 103.37% 105.62% 101.12% 
13-Plex 09 97.25% 107.14% 12.64% 111.54% 112.09% 115.38% 102.75% 99.45% 
13-Plex 19 106.97% 116.09% 1.34% 102.41% 115.28% 113.94% 113.67% 110.99% 
13-Plex 28 95.79% 77.89% 35.79% 108.42% 75.79% 104.21% 108.42% 109.47% 
13-Plex 39 100.00% 107.14% 17.86% 102.38% 115.48% 104.76% 121.43% 119.05% 
13-Plex 46 107.69% 98.46% 24.62% 110.77% 106.15% 106.15% 104.62% 113.85% 
13-Plex 49 100.00% 96.55% 55.17% 89.66% 86.21% 100.00% 113.79% 120.69% 
13-Plex 50 102.70% 95.95% 6.76% 74.32% 102.70% 82.43% 91.89% 91.89% 
13-Plex 54 115.99% 117.47% 1.86% 96.65% 102.23% 103.35% 94.05% 98.88% 
Total no. of results 10 10 10 10 10 10 10 10 
No. of results with 
<50% Recovery with 
homologous 
inhibition 
- - 9 - - - - - 
Percentage of 
sample results with 
<50% Recovery with 
homologous 
inhibition 
- - 90 - - - - - 
No. of results with 
>70% Recovery with 
heterologous 
inhibition 
10 10 - 10 10 10 10 10 
Percentage of 
sample results with 
>70% Recovery with 
heterologous 
inhibition 
100 100 - 100 100 100 100 100 
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Pn4 Pn6B Pn9V Pn14 Pn19A Pn23F MnA MnC 
13-Plex 05 113.79% 112.23% 111.29% 1.57% 106.58% 104.70% 108.15% 120.06% 
13-Plex 08 102.56% 100.00% 98.60% 2.33% 97.67% 101.86% 104.65% 99.07% 
13-Plex 28 116.51% 111.49% 105.45% 4.01% 104.97% 114.42% 107.05% 105.61% 
13-Plex 29 107.69% 94.87% 102.56% 6.41% 97.44% 102.56% 105.13% 98.72% 
13-Plex 32 109.09% 106.82% 97.73% 25.00% 111.36% 111.36% 109.09% 118.18% 
13-Plex 39 97.92% 110.07% 112.15% 4.51% 111.81% 104.17% 119.44% 114.58% 
13-Plex 46 111.18% 99.41% 108.24% 12.35% 107.06% 112.94% 111.76% 114.12% 
13-Plex 49 100.00% 100.00% 100.00% 31.25% 93.75% 100.00% 112.50% 125.00% 
13-Plex 50 104.21% 106.32% 92.63% 5.26% 104.21% 85.26% 94.74% 93.68% 
13-Plex 54 112.41% 118.44% 106.03% 1.77% 99.29% 98.58% 91.84% 96.10% 
Total no. of results 10 10 10 10 10 10 10 10 
No. of results with 
<50% Recovery with 
homologous 
inhibition 
- - - 10 - - - - 
Percentage of 
sample results with 
<50% Recovery with 
homologous 
inhibition 
- - - 100 - - - - 
No. of results with 
>70% Recovery with 
heterologous 
inhibition 
10 10 10 - 10 10 10 10 
Percentage of 
sample results with 
>70% Recovery with 
heterologous 
inhibition 
100 100 100 - 100 100 100 100 
vi 
 




Pn4 Pn6B Pn9V Pn14 Pn19A Pn23F MnA MnC 
13-Plex 05 153.03% 164.77% 133.66% 137.18% 0.98% 139.33% 145.40% 114.87% 
13-Plex 08 99.18% 99.45% 97.16% 101.26% 0.55% 100.11% 98.74% 95.19% 
13-Plex 09 91.98% 100.00% 98.85% 108.40% 11.83% 108.02% 104.20% 103.05% 
13-Plex 19 104.64% 111.26% 102.65% 98.01% 6.62% 106.62% 109.27% 106.62% 
13-Plex 29 97.37% 92.11% 92.11% 102.63% 13.16% 100.00% 105.26% 89.47% 
13-Plex 37 103.92% 92.16% 88.24% 100.00% 47.06% 94.12% 100.00% 109.80% 
13-Plex 39 93.77% 110.28% 125.86% 105.61% 36.45% 101.87% 129.60% 133.64% 
13-Plex 49 98.07% 101.50% 101.93% 100.00% 10.30% 102.15% 116.95% 123.61% 
13-Plex 54 100.96% 112.50% 100.96% 91.35% 25.00% 96.15% 93.27% 102.88% 
13-Plex 58 100.00% 105.13% 107.69% 12.82% 12.82% 100.00% 112.82% 105.13% 
Total no. of results 10 10 10 10 10 10 10 10 
No. of results with 
<50% Recovery with 
homologous 
inhibition 
- - - - 10 - - - 
Percentage of 
sample results with 
<50% Recovery with 
homologous 
inhibition 
- - - - 100 - - - 
No. of results with 
>70% Recovery with 
heterologous 
inhibition 
10 10 10 9 - 10 10 10 
Percentage of 
sample results with 
>70% Recovery with 
heterologous 
inhibition 
100 100 100 90 - 100 100 100 
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Pn4 Pn6B Pn9V Pn14 Pn19A Pn23F MnA MnC 
13-Plex 05 117.95% 85.47% 105.13% 102.14% 91.03% 2.14% 111.97% 128.21% 
13-Plex 08 123.68% 97.37% 107.89% 126.32% 115.79% 13.16% 121.05% 121.05% 
13-Plex 09 113.18% 82.17% 89.15% 120.16% 121.71% 17.83% 91.47% 117.05% 
13-Plex 12 122.07% 87.59% 115.17% 127.93% 117.59% 10.00% 104.48% 98.62% 
13-Plex 18 81.65% 43.58% 98.17% 80.73% 94.04% 5.05% 99.08% 94.50% 
13-Plex 19 106.32% 87.36% 126.95% 114.31% 107.62% 0.93% 111.90% 106.13% 
13-Plex 46 74.14% 65.52% 67.24% 75.86% 75.86% 8.62% 67.24% 79.31% 
13-Plex 54 111.33% 82.44% 103.11% 94.22% 102.89% 3.78% 92.89% 94.44% 
13-Plex 58 94.12% 78.43% 111.76% 111.76% 94.12% 29.41% 103.92% 90.20% 
13-Plex 78 101.52% 98.48% 102.70% 107.76% 119.90% 8.60% 114.84% 114.00% 
Total no. of results 10 10 10 10 10 10 10 10 
No. of results with 
<50% Recovery with 
homologous 
inhibition 
- - - - - 10 - - 
Percentage of 
sample results with 
<50% Recovery with 
homologous 
inhibition 
- - - - - 100 - - 
No. of results with 
>70% Recovery with 
heterologous 
inhibition 
10 8 9 10 10 - 9 10 
Percentage of 
sample results with 
>70% Recovery with 
heterologous 
inhibition 
100 80 90 100 100 - 90 100 
viii 
 





Pn1 Pn3 Pn5 Pn6A Pn7F Pn18C Pn19F MnA MnC 
13-Plex 10 35.71% 92.86% 85.71% 92.86% 92.86% 92.86% 114.29% 92.86% 85.71% 
13-Plex 12 1.88% 125.86% 124.80% 134.04% 111.62% 112.03% 126.84% 108.10% 115.88% 
13-Plex 16 4.95% 102.64% 90.76% 105.45% 105.12% 98.84% 110.73% 106.11% 114.19% 
13-Plex 18 27.78% 105.56% 161.11% 105.56% 122.22% 94.44% 97.22% 102.78% 122.22% 
13-Plex 37 86.11% 108.33% 127.78% 116.67% 119.44% 111.11% 111.11% 116.67% 97.22% 
13-Plex 39 54.55% 99.24% 95.45% 88.64% 93.18% 96.97% 99.24% 92.42% 102.27% 
13-Plex 42 33.99% 97.80% 104.16% 100.24% 97.07% 97.80% 98.29% 95.84% 106.60% 
13-Plex 46 31.50% 108.06% 118.32% 108.06% 119.78% 127.84% 137.36% 121.61% 106.59% 
13-Plex 50 24.00% 97.33% 104.67% 98.67% 116.00% 112.67% 71.33% 66.67% 67.33% 
13-Plex 54 33.52% 106.82% 103.4 % 102.27% 157.39% 157.39% 159.66% 148.86% 117.61% 
Total no. of results 10 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
8 - - - - - - - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
80 - - - - - - - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
- 10 10 10 10 10 10 9 9 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
- 100 100 100 100 100 100 90 90 
ix 
 







Pn1 Pn3 Pn5 Pn6A Pn7F Pn18C Pn19F MnA MnC 
13-Plex 08 102.96% 1.64% 83.09% 97.21% 94.42% 88.51% 92.61% 89.82% 75.37% 
13-Plex 10 108.93% 8.93% 96.43% 103.57% 101.79% 96.43% 107.14% 96.43% 96.43% 
13-Plex 12 102.63% 2.19% 104.39% 103.07% 109.21% 110.53% 112.28% 124.56% 103.07% 
13-Plex 27 104.76% 7.94% 109.52% 87.30% 119.05% 114.29% 103.17% 103.17% 115.87% 
13-Plex 37 97.12% 12.95% 116.55% 110.79% 117.99% 120.86% 112.23% 105.04% 89.21% 
13-Plex 39 87.50% 35.42% 104.17% 97.92% 100.00% 102.08% 95.83% 91.67% 97.92% 
13-Plex 40 127.27% 9.09% 120.00% 130.91% 141.82% 130.91% 90.91% 96.36% 136.36% 
13-Plex 42 102.09% 34.84% 110.80% 100.00% 97.91% 103.83% 101.05% 99.30% 108.01% 
13-Plex 46 147.01% 6.72% 109.33% 96.64% 141.98% 154.10% 141.79% 126.68% 97.76% 
13-Plex 49 90.32% 6.45% 93.55% 90.32% 103.23% 87.10% 96.77% 87.10% 93.55% 
Total no. of results 10 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
- 10 - - - - - - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
- 100 - - - - - - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
10 - 10 10 10 10 10 10 10 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
100 - 100 100 100 100 100 100 100 
x 
 







Pn1 Pn3 Pn5 Pn6A Pn7F Pn18C Pn19F MnA MnC 
13-Plex 08 102.73% 103.64% 1.14% 96.36% 108.64% 90.23% 93.86% 94.55% 90.00% 
13-Plex 12 108.00% 109.45% 5.45% 116.00% 102.91% 112.73% 111.64% 103.27% 102.55% 
13-Plex 18 97.74% 112.78% 3.76% 106.02% 120.30% 98.50% 109.02% 106.02% 116.54% 
13-Plex 39 80.00% 98.95% 73.68% 88.42% 98.95% 94.74% 98.95% 98.95% 103.16% 
13-Plex 42 101.89% 100.94% 4.72% 96.23% 98.11% 98.11% 97.17% 96.23% 97.17% 
13-Plex 43 117.74% 103.23% 16.13% 103.23% 114.52% 100.00% 129.03% 109.68% 96.77% 
13-Plex 46 107.04% 102.82% 18.31% 104.23% 114.08% 114.08% 130.99% 121.13% 105.63% 
13-Plex 49 78.85% 84.62% 34.62% 82.69% 90.38% 80.77% 82.69% 80.77% 84.62% 
13-Plex 50 104.11% 96.21% 2.37% 99.84% 120.54% 112.95% 61.61% 58.77% 60.35% 
13-Plex 54 101.47% 111.03% 8.09% 102.21% 159.56% 166.91% 168.38% 157.35% 161.03% 
Total no. of results 10 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
- - 9 - - - - - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
- - 90 - - - - - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
10 10 - 10 10 10 9 9 9 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
100 100 - 100 100 100 90 90 90 
xi 
 







Pn1 Pn3 Pn5 Pn6A Pn7F Pn18C Pn19F MnA MnC 
13-Plex 08 103.31% 101.93% 89.24% 2.76% 107.45% 90.21% 93.93% 96.69% 89.24% 
13-Plex 12 100.00% 109.09% 100.00% 45.45% 100.00% 109.09% 109.09% 100.00% 109.09% 
13-Plex 18 93.64% 110.00% 180.91% 4.55% 120.91% 96.36% 110.91% 106.36% 120.91% 
13-Plex 39 79.17% 98.21% 94.64% 76.79% 96.43% 94.05% 97.62% 95.83% 98.21% 
13-Plex 40 85.71% 128.57% 92.86% 17.86% 96.43% 85.71% 92.86% 89.29% 135.71% 
13-Plex 42 106.58% 104.61% 115.13% 6.58% 102.63% 103.29% 100.00% 103.29% 102.63% 
13-Plex 43 118.75% 103.13% 109.38% 21.88% 112.50% 96.88% 131.25% 109.38% 100.00% 
13-Plex 46 100.56% 101.11% 101.11% 11.11% 108.89% 113.33% 130.00% 112.78% 98.89% 
13-Plex 50 101.06% 92.61% 103.69% 1.32% 111.08% 106.60% 66.49% 62.53% 64.91% 
13-Plex 54 100.00% 106.76% 104.05% 12.16% 155.41% 163.51% 160.81% 155.41% 144.59% 
Total no. of results 10 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
- - - 9 - - - - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
- - - 90 - - - - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
10 10 10 - 10 10 9 9 9 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
100 100 100 - 100 100 90 90 90 
xii 
 






Pn1 Pn3 Pn5 Pn6A Pn7F Pn18C Pn19F MnA MnC 
13-Plex 08 106.94% 112.15% 96.18% 103.47% 4.17% 98.96% 93.75% 100.35% 88.89% 
13-Plex 10 95.58% 93.81% 85.84% 95.58% 14.16% 92.92% 102.65% 92.92% 95.58% 
13-Plex 12 123.40% 112.77% 110.64% 104.26% 34.04% 114.89% 110.64% 112.77% 110.64% 
13-Plex 18 95.51% 107.87% 133.71% 95.51% 15.73% 96.63% 104.49% 104.49% 114.61% 
13-Plex 37 100.00% 91.43% 102.86% 91.43% 68.57% 82.86% 97.14% 105.71% 91.43% 
13-Plex 39 89.33% 102.67% 103.33% 89.33% 50.00% 99.33% 100.00% 100.00% 104.00% 
13-Plex 40 98.25% 119.30% 94.74% 84.21% 40.35% 82.46% 94.74% 96.49% 124.56% 
13-Plex 42 109.97% 95.95% 110.59% 102.18% 15.89% 101.25% 102.80% 99.07% 101.25% 
13-Plex 50 94.70% 96.97% 100.00% 100.76% 9.85% 106.06% 79.55% 75.00% 75.00% 
13-Plex 54 103.56% 110.44% 102.00% 101.33% 8.67% 163.11% 157.78% 142.00% 122.44% 
Total no. of results 10 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
- - - - 8 - - - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
- - - - 80 - - - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
10 10 10 10 - 10 10 10 10 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
100 100 100 100 - 100 100 100 100 
xiii 
 







Pn1 Pn3 Pn5 Pn6A Pn7F Pn18C Pn19F MnA MnC 
13-Plex 10 101.49% 97.01% 53.73% 98.51% 95.52% 28.36% 100.00% 94.03% 95.52% 
13-Plex 12 106.94% 105.56% 74.31% 113.19% 100.00% 16.67% 100.69% 104.17% 105.56% 
13-Plex 18 97.22% 97.22% 37.50% 84.72% 108.33% 6.94% 44.44% 95.83% 93.06% 
13-Plex 39 82.81% 98.44% 78.13% 89.06% 98.44% 65.63% 101.56% 96.88% 104.69% 
13-Plex 40 116.77% 132.30% 84.16% 120.50% 124.22% 1.55% 100.00% 102.48% 127.02% 
13-Plex 42 100.77% 104.62% 73.08% 97.69% 103.08% 5.38% 93.08% 98.46% 101.54% 
13-Plex 46 113.66% 112.42% 107.45% 111.80% 126.09% 10.56% 138.51% 126.71% 104.97% 
13-Plex 49 79.62% 82.80% 84.08% 86.62% 95.54% 29.30% 91.72% 82.17% 82.17% 
13-Plex 50 104.11% 96.58% 82.19% 104.79% 117.81% 8.90% 68.49% 67.12% 69.18% 
13-Plex 54 100.00% 106.52% 73.91% 100.00% 147.83% 15.22% 145.65% 143.48% 136.96% 
Total no. of results 10 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
- - - - - 9 - - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
- - - - - 90 - - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
10 10 8 10 10 - 8 9 9 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
100 100 80 100 100 - 80 90 90 
xiv 
 






Pn1 Pn3 Pn5 Pn6A Pn7F Pn18C Pn19F MnA MnC 
13-Plex 08 110.12% 100.86% 85.25% 100.17% 108.40% 93.14% 1.72% 94.34% 90.39% 
13-Plex 12 107.59% 115.19% 108.86% 121.52% 106.33% 117.72% 13.92% 113.92% 112.66% 
13-Plex 18 97.02% 115.59% 189.67% 102.80% 129.25% 101.23% 0.88% 109.81% 120.49% 
13-Plex 27 109.52% 100.00% 114.29% 90.48% 109.52% 109.52% 23.81% 104.76% 123.81% 
13-Plex 37 98.73% 101.27% 103.80% 105.06% 110.13% 102.53% 20.25% 105.06% 91.14% 
13-Plex 42 104.31% 102.01% 106.90% 102.87% 100.57% 100.57% 11.21% 94.54% 100.86% 
13-Plex 43 113.95% 102.33% 120.93% 106.98% 111.63% 93.02% 34.88% 127.91% 100.00% 
13-Plex 49 69.09% 78.18% 67.27% 74.55% 80.00% 70.91% 58.18% 69.09% 76.36% 
13-Plex 50 101.71% 96.83% 87.32% 101.22% 112.44% 107.32% 2.44% 67.32% 70.49% 
13-Plex 54 96.85% 104.50% 97.75% 100.90% 153.15% 159.46% 18.92% 145.50% 105.86% 
Total no. of results 10 10 10 10 10 10 10 10 10 
No. of results with < 
50 % Recovery with 
homologous 
inhibition 
- - - - - - 9 - - 
Percentage of 
sample results with 
< 50 % Recovery 
with homologous 
inhibition 
- - - - - - 90 - - 
No. of results with > 
70 % Recovery with 
heterologous 
inhibition 
9 10 9 10 10 10 - 8 10 
Percentage of 
sample results with 
> 70 % Recovery 
with heterologous 
inhibition 
90 100 90 100 100 100 - 80 100 
xv 
 






Result -30% +30% 
2.56 1.79 3.33 
Negative sample Neat 
Spiked result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 2.38 2.37 1.72 
13-Plex 67 0.05 1.86 2.42 3.06 
13-Plex 70 0.05 2.13 2.38 2.60 
13-Plex 74 0.05 1.75 2.36 2.92 
13-Plex 76 0.05 2.90 2.40 3.03 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 13 




Result -30% +30% 
3.64 2.55 4.73 
Negative sample Neat 
Spiked result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 3.12 2.15 3.54 
13-Plex 67 0.05 3.68 2.66 4.04 
13-Plex 70 0.05 3.79 2.73 3.48 
13-Plex 74 0.05 3.72 2.60 2.64 
13-Plex 76 0.05 3.59 2.90 3.20 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 14 




Result -30% +30% 
1.78 1.25 2.31 
Negative sample Neat 
Spiked result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 1.50 1.80 2.02 
13-Plex 67 0.05 1.78 1.84 1.89 
13-Plex 70 0.05 1.59 1.64 1.75 
13-Plex 74 0.05 1.40 1.75 1.80 
13-Plex 76 0.05 1.51 1.73 1.81 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 




Result -30% +30% 
3.23 2.26 4.20 
Negative sample Neat 
Spiked result adjusted for 
dilution factor 





Appendix II-14: Spiking results for beads prepared using panel A 
serotypes (continued) 
 
13-Plex 64 0.05 2.74 3.10 3.69 
13-Plex 67 0.05 3.18 3.39 3.50 
13-Plex 70 0.05 2.88 3.03 3.12 
13-Plex 74 0.05 2.59 3.23 3.45 
13-Plex 76 0.05 2.78 3.22 3.29 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 13 




Result -30% +30% 
18.24 12.77 23.71 
Negative sample Neat 
Spiked result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 19.51 13.95 16.87 
13-Plex 67 0.05 17.94 10.86 15.09 
13-Plex 70 0.05 16.03 13.95 17.05 
13-Plex 74 0.05 16.85 11.70 14.38 
13-Plex 76 0.05 18.13 15.28 15.97 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 13 




Result -30% +30% 
4.78 3.35 6.21 
Negative sample Neat 
Spiked result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 4.11 4.33 4.75 
13-Plex 67 0.05 4.69 5.18 5.67 
13-Plex 70 0.05 4.42 4.56 4.35 
13-Plex 74 0.05 4.52 5.22 5.69 
13-Plex 76 0.05 4.30 4.57 5.84 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 











Result -30% +30% 
3.00 2.10 3.90 
Negative sample Neat 
Spiked Result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 2.73 2.72 3.04 
13-Plex 67 0.05 3.02 3.07 3.29 
13-Plex 70 0.05 2.47 2.64 2.73 
13-Plex 74 0.05 2.83 3.06 3.10 
13-Plex 76 0.05 2.70 2.67 3.32 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 




Result -30% +30% 
2.48 1.74 3.22 
Negative sample Neat 
Spiked Result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 2.17 2.44 2.79 
13-Plex 67 0.05 2.55 2.50 2.93 
13-Plex 70 0.05 2.09 2.18 2.34 
13-Plex 74 0.05 2.40 2.43 2.71 
13-Plex 76 0.05 2.24 2.34 2.94 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 




Result -30% +30% 
3.31 2.32 4.30 
Negative sample Neat 
Spiked Result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 3.12 3.28 3.92 
13-Plex 67 0.05 3.50 3.67 4.28 
13-Plex 70 0.05 2.80 3.18 3.60 
13-Plex 74 0.05 3.17 3.54 4.04 
13-Plex 76 0.05 3.16 3.28 4.29 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 




Result -30% +30% 
10.02 7.01 13.03 
Negative sample Neat 
Spiked Result adjusted for 
dilution factor 
1/2 1/4 1/8 









13-Plex 67 0.05 10.01 9.72 10.96 
13-Plex 70 0.05 7.78 8.45 9.31 
13-Plex 74 0.05 9.19 9.23 10.11 
13-Plex 76 0.05 8.82 8.64 10.68 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 




Result -30% +30% 
1.13 0.79 1.47 
Negative sample Neat 
Spiked Result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 1.01 1.34 1.35 
13-Plex 67 0.05 1.03 1.13 1.30 
13-Plex 70 0.05 1.09 1.35 1.58 
13-Plex 74 0.05 1.00 1.26 1.24 
13-Plex 76 0.05 1.10 1.04 1.34 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 14 




Result -30% +30% 
2.71 1.90 3.52 
Negative sample Neat 
Spiked Result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 2.29 2.35 2.82 
13-Plex 67 0.05 2.60 2.55 3.09 
13-Plex 70 0.05 2.08 2.39 2.48 
13-Plex 74 0.05 2.51 2.54 2.75 
13-Plex 76 0.05 2.34 2.32 2.99 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 




Result -30% +30% 
5.49 3.84 7.14 
Negative sample Neat 
Spiked Result adjusted for 
dilution factor 
1/2 1/4 1/8 
13-Plex 64 0.05 5.33 5.46 6.64 
13-Plex 67 0.05 4.97 5.68 5.96 
13-Plex 70 0.05 5.19 5.46 6.52 
13-Plex 74 0.05 5.31 5.89 6.66 
13-Plex 76 0.05 5.30 5.87 6.68 
Total number or results 15 
Number of results within ± 30 % of neat positive sample 15 





Appendix III. Assay Validation: Accuracy 
 







Positive sample Spiked Result adjusted 
for dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 64 
1 0.05 2.56 1.79 3.33 2.38 2.37 1.72 
2 0.05 2.06 1.44 2.68 2.02 1.88 1.71 
3 0.05 2.27 1.59 2.95 2.22 2.33 2.48 
4 0.05 1.98 1.39 2.57 1.84 1.77 1.81 
5 0.05 1.78 1.25 2.31 1.75 1.72 1.87 
Median 
Result 2.02 1.88 1.81 
- 30 % 1.41 1.32 1.27 
+ 30 % 2.63 2.44 2.35 
13-Plex 67 
1 0.05 2.56 1.79 3.33 1.86 2.42 3.06 
2 0.05 2.06 1.44 2.68 1.95 2.00 2.78 
3 0.05 2.27 1.59 2.95 1.99 2.25 2.32 
4 0.05 1.98 1.39 2.57 1.74 1.91 1.61 
5 0.05 1.78 1.25 2.31 2.08 2.15 2.43 
Median 
Result 1.95 2.15 2.43 
- 30 % 1.37 1.51 1.70 
+ 30 % 2.54 2.80 3.16 
13-Plex 70 
1 0.05 2.56 1.79 3.33 2.13 2.38 2.60 
2 0.05 2.06 1.44 2.68 2.00 2.09 2.74 
3 0.05 2.27 1.59 2.95 2.11 2.20 2.51 
4 0.05 1.98 1.39 2.57 1.82 1.85 1.97 
5 0.05 1.78 1.25 2.31 1.92 1.88 2.11 
Median 
Result 2.00 2.09 2.51 
- 30 % 1.40 1.46 1.76 
+ 30 % 2.60 2.72 3.26 
13-Plex 74 
1 0.05 2.56 1.79 3.33 1.75 2.36 2.92 
2 0.05 2.06 1.44 2.68 2.24 1.88 2.78 
3 0.05 2.27 1.59 2.95 1.96 2.28 2.41 
4 0.05 1.98 1.39 2.57 1.71 1.68 1.55 
5 0.05 1.78 1.25 2.31 1.94 1.82 2.30 
Median 
Result 1.94 1.88 2.41 
- 30 % 1.36 1.32 1.69 
+ 30 % 2.52 2.44 3.13 
13-Plex 76 
1 0.05 2.56 1.79 3.33 2.90 2.40 3.03 
2 0.05 2.06 1.44 2.68 1.60 1.94 2.66 
3 0.05 2.27 1.59 2.95 2.12 2.18 2.61 
4 0.05 1.98 1.39 2.57 1.56 1.65 1.86 
5 0.05 1.78 1.25 2.31 2.39 2.24 2.55 
Median 
Result 2.12 2.18 2.61 
- 30 % 1.48 1.53 1.83 
+ 30 % 2.76 2.83 3.39 
Total number of results 75 
Number of results within ± 30 % of neat positive 67 
Percentage of results within ± 30 % of neat positive 89.33 % 
Number of results within ± 30 % of median 71 













Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 3.64 2.55 4.73 3.12 2.15 3.54 
2 0.05 4.71 3.30 6.12 4.13 3.96 2.92 
3 0.05 3.59 2.51 4.67 3.25 3.08 3.89 
4 0.05 4.01 2.81 5.21 3.06 2.99 3.25 
5 0.05 3.67 2.57 4.77 3.67 3.29 3.52 
Median 
Result 3.25 3.08 3.52 
- 30 % 2.28 2.16 2.46 
+ 30% 4.23 4.00 4.58 
13-Plex 
67 
1 0.05 3.64 2.55 4.73 3.68 2.66 4.04 
2 0.05 4.71 3.30 6.12 3.19 3.93 5.07 
3 0.05 3.59 2.51 4.67 3.65 3.33 4.74 
4 0.05 4.01 2.81 5.21 3.12 3.32 3.03 
5 0.05 3.67 2.57 4.77 4.57 4.18 4.41 
Median 
Result 3.65 3.33 4.41 
- 30 % 2.56 2.33 3.09 
+ 30% 4.75 4.33 5.73 
13-Plex 
70 
1 0.05 3.64 2.55 4.73 3.79 2.73 3.48 
2 0.05 4.71 3.30 6.12 3.59 4.05 4.22 
3 0.05 3.59 2.51 4.67 3.42 3.72 4.67 
4 0.05 4.01 2.81 5.21 3.34 3.29 3.53 
5 0.05 3.67 2.57 4.77 4.08 3.62 4.06 
Median 
Result 3.59 3.62 4.06 
- 30 % 2.51 2.53 2.84 
+ 30 % 4.67 4.71 5.28 
13-Plex 
74 
1 0.05 3.64 2.55 4.73 3.72 2.60 2.64 
2 0.05 4.71 3.30 6.12 3.04 4.03 5.41 
3 0.05 3.59 2.51 4.67 3.85 3.22 5.04 
4 0.05 4.01 2.81 5.21 3.05 2.97 3.16 
5 0.05 3.67 2.57 4.77 4.18 3.62 4.43 
Median 
Result 3.72 3.22 4.43 
- 30 % 2.60 2.25 3.10 
+ 30 % 4.84 4.19 5.76 
13-Plex 
76 
1 0.05 3.64 2.55 4.73 3.59 2.90 3.20 
2 0.05 4.71 3.30 6.12 5.12 4.06 5.22 
3 0.05 3.59 2.51 4.67 3.04 3.32 4.83 
4 0.05 4.01 2.81 5.21 2.68 2.90 3.18 
5 0.05 3.67 2.57 4.77 5.03 4.29 4.63 
Median 
Result 3.59 3.32 4.63 
- 30 % 2.51 2.32 3.24 
+ 30 % 4.67 4.32 6.02 
Total number of results 75 
Number of results within ± 30 % of neat positive 65 
Percentage of results within ± 30 % of neat positive 86.67 % 
Number of results within ± 30 % of median 68 












Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 1.78 1.25 2.31 1.50 1.80 2.02 
2 0.05 1.96 1.37 2.55 1.69 1.62 1.99 
3 0.05 1.48 1.04 1.92 1.77 1.92 2.16 
4 0.05 2.09 1.46 2.72 1.86 1.57 2.14 
5 0.05 1.88 1.32 2.44 1.59 1.39 2.09 
Median 
Result 1.69 1.62 2.09 
- 30 % 1.18 1.13 1.46 
+ 30 % 2.20 2.11 2.72 
13-Plex 
67 
1 0.05 1.78 1.25 2.31 1.78 1.84 1.89 
2 0.05 1.96 1.37 2.55 1.86 1.86 1.95 
3 0.05 1.48 1.04 1.92 1.51 1.85 1.88 
4 0.05 2.09 1.46 2.72 2.82 - 1.96 
5 0.05 1.88 1.32 2.44 2.82 - 2.26 
Median 
Result 1.86 1.85 1.95 
- 30 % 1.30 1.30 1.37 
+ 30 % 2.42 2.41 2.54 
13-Plex 
70 
1 0.05 1.78 1.25 2.31 1.59 1.64 1.75 
2 0.05 1.96 1.37 2.55 1.73 1.65 1.68 
3 0.05 1.48 1.04 1.92 1.71 1.86 2.16 
4 0.05 2.09 1.46 2.72 1.57 1.66 1.93 
5 0.05 1.88 1.32 2.44 1.62 1.70 1.87 
Median 
Result 1.62 1.66 1.87 
- 30 % 1.13 1.16 1.31 
+ 30 % 2.11 2.16 2.43 
13-Plex 
74 
1 0.05 1.78 1.25 2.31 1.40 1.75 1.80 
2 0.05 1.96 1.37 2.55 1.66 1.36 1.84 
3 0.05 1.48 1.04 1.92 1.71 1.69 2.18 
4 0.05 2.09 1.46 2.72 1.77 1.72 2.25 
5 0.05 1.88 1.32 2.44 1.61 1.67 2.00 
Median 
Result 1.66 1.69 2.00 
- 30 % 1.16 1.18 1.40 
+ 30 % 2.16 2.20 2.60 
13-Plex 
76 
1 0.05 1.78 1.25 2.31 1.51 1.73 1.81 
2 0.05 1.96 1.37 2.55 1.55 1.79 1.89 
3 0.05 1.48 1.04 1.92 1.66 1.61 2.01 
4 0.05 2.09 1.46 2.72 1.59 1.45 2.31 
5 0.05 1.88 1.32 2.44 1.66 1.54 1.74 
Median 
Result 1.59 1.61 1.89 
- 30 % 1.11 1.13 1.32 
+ 30 % 2.07 2.09 2.46 
Total number of results 73 
Number of results within ± 30% of neat positive 65 
Percentage of results within ± 30% of neat positive 89.04 % 
Number of results within ± 30% of median 71 












Positive sample Spiked Result adjusted 
for dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 64 
025 0.05 3.23 2.26 4.20 2.74 3.10 3.69 
026 0.05 3.54 2.48 4.60 2.86 2.71 3.06 
027 0.05 3.11 2.18 4.04 3.44 3.77 4.14 
028 0.05 3.66 2.56 4.76 3.15 2.79 3.52 
029 0.05 3.13 2.19 4.07 2.51 2.18 3.69 
Median 
Result 2.86 2.79 3.69 
- 30 % 2.00 1.95 2.58 
+ 30 % 3.72 3.63 4.80 
13-Plex 67 
025 0.05 3.23 2.26 4.20 3.18 3.39 3.50 
026 0.05 3.54 2.48 4.60 3.23 2.95 3.23 
027 0.05 3.11 2.18 4.04 2.97 3.77 3.85 
028 0.05 3.66 2.56 4.76 5.21 - 3.23 
029 0.05 3.13 2.19 4.07 4.48 - 3.48 
Median 
Result 3.23 3.39 3.48 
-30 % 2.26 2.37 2.44 
+ 30 % 4.20 4.41 4.52 
13-Plex 70 
025 0.05 3.23 2.26 4.20 2.88 3.03 3.12 
026 0.05 3.54 2.48 4.60 3.18 2.75 2.58 
027 0.05 3.11 2.18 4.04 3.39 3.62 3.83 
028 0.05 3.66 2.56 4.76 2.81 2.65 3.27 
029 0.05 3.13 2.19 4.07 2.68 2.58 2.98 
Median 
Result 2.88 2.75 3.12 
- 30 % 2.02 1.93 2.18 
+ 30 % 3.74 3.58 4.06 
13-Plex 74 
025 0.05 3.23 2.26 4.20 2.59 3.23 3.45 
026 0.05 3.54 2.48 4.60 2.97 2.35 3.31 
027 0.05 3.11 2.18 4.04 3.37 3.28 4.30 
028 0.05 3.66 2.56 4.76 3.22 3.04 3.73 
029 0.05 3.13 2.19 4.07 2.75 2.79 3.36 
Median 
Result 2.97 3.04 3.45 
- 30 % 2.08 2.13 2.42 
+ 30 % 3.86 3.95 4.49 
13-Plex 76 
025 0.05 3.23 2.26 4.20 2.78 3.22 3.29 
026 0.05 3.54 2.48 4.60 2.82 2.83 3.10 
027 0.05 3.11 2.18 4.04 3.22 3.10 3.68 
028 0.05 3.66 2.56 4.76 2.74 2.25 3.90 
029 0.05 3.13 2.19 4.07 2.61 2.35 2.84 
Median 
Result 2.78 2.83 3.29 
- 30 % 1.95 1.98 2.30 
+ 30 % 3.61 3.68 4.28 
Total number of results 73 
Number of results within ± 30 % of neat positive 67 
Percentage of results within ± 30 % of neat positive 91.78% 
Number of results within ± 30 % of median 69 











Positive sample Spiked Result adjusted 
for dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 64 
1 0.05 18.24 12.77 23.71 19.51 13.95 16.87 
2 0.05 17.00 11.90 22.10 12.99 10.65 7.74 
3 0.05 14.11 9.88 18.34 10.72 8.84 10.57 
4 0.05 17.48 12.24 22.72 14.94 11.45 10.97 
5 0.05 21.08 14.76 27.40 35.45 24.60 22.09 
Median 
Result 14.94 11.45 10.97 
- 30 % 10.46 8.02 7.68 
+ 30 % 19.42 14.89 14.26 
13-Plex 67 
1 0.05 18.24 12.77 23.71 17.94 10.86 15.09 
2 0.05 17.00 11.90 22.10 9.48 10.66 13.64 
3 0.05 14.11 9.88 18.34 12.26 9.81 12.61 
4 0.05 17.48 12.24 22.72 13.28 11.96 10.31 
5 0.05 21.08 14.76 27.40 37.34 32.31 24.80 
Median 
Result 13.28 10.86 13.64 
- 30 % 9.30 7.60 9.55 
+ 30 % 17.26 14.12 17.73 
13-Plex 70 
1 0.05 18.24 12.77 23.71 16.03 13.95 17.05 
2 0.05 17.00 11.90 22.10 10.64 10.93 11.19 
3 0.05 14.11 9.88 18.34 10.82 10.81 13.09 
4 0.05 17.48 12.24 22.72 16.39 11.52 11.57 
5 0.05 21.08 14.76 27.40 36.86 26.23 20.68 
Median 
Result 16.03 11.52 13.09 
- 30 % 11.22 8.06 9.16 
+ 30 % 20.84 14.98 17.02 
13-Plex 74 
1 0.05 18.24 12.77 23.71 16.85 11.70 14.38 
2 0.05 17.00 11.90 22.10 8.71 10.74 13.30 
3 0.05 14.11 9.88 18.34 12.82 9.22 13.30 
4 0.05 17.48 12.24 22.72 13.26 10.46 10.39 
5 0.05 21.08 14.76 27.40 38.25 25.40 25.98 
Median 
Result 13.26 10.74 13.30 
- 30 % 9.28 7.52 9.31 
+ 30 % 17.24 13.96 17.29 
13-Plex 76 
1 0.05 18.24 12.77 23.71 18.13 15.28 15.97 
2 0.05 17.00 11.90 22.10 18.12 11.18 13.56 
3 0.05 14.11 9.88 18.34 9.11 8.95 12.89 
4 0.05 17.48 12.24 22.72 11.43 10.61 10.59 
5 0.05 21.08 14.76 27.40 37.45 23.91 22.66 
Median 
Result 18.12 11.18 13.56 
- 30 % 12.68 7.83 9.49 
+ 30 % 23.56 14.53 17.63 
Total number of results 75 
Number of results within ± 30% of neat positive 41 
Percentage of results within ± 30% of neat positive 54.67% 
Number of results within ± 30% of median 58 











Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 4.78 3.35 6.21 4.11 4.33 4.75 
2 0.05 4.69 3.28 6.10 4.93 4.93 5.49 
3 0.05 5.07 3.55 6.59 4.33 3.66 6.76 
4 0.05 5.99 4.19 7.79 4.71 4.23 7.44 
5 0.05 5.07 3.55 6.59 3.91 3.86 4.31 
Median 
Result 4.33 4.23 5.49 
- 30 % 3.03 2.96 3.84 
+ 30 % 5.63 5.50 7.14 
13-Plex 
70 
1 0.05 4.78 3.35 6.21 4.69 5.18 5.67 
2 0.05 4.69 3.28 6.10 4.48 5.19 5.12 
3 0.05 5.07 3.55 6.59 4.57 4.14 5.39 
4 0.05 5.99 4.19 7.79 4.19 5.71 8.19 
5 0.05 5.07 3.55 6.59 3.58 3.86 5.00 
Median 
Result 4.48 5.18 5.39 
- 30 % 3.14 3.63 3.77 
+ 30 % 5.82 6.73 7.01 
13-Plex 
72 
1 0.05 4.78 3.35 6.21 4.42 4.56 4.35 
2 0.05 4.69 3.28 6.10 4.44 4.48 5.75 
3 0.05 5.07 3.55 6.59 4.87 4.88 5.24 
4 0.05 5.99 4.19 7.79 4.88 5.64 6.74 
5 0.05 5.07 3.55 6.59 4.26 4.59 5.23 
Median 
Result 4.44 4.59 5.24 
- 30 % 3.11 3.21 3.67 
+ 30 % 5.77 5.97 6.81 
13-Plex 
74 
1 0.05 4.78 3.35 6.21 4.52 5.22 5.69 
2 0.05 4.69 3.28 6.10 4.79 5.07 5.65 
3 0.05 5.07 3.55 6.59 4.29 4.71 5.73 
4 0.05 5.99 4.19 7.79 4.71 5.61 7.64 
5 0.05 5.07 3.55 6.59 3.60 3.34 4.89 
Median 
Result 4.52 5.07 5.69 
- 30 % 3.16 3.55 3.98 
+ 30 % 5.88 6.59 7.40 
13-Plex 
76 
1 0.05 4.78 3.35 6.21 4.30 4.57 5.84 
2 0.05 4.69 3.28 6.10 4.94 5.21 5.48 
3 0.05 5.07 3.55 6.59 5.05 4.70 6.46 
4 0.05 5.99 4.19 7.79 3.98 6.98 6.11 
5 0.05 5.07 3.55 6.59 3.96 5.77 5.29 
Median 
Result 4.30 5.21 5.84 
- 30 % 3.01 3.65 4.09 
+ 30 % 5.59 6.77 7.59 
Total number of results 75 
Number of results within ± 30% of neat positive 71 
Percentage of results within ± 30% of neat positive 94.67% 
Number of results within ± 30% of median 72 












Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 3.00 2.10 3.90 2.73 2.72 3.04 
2 0.05 3.23 2.26 4.20 3.24 2.99 3.77 
3 0.05 2.95 2.07 3.84 2.93 2.34 4.09 
4 0.05 3.82 2.67 4.97 3.03 2.93 5.19 
5 0.05 3.68 2.58 4.78 5.48 4.51 4.63 
Median 
Result 3.03 2.93 4.09 
- 30 % 2.12 2.05 2.86 
+ 30 % 3.94 3.81 5.32 
13-Plex 
70 
1 0.05 3.00 2.10 3.90 2.47 2.64 2.73 
2 0.05 3.23 2.26 4.20 2.99 3.05 3.57 
3 0.05 2.95 2.07 3.84 3.07 2.95 3.31 
4 0.05 3.82 2.67 4.97 3.35 3.97 4.43 
5 0.05 3.68 2.58 4.78 2.52 2.52 3.22 
Median 
Result 2.99 2.95 3.31 
- 30 % 2.09 2.07 2.32 
+ 30 % 3.89 3.84 4.30 
13-Plex 
74 
1 0.05 3.00 2.10 3.90 2.83 3.06 3.10 
2 0.05 3.23 2.26 4.20 3.16 3.40 3.58 
3 0.05 2.95 2.07 3.84 2.66 2.97 3.32 
4 0.05 3.82 2.67 4.97 3.08 3.40 4.59 
5 0.05 3.68 2.58 4.78 3.02 3.92 4.37 
Median 
Result 3.02 3.40 3.58 
- 30 % 2.11 2.38 2.51 
+ 30 % 3.93 4.42 4.65 
13-Plex 
75 
1 0.05 2.95 2.07 3.84 3.15 2.66 3.92 
2 0.05 3.82 2.67 4.97 3.29 2.95 5.58 
3 0.05 3.68 2.58 4.78 3.96 4.05 4.28 
4 0.05 3.70 2.59 4.81 3.36 4.33 9.86 
5 0.05 3.75 2.63 4.88 3.45 3.72 4.28 
Median 
Result 3.36 3.72 4.28 
- 30 % 2.35 2.60 3.00 
+ 30 % 4.37 4.84 5.56 
13-Plex 
76 
1 0.05 3.00 2.10 3.90 2.70 2.67 3.32 
2 0.05 3.23 2.26 4.20 3.05 3.33 3.80 
3 0.05 2.95 2.07 3.84 3.08 3.06 3.46 
4 0.05 3.82 2.67 4.97 2.89 4.91 4.00 
5 0.05 3.68 2.58 4.78 3.91 4.14 9.42 
Median 
Result 3.05 3.33 3.80 
- 30 % 2.14 2.33 2.66 
+ 30 % 3.97 4.33 4.94 
Total number of results 75 
Number of results within ± 30% of neat positive 67 
Percentage of results within ± 30% of neat positive 89.33% 
Number of results within ± 30% of median 68 












Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 2.48 1.74 3.22 2.17 2.44 2.79 
2 0.05 2.18 1.53 2.83 2.29 2.28 2.79 
3 0.05 2.01 1.41 2.61 2.20 2.06 3.68 
4 0.05 2.68 1.88 3.48 2.46 2.53 4.37 
5 0.05 2.49 1.74 3.24 3.37 3.00 3.20 
Median 
Result 2.29 2.44 3.20 
- 30 % 1.60 1.71 2.24 
+ 30 % 2.98 3.17 4.16 
13-Plex 
70 
1 0.05 2.48 1.74 3.22 2.09 2.18 2.34 
2 0.05 2.18 1.53 2.83 1.97 2.31 2.64 
3 0.05 2.01 1.41 2.61 2.20 2.33 3.09 
4 0.05 2.49 1.74 3.24 2.44 2.44 3.77 
5 0.05 2.35 1.65 3.06 1.78 1.89 2.67 
Median 
Result 2.09 2.31 2.67 
- 30 % 1.46 1.62 1.87 
+ 30 % 2.72 3.00 3.47 
13-Plex 
74 
1 0.05 2.48 1.74 3.22 2.40 2.43 2.71 
2 0.05 2.18 1.53 2.83 2.03 2.42 2.63 
3 0.05 2.01 1.41 2.61 1.92 2.19 3.21 
4 0.05 2.68 1.88 3.48 2.19 2.91 3.68 
5 0.05 2.49 1.74 3.24 2.09 2.55 2.97 
Median 
Result 2.09 2.43 2.97 
- 30 % 1.46 1.70 2.08 
+ 30 % 2.72 3.16 3.86 
13-Plex 
75 
1 0.05 2.01 1.41 2.61 2.30 2.12 3.24 
2 0.05 2.68 1.88 3.48 2.42 2.50 4.54 
3 0.05 2.35 1.65 3.06 2.46 2.61 3.29 
4 0.05 2.30 1.61 2.99 2.24 2.94 7.00 
5 0.05 2.49 1.74 3.24 2.40 2.58 2.91 
Median 
Result 2.40 2.58 3.29 
- 30 % 1.68 1.81 2.30 
+ 30 % 3.12 3.35 4.28 
13-Plex 
76 
1 0.05 2.48 1.74 3.22 2.24 2.34 2.94 
2 0.05 2.18 1.53 2.83 2.12 2.43 2.78 
3 0.05 2.01 1.41 2.61 2.22 2.52 2.68 
4 0.05 2.68 1.88 3.48 2.37 3.77 3.20 
5 0.05 2.35 1.65 3.06 2.61 2.98 6.94 
Median 
Result 2.24 2.52 2.94 
- 30 % 1.57 1.76 2.06 
+ 30 % 2.91 3.28 3.82 
Total number of results 75 
Number of results within ± 30% of neat positive 61 
Percentage of results within ± 30% of neat positive 81.33% 
Number of results within ± 30% of median 67 
Percentage of results within ± 30% of median 89.33% 
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Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 3.31 2.32 4.30 3.12 3.28 3.92 
2 0.05 3.42 2.39 4.45 3.40 3.45 4.50 
3 0.05 2.97 2.08 3.86 3.16 2.75 4.86 
4 0.05 3.94 2.76 5.12 3.29 3.46 5.91 
5 0.05 3.68 2.58 4.78 3.31 3.37 3.97 
Median 
Result 3.29 3.37 4.50 
- 30 % 2.30 2.36 3.15 
+ 30 % 4.28 4.38 5.85 
13-Plex 
67 
1 0.05 3.31 2.32 4.30 3.50 3.67 4.28 
2 0.05 3.42 2.39 4.45 3.14 3.81 3.94 
3 0.05 2.97 2.08 3.86 2.95 3.09 4.01 
4 0.05 3.94 2.76 5.12 3.10 4.10 5.71 
5 0.05 3.68 2.58 4.78 2.95 3.47 4.02 
Median 
Result 3.10 3.67 4.02 
- 30 % 2.17 2.57 2.81 
+ 30 % 4.03 4.77 5.23 
13-Plex 
70 
1 0.05 3.31 2.32 4.30 2.80 3.18 3.60 
2 0.05 3.42 2.39 4.45 3.34 3.61 4.38 
3 0.05 2.97 2.08 3.86 3.14 3.37 4.38 
4 0.05 3.94 2.76 5.12 3.56 4.26 5.32 
5 0.05 3.68 2.58 4.78 3.26 3.87 4.70 
Median 
Result 3.26 3.61 4.38 
- 30 % 2.28 2.53 3.07 
+ 30 % 4.24 4.69 5.69 
13-Plex 
74 
1 0.05 3.31 2.32 4.30 3.17 3.54 4.04 
2 0.05 3.42 2.39 4.45 3.29 3.86 4.37 
3 0.05 2.97 2.08 3.86 2.80 3.36 4.34 
4 0.05 3.94 2.76 5.12 3.30 4.08 5.50 
5 0.05 3.68 2.58 4.78 3.12 3.15 3.90 
Median 
Result 3.17 3.54 4.34 
- 30 % 2.22 2.48 3.04 
+ 30 % 4.12 4.60 5.64 
13-Plex 
76 
1 0.05 3.31 2.32 4.30 3.16 3.28 4.29 
2 0.05 3.42 2.39 4.45 3.24 3.85 4.54 
3 0.05 2.97 2.08 3.86 3.16 3.49 4.10 
4 0.05 3.94 2.76 5.12 3.10 5.00 4.75 
5 0.05 3.68 2.58 4.78 3.18 4.19 4.21 
Median 
Result 3.16 3.85 4.29 
- 30 % 2.21 2.70 3.00 
+ 30 % 4.11 5.01 5.58 
Total number of results 75 
Number of results within ± 30% of neat positive 64 
Percentage of results within ± 30% of neat positive 85.33% 
Number of results within ± 30% of median 73 











Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 10.02 7.01 13.03 8.81 8.48 9.67 
2 0.05 10.28 7.20 13.36 9.53 8.96 11.36 
3 0.05 8.24 5.77 10.71 8.40 7.12 12.57 
4 0.05 11.90 8.33 15.47 9.37 9.27 15.81 
5 0.05 10.91 7.64 14.18 8.99 8.73 10.02 
Median 
Result 8.99 8.73 11.36 
- 30 % 6.29 6.11 7.95 
+ 30 % 11.69 11.35 14.77 
13-Plex 
67 
1 0.05 10.02 7.01 13.03 10.01 9.72 10.96 
2 0.05 10.28 7.20 13.36 8.66 9.89 10.25 
3 0.05 8.24 5.77 10.71 8.26 7.64 10.18 
4 0.05 11.90 8.33 15.47 8.61 11.20 15.23 
5 0.05 10.91 7.64 14.18 8.02 9.16 10.42 
Median 
Result 8.61 9.72 10.42 
- 30 % 6.03 6.80 7.29 
+ 30 % 11.19 12.64 13.55 
13-Plex 
70 
1 0.05 10.02 7.01 13.03 7.78 8.45 9.31 
2 0.05 10.28 7.20 13.36 8.88 8.98 11.30 
3 0.05 8.24 5.77 10.71 8.73 8.78 11.11 
4 0.05 11.90 8.33 15.47 9.90 12.10 14.63 
5 0.05 10.91 7.64 14.18 8.67 10.43 12.34 
Median 
Result 8.73 8.98 11.30 
- 30 % 6.11 6.29 7.91 
+ 30 % 11.35 11.67 14.69 
13-Plex 
74 
1 0.05 10.02 7.01 13.03 9.19 9.23 10.11 
2 0.05 10.28 7.20 13.36 9.28 10.20 10.86 
3 0.05 8.24 5.77 10.71 7.63 8.84 11.27 
4 0.05 11.90 8.33 15.47 9.21 11.30 15.07 
5 0.05 10.91 7.64 14.18 8.54 8.24 9.97 
Median 
Result 9.19 9.23 10.86 
- 30 % 6.43 6.46 7.60 
+ 30 % 11.95 12.00 14.12 
13-Plex 
76 
1 0.05 10.02 7.01 13.03 8.82 8.64 10.68 
2 0.05 10.28 7.20 13.36 8.73 9.78 11.16 
3 0.05 8.24 5.77 10.71 8.78 8.99 9.90 
4 0.05 11.90 8.33 15.47 8.80 14.29 12.70 
5 0.05 10.91 7.64 14.18 8.23 11.10 11.24 
Median 
Result 8.78 9.78 11.16 
- 30 % 6.15 6.85 7.81 
+ 30 % 11.41 12.71 14.51 
Total number of results 75 
Number of results within ± 30% of neat positive 71 
Percentage of results within ± 30% of neat positive 94.67% 
Number of results within ± 30% of median 70 











Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 0.97 0.68 1.26 0.94 1.06 1.16 
2 0.05 1.17 0.82 1.52 1.31 1.21 1.69 
3 0.05 1.06 0.74 1.38 1.14 1.11 1.97 
4 0.05 1.13 0.79 1.47 1.01 1.34 1.35 
5 0.05 1.12 0.78 1.46 1.01 1.52 1.51 
Median 
Result 1.01 1.21 1.51 
- 30 % 0.71 0.85 1.06 
+ 30 % 1.31 1.57 1.96 
13-Plex 
67 
1 0.05 0.97 0.68 1.26 1.10 1.23 1.36 
2 0.05 1.17 0.82 1.52 1.06 1.34 1.54 
3 0.05 1.06 0.74 1.38 1.17 1.08 1.46 
4 0.05 1.13 0.79 1.47 1.03 1.13 1.30 
5 0.05 1.12 0.78 1.46 1.16 0.94 1.32 
Median 
Result 1.10 1.13 1.36 
- 30 % 0.77 0.79 0.95 
+ 30 % 1.43 1.47 1.77 
13-Plex 
70 
1 0.05 0.97 0.68 1.26 0.84 1.07 1.18 
2 0.05 1.17 0.82 1.52 1.02 1.35 1.67 
3 0.05 1.06 0.74 1.38 1.20 1.23 1.48 
4 0.05 1.13 0.79 1.47 1.09 1.35 1.58 
5 0.05 1.12 0.78 1.46 1.12 1.41 1.70 
Median 
Result 1.09 1.35 1.58 
- 30 % 0.76 0.95 1.11 
+ 30 % 1.42 1.76 2.05 
13-Plex 
74 
1 0.05 0.97 0.68 1.26 1.12 1.20 1.28 
2 0.05 1.17 0.82 1.52 1.33 1.32 1.62 
3 0.05 1.06 0.74 1.38 1.07 1.22 1.66 
4 0.05 1.13 0.79 1.47 1.00 1.26 1.24 
5 0.05 1.12 0.78 1.46 1.09 1.10 1.40 
Median 
Result 1.09 1.22 1.40 
- 30 % 0.76 0.85 0.98 
+ 30 % 1.42 1.59 1.82 
13-Plex 
76 
1 0.05 0.97 0.68 1.26 1.02 1.10 1.48 
2 0.05 1.17 0.82 1.52 1.22 1.35 1.59 
3 0.05 1.06 0.74 1.38 1.21 1.13 1.54 
4 0.05 1.13 0.79 1.47 1.10 1.04 1.34 
5 0.05 1.12 0.78 1.46 1.06 1.02 1.23 
Median 
Result 1.10 1.10 1.48 
- 30 % 0.77 0.77 1.04 
+ 30 % 1.43 1.43 1.92 
Total number of results 75 
Number of results within ± 30% of neat positive 57 
Percentage of results within ± 30% of neat positive 76.00% 
Number of results within ± 30% of median 74 











Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 2.71 1.90 3.52 2.29 2.35 2.82 
2 0.05 2.94 2.06 3.82 2.76 2.59 3.21 
3 0.05 2.44 1.71 3.17 2.31 1.97 3.49 
4 0.05 3.57 2.50 4.64 2.64 2.55 4.31 
5 0.05 3.10 2.17 4.03 2.75 2.64 2.90 
Median 
Result 2.64 2.55 3.21 
- 30 % 1.85 1.79 2.25 
+ 30 % 3.43 3.32 4.17 
13-Plex 
67 
1 0.05 2.71 1.90 3.52 2.60 2.55 3.09 
2 0.05 2.94 2.06 3.82 2.60 2.99 2.96 
3 0.05 2.44 1.71 3.17 2.31 2.22 2.92 
4 0.05 3.57 2.50 4.64 2.29 3.01 4.18 
5 0.05 3.10 2.17 4.03 2.50 2.72 3.15 
Median 
Result 2.50 2.72 3.09 
- 30 % 1.75 1.90 2.16 
+ 30 % 3.25 3.54 4.02 
13-Plex 
70 
1 0.05 2.71 1.90 3.52 2.08 2.39 2.48 
2 0.05 2.94 2.06 3.82 2.73 2.65 3.02 
3 0.05 2.44 1.71 3.17 2.36 2.49 2.99 
4 0.05 3.57 2.50 4.64 2.74 3.29 3.71 
5 0.05 3.10 2.17 4.03 2.71 3.17 3.64 
Median 
Result 2.71 2.65 3.02 
- 30 % 1.90 1.86 2.11 
+ 30 % 3.52 3.45 3.93 
13-Plex 
74 
1 0.05 2.71 1.90 3.52 2.51 2.54 2.75 
2 0.05 2.94 2.06 3.82 2.69 2.91 3.13 
3 0.05 2.44 1.71 3.17 2.15 2.42 3.29 
4 0.05 3.57 2.50 4.64 2.67 3.07 4.14 
5 0.05 3.10 2.17 4.03 2.78 2.54 2.98 
Median 
Result 2.67 2.54 3.13 
- 30 % 1.87 1.78 2.19 
+ 30 % 3.47 3.30 4.07 
13-Plex 
76 
1 0.05 2.71 1.90 3.52 2.34 2.32 2.99 
2 0.05 2.94 2.06 3.82 2.66 2.85 3.22 
3 0.05 2.44 1.71 3.17 2.48 2.57 2.99 
4 0.05 3.57 2.50 4.64 2.41 3.96 3.59 
5 0.05 3.10 2.17 4.03 2.44 3.12 3.25 
Median 
Result 2.44 2.85 3.22 
- 30 % 1.71 2.00 2.25 
+ 30 % 3.17 3.71 4.19 
Total number of results 75 
Number of results within ± 30% of neat positive 71 
Percentage of results within ± 30% of neat positive 94.67% 
Number of results within ± 30% of median 72 











Positive sample Spiked Result adjusted for 
dilution factor 13-Plex 08 
Neat Result - 30 % + 30 % 1/2 1/4 1/8 
13-Plex 
64 
1 0.05 5.22 3.65 6.79 4.80 5.03 5.70 
2 0.05 5.49 3.84 7.14 5.33 5.46 6.64 
3 0.05 5.20 3.64 6.76 4.96 4.35 7.80 
4 0.05 6.78 4.75 8.81 5.51 5.48 9.40 
5 0.05 5.07 3.55 6.59 7.55 6.47 7.03 
Median 
Result 5.33 5.46 7.03 
- 30 % 3.73 3.82 4.92 
+ 30 % 6.93 7.10 9.14 
13-Plex 
70 
1 0.05 5.22 3.65 6.79 4.55 4.96 5.35 
2 0.05 5.49 3.84 7.14 5.19 5.46 6.52 
3 0.05 5.20 3.64 6.76 5.46 5.49 6.53 
4 0.05 6.78 4.75 8.81 5.71 7.02 8.44 
5 0.05 5.07 3.55 6.59 3.39 3.53 4.78 
Median 
Result 5.19 5.46 6.52 
- 30 % 3.63 3.82 4.56 
+ 30 % 6.75 7.10 8.48 
13-Plex 
74 
1 0.05 5.22 3.65 6.79 5.24 5.51 6.02 
2 0.05 5.49 3.84 7.14 5.31 5.89 6.66 
3 0.05 5.20 3.64 6.76 4.71 5.54 6.84 
4 0.05 6.78 4.75 8.81 5.34 6.42 8.79 
5 0.05 5.07 3.55 6.59 4.31 5.65 6.43 
Median 
Result 5.24 5.65 6.66 
- 30 % 3.67 3.96 4.66 
+ 30 % 6.81 7.35 8.66 
13-Plex 
75 
1 0.05 5.20 3.64 6.76 5.49 4.62 7.25 
2 0.05 6.78 4.75 8.81 5.72 5.44 9.61 
3 0.05 5.07 3.55 6.59 5.26 5.66 6.03 
4 0.05 5.28 3.70 6.86 4.68 5.92 13.70 
5 0.05 5.16 3.61 6.71 5.03 5.16 6.09 
Median 
Result 5.26 5.44 7.25 
- 30 % 3.68 3.81 5.08 
+ 30 % 6.84 7.07 9.43 
13-Plex 
76 
1 0.05 5.22 3.65 6.79 4.94 5.18 6.26 
2 0.05 5.49 3.84 7.14 5.30 5.87 6.68 
3 0.05 5.20 3.64 6.76 5.47 5.51 6.55 
4 0.05 6.78 4.75 8.81 4.96 8.41 7.61 
5 0.05 5.07 3.55 6.59 5.56 5.99 13.43 
Median 
Result 5.30 5.87 6.68 
- 30 % 3.71 4.11 4.68 
+ 30 % 6.89 7.63 8.68 
Total number of results 75 
Number of results within ± 30% of neat positive 64 
Percentage of results within ± 30% of neat positive 85.33% 
Number of results within ± 30% of median 71 




Appendix IV. Assay Validation: Reproducibility 
 
Appendix IV-1 Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 05 0.65 0.78 0.82 0.73 0.74 0.74 0.06 8.53 % 
13-Plex 06 0.26 0.26 0.28 0.18 0.19 0.23 0.05 19.49 % 
13-Plex 08 1.62 2.00 2.30 2.14 1.99 2.01 0.25 12.53 % 
13-Plex 12 0.47 0.36 0.50 0.40 0.44 0.43 0.06 12.79 % 
13-Plex 17 0.05 0.10 0.10 0.05 0.05 0.10 0.00 0.00 % 
13-Plex 18 0.41 0.57 0.69 0.52 0.49 0.54 0.10 19.37 % 
13-Plex 20 0.80 0.82 0.92 0.72 0.65 0.78 0.10 13.12 % 
13-Plex 21 0.55 0.55 0.60 0.45 0.43 0.52 0.07 14.08 % 
13-Plex 28 0.86 0.99 0.88 0.85 0.84 0.88 0.06 6.91 % 
13-Plex 32 0.20 0.29 0.27 0.26 0.25 0.25 0.03 13.23 % 
13-Plex 39 1.56 1.88 3.44 2.12 1.92 2.18 0.73 33.44 % 
13-Plex 42 1.35 1.51 1.79 1.68 1.60 1.59 0.17 10.56 % 
13-Plex 46 0.47 0.58 0.72 0.63 0.65 0.61 0.09 15.25 % 
13-Plex 59 0.11 0.15 0.16 0.13 0.11 0.13 0.02 17.28 % 
13-Plex 60 0.44 0.40 0.47 0.41 0.35 0.41 0.05 10.88 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.16 0.15 0.15 0.13 0.13 0.14 0.01 9.32 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 16 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-2: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.25 0.26 0.20 0.20 0.18 0.22 0.03 16.02 % 
13-Plex 05 0.37 0.44 0.28 0.27 0.29 0.33 0.07 22.16 % 
13-Plex 08 4.04 5.05 6.48 4.98 4.87 5.08 0.88 17.31 % 
13-Plex 09 9.43 16.06 16.02 12.33 12.28 13.22 2.83 21.37 % 
13-Plex 10 3.28 3.16 3.76 3.04 3.20 3.29 0.28 8.45 % 
13-Plex 11 2.87 2.66 3.27 2.45 2.72 2.79 0.31 10.95 % 
13-Plex 18 1.10 1.50 1.85 1.23 1.29 1.39 0.29 21.02 % 
13-Plex 20 0.34 0.55 0.49 0.37 0.35 0.42 0.09 22.46 % 
13-Plex 21 1.23 1.51 1.61 1.03 1.06 1.29 0.26 20.35 % 
13-Plex 25 0.20 0.29 0.19 0.20 0.18 0.21 0.04 20.94 % 
13-Plex 28 1.04 1.12 1.16 1.04 1.02 1.08 0.06 5.64 % 
13-Plex 31 6.47 10.33 14.08 9.35 8.86 9.82 2.77 28.25 % 
13-Plex 42 0.44 0.64 0.58 0.43 0.45 0.51 0.10 18.85 % 
13-Plex 46 0.69 0.86 0.91 0.70 0.74 0.78 0.10 12.72 % 
13-Plex 50 1.35 1.53 2.11 1.34 1.43 1.55 0.32 20.69 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.13 0.05 0.05 0.05 0.07 0.04 
 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-3: Inter assay reproducibility results generated for beads 













Mean SD % CV 
13-Plex 03 0.28 0.31 0.27 0.38 0.23 0.29 0.06 19.03% 
13-Plex 05 1.09 1.07 1.24 1.35 1.07 1.16 0.13 10.83% 
13-Plex 06 0.52 0.56 0.58 0.55 0.49 0.54 0.04 6.55% 
13-Plex 08 2.89 2.96 3.68 2.96 2.54 3.01 0.42 13.81% 
13-Plex 10 4.23 5.26 5.17 3.94 3.61 4.44 0.74 16.65% 
13-Plex 11 1.18 1.18 1.28 1.41 1.11 1.23 0.12 9.46% 
13-Plex 16 0.66 0.55 0.64 0.60 0.53 0.60 0.06 9.39% 
13-Plex 17 0.17 0.15 0.15 0.16 0.16 0.16 0.01 5.30% 
13-Plex 28 0.70 0.63 0.72 0.70 0.63 0.68 0.04 6.33% 
13-Plex 31 0.44 0.41 0.54 0.50 0.46 0.47 0.05 10.85% 
13-Plex 42 1.42 1.01 1.57 1.47 1.28 1.35 0.22 16.07% 
13-Plex 46 0.58 0.51 0.60 0.58 0.50 0.55 0.05 8.23% 
13-Plex 50 0.75 0.67 0.77 0.79 0.69 0.73 0.05 7.05% 
13-Plex 51 0.21 0.19 0.24 0.23 0.18 0.21 0.03 12.14% 
13-Plex 52 0.18 0.18 0.18 0.15 0.12 0.16 0.03 16.56% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.13 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with %CV of less than or equal to 25.00 15 




Appendix IV-4: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.89 0.81 0.72 0.66 0.90 0.80 0.11 13.19 % 
13-Plex 08 4.39 4.67 3.89 3.58 4.25 4.16 0.43 10.28 % 
13-Plex 10 5.50 6.10 5.18 4.90 4.98 5.33 0.49 9.15 % 
13-Plex 11 0.82 0.65 0.68 0.60 0.71 0.69 0.08 11.89 % 
13-Plex 12 2.96 3.63 3.36 2.89 3.26 3.22 0.30 9.39 % 
13-Plex 16 1.37 1.27 1.28 1.16 1.14 1.24 0.09 7.60 % 
13-Plex 18 1.08 0.99 0.76 0.83 0.95 0.92 0.13 13.83 % 
13-Plex 25 0.40 0.27 0.23 0.34 0.23 0.29 0.07 25.29 % 
13-Plex 28 8.05 8.59 6.76 7.19 6.55 7.43 0.87 11.68 % 
13-Plex 31 0.95 0.92 0.77 0.83 0.70 0.83 0.10 12.42 % 
13-Plex 32 0.58 0.44 0.43 0.37 0.42 0.45 0.08 17.53 % 
13-Plex 42 2.03 2.09 1.99 1.84 2.00 1.99 0.09 4.65 % 
13-Plex 44 1.83 1.86 1.71 1.44 2.01 1.77 0.21 12.04 % 
13-Plex 51 1.16 1.11 0.97 1.01 1.03 1.06 0.08 7.32 % 
13-Plex 60 0.38 0.27 0.26 0.23 0.28 0.28 0.06 20.01 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-5: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 1.17 1.05 0.88 1.42 0.82 1.07 0.24 22.52% 
13-Plex 05 7.51 7.50 5.69 7.28 6.16 6.83 0.85 12.39% 
13-Plex 06 0.46 0.41 0.38 0.59 0.34 0.44 0.10 22.15% 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 10 21.55 16.69 13.53 19.92 18.99 18.14 3.12 17.19% 
13-Plex 11 6.26 5.16 3.81 11.64 7.47 6.87 2.99 43.54% 
13-Plex 16 4.26 3.70 2.96 4.95 3.49 3.87 0.76 19.67% 
13-Plex 17 1.31 1.15 0.94 1.41 1.01 1.16 0.20 16.96% 
13-Plex 18 10.93 7.52 5.32 8.56 5.60 7.59 2.30 30.36% 
13-Plex 21 0.65 0.56 0.47 0.78 0.47 0.59 0.13 22.46% 
13-Plex 25 1.25 1.18 0.94 1.41 1.02 1.16 0.19 16.07% 
13-Plex 32 0.65 0.63 0.47 0.33 0.35 0.49 0.15 30.99% 
13-Plex 33 0.54 0.42 0.33 0.51 0.45 0.45 0.08 18.26% 
13-Plex 34 1.07 0.86 0.71 1.13 0.80 0.91 0.18 19.61% 
13-Plex 44 0.44 0.34 0.26 0.44 0.26 0.35 0.09 25.89% 
13-Plex 51 0.23 0.16 0.15 0.32 0.23 0.22 0.07 31.35% 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 10 





Appendix IV-6: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 05 2.63 2.70 2.34 2.39 2.77 2.57 0.19 7.44 % 
13-Plex 09 1.84 2.01 1.78 1.81 1.80 1.85 0.09 5.04 % 
13-Plex 10 6.29 6.96 6.34 5.94 5.21 6.15 0.64 10.41 % 
13-Plex 11 5.57 5.58 5.32 5.42 4.78 5.33 0.33 6.15 % 
13-Plex 12 2.63 3.87 3.07 3.33 3.12 3.20 0.45 14.08 % 
13-Plex 16 0.23 0.20 0.20 0.18 0.17 0.20 0.02 11.75 % 
13-Plex 18 1.90 2.49 1.81 1.92 1.66 1.96 0.32 16.14 % 
13-Plex 20 2.14 2.57 1.93 1.81 2.21 2.13 0.29 13.72 % 
13-Plex 21 3.73 4.21 3.25 3.30 3.56 3.61 0.39 10.75 % 
13-Plex 28 0.52 0.52 0.45 0.46 0.53 0.50 0.04 7.62 % 
13-Plex 34 0.48 0.47 0.40 0.38 0.43 0.43 0.04 10.01 % 
13-Plex 42 0.78 0.91 0.71 0.71 0.62 0.75 0.11 14.46 % 
13-Plex 46 0.70 0.74 0.60 0.65 0.69 0.68 0.05 7.87 % 
13-Plex 50 1.55 2.13 1.64 1.69 1.61 1.72 0.23 13.49 % 
13-Plex 59 0.36 0.34 0.31 0.31 0.45 0.35 0.06 16.30 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-7: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.15 0.15 0.15 0.18 0.15 0.16 0.01 8.60 % 
13-Plex 08 23.02 25.16 29.96 24.43 24.91 25.50 2.63 10.31 % 
13-Plex 10 0.11 0.09 0.11 0.07 0.07 0.09 0.02 22.22 % 
13-Plex 11 4.53 5.5 3.45 2.92 3.19 3.92 1.07 27.44 % 
13-Plex 12 4.76 3.62 5.66 4.21 4.54 4.56 0.75 16.48 % 
13-Plex 16 5.51 4.83 4.51 3.83 3.42 4.42 0.82 18.63 % 
13-Plex 18 0.33 0.31 0.31 0.25 0.26 0.29 0.03 11.96 % 
13-Plex 20 0.12 0.12 0.09 0.08 0.07 0.10 0.02 23.98 % 
13-Plex 21 0.16 0.16 0.13 0.12 0.13 0.14 0.02 13.36 % 
13-Plex 28 0.14 0.10 0.10 0.09 0.09 0.10 0.02 19.94 % 
13-Plex 31 0.87 1.79 1.61 1.35 1.27 1.38 0.35 25.50 % 
13-Plex 32 0.68 0.72 0.71 0.49 0.56 0.63 0.10 16.11 % 
13-Plex 34 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.91 1.92 2.15 1.95 1.80 1.95 0.13 6.55 % 
13-Plex 50 0.79 0.65 0.70 0.63 0.59 0.67 0.08 11.45 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 12 





Appendix IV-8: Inter assay reproducibility results for beads prepared 













Mean SD %CV 
13-Plex 03 0.27 0.31 0.27 0.30 0.37 0.30 0.04 13.48% 
13-Plex 08 2.96 3.49 2.41 3.28 5.35 3.50 1.11 31.80% 
13-Plex 10 1.04 1.03 1.02 0.77 0.86 0.94 0.12 12.94% 
13-Plex 16 0.71 0.69 0.67 0.78 0.95 0.76 0.11 15.00% 
13-Plex 18 3.56 3.91 3.07 3.68 5.02 3.85 0.72 18.80% 
13-Plex 20 1.69 2.12 1.80 2.19 2.46 2.05 0.31 15.11% 
13-Plex 21 3.86 5.33 3.30 5.41 6.74 4.93 1.37 27.73% 
13-Plex 28 0.23 0.20 0.27 0.14 0.14 0.20 0.06 29.00% 
13-Plex 32 0.34 0.53 0.51 0.43 0.73 0.51 0.14 28.54% 
13-Plex 34 1.70 1.51 1.60 1.06 1.50 1.47 0.25 16.63% 
13-Plex 44 0.60 0.57 0.72 0.49 0.64 0.60 0.09 14.08% 
13-Plex 46 7.41 11.19 8.71 12.29 9.71 9.86 1.94 19.65% 
13-Plex 51 0.60 0.77 0.77 0.71 0.96 0.76 0.13 17.15% 
13-Plex 52 0.38 0.45 0.40 0.36 0.40 0.40 0.03 8.41% 
13-Plex 59 0.23 0.28 0.32 0.17 0.19 0.24 0.06 26.14% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with %CV of less than or equal to 25.00 10 





Appendix IV-9: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 08 4.19 4.95 5.38 4.78 5.03 4.87 0.44 8.97 % 
13-Plex 09 0.61 0.63 0.67 0.50 0.58 0.60 0.06 10.67 % 
13-Plex 10 0.21 0.25 0.22 0.20 0.21 0.22 0.02 8.82 % 
13-Plex 11 2.85 2.74 2.87 2.51 2.56 2.71 0.16 6.09 % 
13-Plex 12 3.08 2.87 3.60 3.11 3.33 3.20 0.28 8.68 % 
13-Plex 18 1.78 1.84 2.12 1.54 1.76 1.81 0.21 11.51 % 
13-Plex 20 1.13 1.37 1.51 1.12 1.21 1.27 0.17 13.27 % 
13-Plex 28 0.25 0.27 0.34 0.24 0.24 0.27 0.04 15.70 % 
13-Plex 31 0.19 0.17 0.26 0.15 0.19 0.19 0.04 21.60 % 
13-Plex 33 0.15 0.17 0.26 0.16 0.18 0.18 0.04 23.88 % 
13-Plex 44 1.28 1.40 1.62 1.25 1.40 1.39 0.15 10.47 % 
13-Plex 46 0.76 0.84 1.13 0.72 0.80 0.85 0.16 19.15 % 
13-Plex 50 6.45 9.27 9.49 8.18 8.23 8.32 1.20 14.46 % 
13-Plex 51 0.51 0.41 0.57 0.41 0.46 0.47 0.07 14.56 % 
13-Plex 62 1.20 1.24 1.41 1.12 1.22 1.24 0.11 8.59 % 
13-Plex 59 0.05 0.05 0.11 0.05 0.05 0.06 0.03 - 
13-Plex 71 0.10 0.10 0.15 0.05 0.11 0.12 0.02 20.70 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 16 
Number of samples with % CV of less than or equal to 25.00 16 





Appendix IV-10: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.27 0.31 0.26 0.29 0.30 0.29 0.02 7.25 % 
13-Plex 05 1.35 1.67 1.76 1.31 1.71 1.56 0.21 13.64 % 
13-Plex 08 6.25 6.62 6.28 4.37 6.22 5.95 0.90 15.08 % 
13-Plex 10 4.35 3.71 3.64 3.47 2.81 3.60 0.55 15.34 % 
13-Plex 11 4.02 4.58 4.95 3.96 4.77 4.46 0.45 10.00 % 
13-Plex 17 0.19 0.19 0.19 0.18 0.14 0.18 0.02 12.18 % 
13-Plex 18 1.70 1.78 1.88 1.60 1.68 1.73 0.11 6.16 % 
13-Plex 21 1.75 2.18 1.83 1.66 1.83 1.85 0.20 10.67 % 
13-Plex 31 1.41 1.66 1.58 1.26 1.75 1.53 0.20 12.85 % 
13-Plex 34 0.17 0.19 0.28 0.13 0.19 0.19 0.05 28.62 % 
13-Plex 42 1.73 2.18 2.07 1.60 2.03 1.92 0.25 12.76 % 
13-Plex 46 1.90 1.73 1.86 1.62 1.51 1.72 0.16 9.45 % 
13-Plex 50 4.12 5.47 6.14 4.89 4.53 5.03 0.79 15.79 % 
13-Plex 51 0.41 0.52 0.63 0.43 0.43 0.48 0.09 19.03 % 
13-Plex 52 0.11 0.14 0.14 0.11 0.11 0.12 0.02 13.47% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-11: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 05 1.29 1.18 1.29 1.05 1.07 1.18 0.12 9.80 % 
13-Plex 08 4.56 4.93 5.04 5.12 5.16 4.96 0.24 4.86 % 
13-Plex 12 0.72 0.50 0.75 0.55 0.60 0.62 0.11 17.28 % 
13-Plex 16 1.47 1.49 1.66 1.24 1.29 1.43 0.17 11.80 % 
13-Plex 17 0.89 0.59 0.74 0.65 0.79 0.73 0.12 16.06 % 
13-Plex 18 0.92 0.99 1.08 0.77 0.83 0.92 0.12 13.46 % 
13-Plex 20 0.46 0.47 0.51 0.36 0.42 0.44 0.06 12.80 % 
13-Plex 28 6.33 5.88 5.94 7.13 6.18 6.29 0.50 7.99 % 
13-Plex 31 0.89 1.00 1.21 0.93 1.07 1.02 0.13 12.40 % 
13-Plex 34 3.93 3.68 3.38 3.26 3.44 3.54 0.27 7.55 % 
13-Plex 39 1.99 1.67 2.67 1.73 1.75 1.96 0.41 21.11 % 
13-Plex 42 3.16 3.03 3.58 2.93 3.04 3.15 0.25 8.10 % 
13-Plex 46 1.79 1.50 1.98 1.49 1.60 1.67 0.21 12.57 % 
13-Plex 51 0.24 0.21 0.30 0.18 0.20 0.23 0.05 20.66 % 
13-Plex 52 0.14 0.10 0.15 0.10 0.10 0.12 0.02 21.10 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 




Appendix IV-12: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.18 0.18 0.23 0.20 0.18 0.19 0.02 11.29 % 
13-Plex 05 2.37 2.91 2.73 2.54 2.67 2.64 0.20 7.68 % 
13-Plex 06 1.11 1.28 1.31 1.11 1.09 1.18 0.11 8.97 % 
13-Plex 09 4.62 4.19 3.93 4.02 4.06 4.16 0.27 6.52 % 
13-Plex 10 0.60 0.76 0.57 0.60 0.64 0.63 0.07 11.78 % 
13-Plex 16 2.01 2.45 2.48 2.28 2.20 2.28 0.19 8.43 % 
13-Plex 17 0.47 0.54 0.63 0.53 0.58 0.55 0.06 10.83 % 
13-Plex 18 0.65 0.83 0.88 0.67 0.72 0.75 0.10 13.43 % 
13-Plex 21 3.14 3.30 2.94 2.54 2.61 2.91 0.33 11.32 % 
13-Plex 28 4.24 4.34 4.55 4.74 4.36 4.45 0.20 4.47 % 
13-Plex 34 4.69 5.43 5.14 5.49 4.78 5.11 0.37 7.15 % 
13-Plex 39 0.88 0.92 1.36 0.90 0.97 1.01 0.20 19.95 % 
13-Plex 46 1.72 2.09 2.30 1.94 2.06 2.02 0.21 10.53 % 
13-Plex 50 1.41 1.86 2.03 1.57 1.68 1.71 0.24 14.19 % 
13-Plex 62 0.44 0.47 0.53 0.43 0.45 0.46 0.04 8.57 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-13: Inter assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 9.36 10.37 11.43 14.34 10.83 11.27 1.88 16.67 % 
13-Plex 05 2.83 3.39 3.34 2.79 3.03 3.08 0.28 9.09 % 
13-Plex 08 4.64 5.48 6.18 5.35 5.65 5.46 0.56 10.19 % 
13-Plex 10 9.15 11.47 7.68 10.96 10.03 9.86 1.51 15.29 % 
13-Plex 11 6.84 7.35 7.48 6.93 6.76 7.07 0.32 4.56 % 
13-Plex 12 1.01 0.85 1.26 0.90 1.01 1.01 0.16 15.73 % 
13-Plex 16 1.45 1.62 1.87 1.40 1.54 1.58 0.18 11.72 % 
13-Plex 18 5.38 7.10 7.58 5.56 5.84 6.29 0.99 15.66 % 
13-Plex 20 2.09 2.52 2.77 2.12 2.35 2.37 0.28 12.00 % 
13-Plex 25 0.16 0.20 0.25 0.19 0.17 0.19 0.04 18.08 % 
13-Plex 28 0.74 0.79 0.99 0.80 0.75 0.81 0.10 12.49 % 
13-Plex 32 0.58 0.47 0.50 0.43 0.54 0.50 0.06 11.62 % 
13-Plex 44 0.89 1.04 1.29 0.84 1.00 1.01 0.18 17.31 % 
13-Plex 50 3.62 5.05 5.85 4.26 4.58 4.67 0.84 17.96 % 
13-Plex 51 0.32 0.25 0.35 0.23 0.26 0.28 0.05 17.98 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with %CV of less than or equal to 25.00 15 









Appendix IV-14: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 05 0.66 0.72 0.75 0.85 0.77 0.75 0.07 9.29 % 
13-Plex 06 0.55 0.23 0.29 0.25 0.24 0.31 0.13 
43.26 
% 
13-Plex 08 2.14 1.96 1.94 2.32 2.17 2.11 0.16 7.50 % 
13-Plex 12 0.40 0.55 0.49 0.46 0.49 0.48 0.05 
11.40 
% 
13-Plex 17 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 18 0.45 0.51 0.49 0.44 0.44 0.47 0.03 6.89 % 
13-Plex 20 0.75 0.44 0.69 0.71 0.63 0.64 0.12 
18.94 
% 
13-Plex 21 0.33 0.31 0.36 0.37 0.44 0.36 0.05 
13.73 
% 
13-Plex 22 1.50 1.43 1.53 1.47 1.51 1.49 0.04 2.62 % 
13-Plex 28 0.58 0.59 0.69 0.61 0.64 0.62 0.04 7.14 % 
13-Plex 32 0.20 0.24 0.24 0.27 0.23 0.24 0.03 
10.64 
% 
13-Plex 42 1.24 1.24 1.44 1.24 1.33 1.30 0.09 6.81 % 
13-Plex 46 0.50 0.50 0.51 0.42 0.46 0.48 0.04 7.88 % 
13-Plex 59 0.10 0.12 0.11 0.11 0.11 0.11 0.01 6.43 % 
13-Plex 60 0.32 0.30 0.29 0.32 0.31 0.31 0.01 4.23 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.10 0.11 0.10 0.10 0.11 0.10 0.01 5.27 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 







Appendix IV-15: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.16 0.14 0.15 0.18 0.18 0.16 0.02 11.04 % 
13-Plex 05 0.22 0.28 0.27 0.33 0.27 0.27 0.04 14.28 % 
13-Plex 08 4.78 4.56 4.14 4.96 5.16 4.72 0.39 8.32 % 
13-Plex 10 2.66 2.72 3.24 3.26 2.93 2.96 0.28 9.50 % 
13-Plex 18 1.31 1.43 1.43 1.34 1.31 1.36 0.06 4.51 % 
13-Plex 20 0.44 0.27 0.40 0.42 0.39 0.38 0.07 17.33 % 
13-Plex 21 0.95 0.95 1.11 1.18 1.38 1.11 0.18 16.12 % 
13-Plex 22 4.23 4.54 4.66 4.69 4.35 4.49 0.20 4.43 % 
13-Plex 25 0.17 0.20 0.20 0.18 0.18 0.19 0.01 7.21 % 
13-Plex 28 0.76 0.80 0.89 0.83 0.89 0.83 0.06 6.81 % 
13-Plex 31 10.30 9.26 10.42 9.85 10.20 10.01 0.47 4.68 % 
13-Plex 42 0.49 0.51 0.56 0.52 0.51 0.52 0.03 5.00 % 
13-Plex 46 0.58 0.60 0.57 0.51 0.58 0.57 0.03 6.02 % 
13-Plex 50 1.32 1.37 1.34 1.43 1.40 1.37 0.04 3.24 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.17 0.19 0.16 0.17 0.18 0.17 0.01 6.55 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 
 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-16: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.29 0.28 0.28 0.33 0.38 0.31 0.04 13.86 % 
13-Plex 05 0.99 1.18 1.17 1.29 1.12 1.15 0.11 9.47 % 
13-Plex 06 0.86 0.46 0.50 0.42 0.45 0.54 0.18 33.88 % 
13-Plex 08 3.31 3.32 2.67 3.49 3.41 3.24 0.33 10.09 % 
13-Plex 10 3.85 4.18 4.96 4.38 3.80 4.23 0.47 11.12 % 
13-Plex 16 0.48 0.58 0.61 0.62 0.77 0.61 0.10 17.04 % 
13-Plex 20 3.16 1.99 3.15 3.13 2.93 2.87 0.50 17.48 % 
13-Plex 22 1.81 1.80 1.89 1.85 1.80 1.83 0.04 2.15 % 
13-Plex 28 0.49 0.52 0.55 0.50 0.60 0.53 0.04 8.34 % 
13-Plex 31 0.56 0.46 0.55 0.58 0.54 0.54 0.05 8.56 % 
13-Plex 42 1.26 1.38 1.46 1.42 1.35 1.37 0.08 5.53 % 
13-Plex 46 0.54 0.55 0.56 0.48 0.51 0.53 0.03 6.20 % 
13-Plex 50 0.75 0.66 0.70 0.75 0.74 0.72 0.04 5.47 % 
13-Plex 51 0.14 0.17 0.21 0.19 0.16 0.17 0.03 15.53 % 
13-Plex 52 0.13 0.13 0.14 0.12 0.14 0.13 0.01 6.34 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-17: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.65 0.59 0.61 0.70 0.75 0.66 0.07 9.94 % 
13-Plex 08 4.34 4.00 3.65 4.42 4.33 4.15 0.32 7.75 % 
13-Plex 10 4.40 4.58 5.20 5.01 5.19 4.88 0.37 7.51 % 
13-Plex 12 2.65 3.72 3.31 3.23 3.56 3.29 0.41 12.44 % 
13-Plex 16 0.74 0.82 0.84 0.93 1.06 0.88 0.12 13.91 % 
13-Plex 18 0.79 0.84 0.84 0.77 0.75 0.80 0.04 5.12 % 
13-Plex 22 2.66 2.89 2.97 2.94 2.89 2.87 0.12 4.26 % 
13-Plex 25 0.19 0.22 0.22 0.20 0.19 0.20 0.02 7.43 % 
13-Plex 28 4.82 5.22 5.75 5.69 6.34 5.56 0.58 10.34 % 
13-Plex 31 0.89 0.77 0.89 0.91 0.91 0.87 0.06 6.75 % 
13-Plex 32 0.33 0.36 0.38 0.39 0.36 0.36 0.02 6.32 % 
13-Plex 42 1.09 1.17 1.34 1.23 1.20 1.21 0.09 7.57 % 
13-Plex 44 1.08 1.31 1.25 1.18 1.10 1.18 0.10 8.25 % 
13-Plex 51 0.67 0.71 0.83 0.75 0.69 0.73 0.06 8.66 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.18 0.17 0.19 0.19 0.18 0.18 0.01 4.60 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-18: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.59 0.49 0.54 0.68 0.73 0.61 0.10 16.28 % 
13-Plex 05 7.51 8.34 9.37 11.22 8.62 9.01 1.40 15.56 % 
13-Plex 06 2.83 0.29 0.45 0.27 0.29 0.83 1.12 135.91 % 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 10 26.32 26.40 30.78 26.69 25.28 27.09 2.13 7.86 % 
13-Plex 16 3.94 4.58 5.08 5.54 6.81 5.19 1.08 20.87 % 
13-Plex 17 0.58 0.77 0.66 0.72 0.77 0.70 0.08 11.56 % 
13-Plex 18 9.33 9.26 9.04 8.75 7.19 8.71 0.88 10.12 % 
13-Plex 21 0.39 0.44 0.43 0.43 0.52 0.44 0.05 10.78 % 
13-Plex 22 2.42 2.16 2.37 2.31 2.39 2.33 0.10 4.43 % 
13-Plex 25 1.12 1.28 1.29 1.16 1.09 1.19 0.09 7.75 % 
13-Plex 32 0.37 0.42 0.45 0.46 0.41 0.42 0.04 8.44 % 
13-Plex 33 0.53 0.54 0.60 0.51 0.53 0.54 0.03 6.31 % 
13-Plex 34 0.64 0.62 0.60 0.66 0.74 0.65 0.05 8.29 % 
13-Plex 46 1.90 2.09 1.77 1.67 1.73 1.83 0.17 9.12 % 
13-Plex 51 0.05 0.05 0.10 0.05 0.05 0.06 0.02 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 13 





Appendix IV-19: Intra assay reproducibility results generated for 













Mean SD % CV 
13-Plex 05 2.31 2.51 2.47 2.94 2.79 2.60 0.26 9.80 % 
13-Plex 10 5.91 5.53 6.91 7.01 6.40 6.35 0.64 10.01 % 
13-Plex 12 2.74 3.63 3.53 3.02 3.71 3.33 0.42 12.74 % 
13-Plex 16 0.15 0.16 0.17 0.18 0.22 0.18 0.03 15.35 % 
13-Plex 18 1.74 1.90 2.02 1.73 1.80 1.84 0.12 6.65 % 
13-Plex 20 2.12 1.37 2.10 2.01 1.89 1.90 0.31 16.27 % 
13-Plex 21 2.50 2.40 2.88 2.70 3.78 2.85 0.55 19.31 % 
13-Plex 22 4.63 4.66 4.90 4.73 4.51 4.69 0.14 3.07 % 
13-Plex 28 0.32 0.36 0.40 0.37 0.36 0.36 0.03 7.91 % 
13-Plex 34 0.36 0.35 0.33 0.34 0.37 0.35 0.02 4.52 % 
13-Plex 42 0.82 0.86 0.95 0.90 0.93 0.89 0.05 5.90 % 
13-Plex 46 0.56 0.58 0.58 0.50 0.50 0.54 0.04 7.53 % 
13-Plex 50 1.64 1.53 1.55 1.70 1.69 1.62 0.08 4.84 % 
13-Plex 59 0.23 0.28 0.25 0.26 0.26 0.26 0.02 7.10 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-20: Intra assay reproducibility results for beads prepared 













Mean SD %CV 
13-Plex 03 0.13 0.15 0.14 0.14 0.14 0.14 0.01 5.05 % 
13-Plex 08 32.08 31.43 30.68 30.05 30.68 30.98 0.78 2.53 % 
13-Plex 10 0.05 0.10 0.05 0.05 0.13 0.12 0.02 18.45 % 
13-Plex 12 5.61 4.99 4.01 4.8 5.08 4.90 0.58 11.85 % 
13-Plex 16 5.30 5.99 5.86 6.18 5.77 5.82 0.33 5.65 % 
13-Plex 18 0.69 0.39 0.51 0.33 0.34 0.45 0.15 33.42 % 
13-Plex 20 0.12 0.05 0.13 0.13 0.12 0.13 0.01 4.62 % 
13-Plex 21 0.15 0.27 0.16 0.17 0.20 0.21 0.08 40.41 % 
13-Plex 22 2.55 2.58 2.44 2.72 2.75 2.61 0.13 4.89 % 
13-Plex 28 0.11 0.14 0.15 0.13 0.75 0.13 0.02 15.61 % 
13-Plex 31 1.51 1.47 1.45 1.51 1.49 1.49 0.03 1.75 % 
13-Plex 32 0.36 0.51 0.53 0.46 0.49 0.47 0.07 14.19 % 
13-Plex 34 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 2.08 2.25 2.27 2.34 2.26 2.24 0.10 4.29 % 
13-Plex 50 0.79 0.79 0.81 0.84 0.80 0.81 0.02 2.57 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with %CV of less than or equal to 25.00 12 





Appendix IV-21: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 08 5.01 8.79 8.27 5.66 5.21 6.59 1.80 27.29 % 
13-Plex 10 0.58 0.65 0.55 0.56 0.79 0.63 0.10 15.92 % 
13-Plex 12 1.65 2.35 1.45 1.50 1.74 1.74 0.36 20.78 % 
13-Plex 16 0.70 0.95 0.94 1.06 0.96 0.92 0.13 14.44 % 
13-Plex 18 4.24 5.04 5.13 3.98 3.93 4.46 0.58 12.99 % 
13-Plex 20 2.30 1.36 2.19 2.33 2.21 2.08 0.41 19.52 % 
13-Plex 21 5.86 5.97 6.00 6.92 8.45 6.64 1.10 16.53 % 
13-Plex 28 0.11 0.12 0.13 0.11 0.21 0.14 0.04 31.02 % 
13-Plex 32 0.11 0.16 0.17 0.14 0.15 0.15 0.02 15.77 % 
13-Plex 34 0.97 1.10 0.88 0.97 1.00 0.98 0.08 8.02 % 
13-Plex 44 0.30 0.39 0.38 0.35 0.35 0.35 0.04 9.91 % 
13-Plex 46 5.50 5.85 6.55 4.20 6.01 5.62 0.88 15.66 % 
13-Plex 51 0.91 0.93 1.07 1.05 0.83 0.96 0.10 10.50 % 
13-Plex 52 0.23 0.23 0.31 0.23 0.27 0.25 0.04 14.09 % 
13-Plex 59 0.18 0.15 0.14 0.17 0.17 0.16 0.02 10.14 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 13 





Appendix IV-22: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 08 3.81 4.54 4.40 3.87 3.84 4.09 0.35 8.53 % 
13-Plex 10 0.24 0.24 0.20 0.20 0.24 0.22 0.02 9.78 % 
13-Plex 12 2.91 2.64 2.34 2.77 2.55 2.64 0.22 8.20 % 
13-Plex 18 1.81 1.80 1.88 1.49 1.45 1.69 0.20 11.87 % 
13-Plex 20 1.16 0.79 1.21 1.18 1.15 1.10 0.17 15.82 % 
13-Plex 22 0.91 0.97 0.98 0.96 0.94 0.95 0.03 2.91 % 
13-Plex 28 0.24 0.25 0.27 0.26 0.28 0.26 0.02 6.08 % 
13-Plex 31 0.19 0.17 0.17 0.18 0.20 0.18 0.01 7.16 % 
13-Plex 33 0.16 0.17 0.19 0.16 0.17 0.17 0.01 7.20 % 
13-Plex 44 1.11 1.20 1.38 1.24 1.21 1.23 0.10 7.97 % 
13-Plex 46 0.63 0.70 0.79 0.68 0.69 0.70 0.06 8.32 % 
13-Plex 50 6.94 6.65 7.00 6.75 6.87 6.84 0.14 2.08 % 
13-Plex 51 0.41 0.43 0.46 0.45 0.40 0.43 0.03 5.93 % 
13-Plex 59 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.19 0.18 0.18 0.20 0.19 0.19 0.01 4.45 % 
13-Plex 62 1.04 1.10 1.17 1.21 1.07 1.12 0.07 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 14 







Appendix IV-23: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.20 0.26 0.25 0.23 0.24 0.24 0.02 9.75 % 
13-Plex 05 1.49 1.47 1.37 1.33 1.55 1.44 0.09 6.25 % 
13-Plex 08 4.85 6.06 6.04 5.03 4.96 5.39 0.61 11.28 % 
13-Plex 10 3.14 3.28 2.83 2.72 3.78 3.15 0.42 13.29 % 
13-Plex 17 0.19 0.24 0.23 0.23 0.23 0.22 0.02 8.70 % 
13-Plex 18 1.75 1.81 1.72 1.42 1.42 1.62 0.19 11.64 % 
13-Plex 21 1.85 2.02 2.03 2.17 2.31 2.08 0.17 8.34 % 
13-Plex 22 5.35 5.73 5.58 5.65 5.94 5.65 0.22 3.81 % 
13-Plex 31 1.37 1.35 1.38 1.45 1.51 1.41 0.07 4.71 % 
13-Plex 34 0.19 0.19 0.14 0.17 0.18 0.17 0.02 11.92 % 
13-Plex 42 1.58 1.62 1.70 1.75 1.74 1.68 0.07 4.47 % 
13-Plex 46 1.46 1.57 1.85 1.64 1.62 1.63 0.14 8.75 % 
13-Plex 50 4.85 4.62 4.81 4.87 4.87 4.80 0.11 2.20 % 
13-Plex 51 0.49 0.52 0.56 0.58 0.50 0.53 0.04 7.31 % 
13-Plex 52 0.12 0.11 0.15 0.12 0.14 0.13 0.02 12.84 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with %CV of less than or equal to 25.00 15 





Appendix IV-24: Intra assay reproducibility results for beads prepared 













Mean SD %CV 
13-Plex 05 1.11 0.98 1.06 1.03 1.10 1.06 0.05 5.04% 
13-Plex 08 3.35 4.20 3.88 3.58 3.29 3.66 0.38 10.40% 
13-Plex 12 0.56 0.65 0.47 0.54 0.52 0.55 0.07 12.06% 
13-Plex 16 1.13 1.29 1.26 1.22 1.21 1.22 0.06 4.96% 
13-Plex 17 0.51 0.71 0.65 0.59 0.58 0.61 0.08 12.44% 
13-Plex 18 0.88 0.89 0.87 0.77 0.79 0.84 0.06 6.63% 
13-Plex 20 0.39 0.28 0.39 0.39 0.36 0.36 0.05 13.16% 
13-Plex 21 0.80 0.75 0.87 0.94 0.99 0.87 0.10 11.29% 
13-Plex 28 4.13 4.36 5.15 4.92 5.08 4.73 0.46 9.65% 
13-Plex 31 1.29 1.21 1.22 1.29 1.30 1.26 0.04 3.43% 
13-Plex 34 2.81 3.19 2.51 2.79 3.28 2.92 0.32 10.84% 
13-Plex 42 2.08 2.29 2.41 2.58 2.33 2.34 0.18 7.79% 
13-Plex 46 1.22 1.39 1.64 1.33 1.40 1.40 0.15 11.03% 
13-Plex 51 0.25 0.24 0.26 0.27 0.23 0.25 0.02 6.32% 
13-Plex 52 0.10 0.10 0.12 0.10 0.12 0.11 0.01 10.14% 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with %CV of less than or equal to 25.00 15 





Appendix IV-25: Intra assay reproducibility results generated for 













Mean SD % CV 
13-Plex 03 0.12 0.15 0.16 0.15 0.15 0.15 0.02 10.39 % 
13-Plex 05 2.58 2.67 2.42 2.37 2.54 2.52 0.12 4.82 % 
13-Plex 06 2.35 0.93 1.15 1.08 1.12 1.33 0.58 43.64 % 
13-Plex 10 0.63 0.63 0.55 0.54 0.69 0.61 0.06 10.30 % 
13-Plex 16 1.96 2.11 2.17 2.42 2.10 2.15 0.17 7.83 % 
13-Plex 17 0.43 0.54 0.53 0.51 0.57 0.52 0.05 10.22 % 
13-Plex 18 0.87 0.85 0.89 0.71 0.70 0.80 0.09 11.39 % 
13-Plex 21 1.58 1.77 1.68 1.93 2.00 1.79 0.17 9.68 % 
13-Plex 22 0.95 1.06 1.04 0.97 1.00 1.00 0.05 4.60 % 
13-Plex 28 2.73 2.89 3.15 2.92 3.28 2.99 0.22 7.32 % 
13-Plex 34 4.32 4.75 4.10 4.42 4.71 4.46 0.27 6.11 % 
13-Plex 46 1.33 1.48 1.70 1.52 1.56 1.52 0.13 8.82 % 
13-Plex 50 1.26 1.30 1.25 1.32 1.29 1.28 0.03 2.24 % 
13-Plex 52 0.19 0.20 0.23 0.22 0.21 0.21 0.02 7.53 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 0.00 % 
13-Plex 62 0.34 0.36 0.40 0.41 0.37 0.38 0.03 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-26: Intra assay reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 7.94 11.03 10.98 10.07 9.30 9.86 1.29 13.09 % 
13-Plex 05 3.52 3.53 3.26 3.25 3.63 3.44 0.17 5.02 % 
13-Plex 08 4.69 6.11 6.28 5.06 5.05 5.44 0.71 13.05 % 
13-Plex 10 9.88 10.82 9.02 9.25 12.59 10.31 1.45 14.08 % 
13-Plex 12 1.06 1.42 0.84 0.97 0.90 1.04 0.23 22.04 % 
13-Plex 16 1.62 1.79 1.86 1.96 1.84 1.81 0.12 6.88 % 
13-Plex 18 7.92 8.13 8.08 6.68 6.38 7.44 0.84 11.28 % 
13-Plex 20 2.84 1.99 2.83 2.81 2.79 2.65 0.37 13.97 % 
13-Plex 22 5.55 6.32 5.56 5.68 5.82 5.79 0.32 5.49 % 
13-Plex 25 0.21 0.22 0.24 0.22 0.24 0.23 0.01 5.94 % 
13-Plex 28 0.74 0.82 0.84 0.81 1.00 0.84 0.10 11.40 % 
13-Plex 32 0.30 0.40 0.39 0.36 0.36 0.36 0.04 10.77 % 
13-Plex 44 1.03 1.12 1.27 1.11 1.09 1.12 0.09 7.90 % 
13-Plex 50 4.87 4.55 4.79 4.86 4.98 4.81 0.16 3.34 % 
13-Plex 51 0.20 0.19 0.22 0.22 0.19 0.20 0.02 7.43 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with %CV of less than or equal to 25.00 15 





Appendix IV-27: Inter operator reproducibility results for beads 
prepared using Pn4 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 05 0.65 0.78 0.72 0.76 0.80 0.68 0.73 0.06 8.04 % 
13-Plex 06 0.26 0.26 0.27 0.31 0.25 0.22 0.26 0.03 11.19 % 
13-Plex 08 1.62 2.00 2.16 3.20 2.21 2.23 2.24 0.52 23.41 % 
13-Plex 11 4.36 5.46 5.28 4.97 3.77 4.58 4.74 0.63 13.26 % 
13-Plex 12 0.47 0.36 0.44 0.41 0.42 0.47 0.43 0.04 9.73 % 
13-Plex 17 0.05 0.10 0.05 0.05 0.05 0.05 0.06 0.02 - 
13-Plex 18 0.41 0.57 0.56 0.66 0.71 0.58 0.58 0.10 17.65 % 
13-Plex 20 0.80 0.82 0.92 1.00 0.86 0.81 0.87 0.08 8.99 % 
13-Plex 21 0.55 0.55 0.51 0.49 0.54 0.54 0.53 0.02 4.62 % 
13-Plex 28 0.86 0.99 0.98 0.93 0.85 0.95 0.93 0.06 6.43 % 
13-Plex 32 0.20 0.29 0.23 0.22 0.22 0.22 0.23 0.03 13.47 % 
13-Plex 42 1.35 1.51 1.49 1.59 1.57 1.50 1.50 0.08 5.63 % 
13-Plex 46 0.47 0.58 0.51 0.46 0.55 0.56 0.52 0.05 9.50 % 
13-Plex 59 0.11 0.15 0.15 0.12 0.14 0.13 0.13 0.02 12.25 % 
13-Plex 60 0.44 0.40 0.35 0.45 0.43 0.43 0.42 0.04 8.81 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.16 0.15 0.15 0.11 0.16 0.15 0.15 0.02 12.69 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-28: Inter operator reproducibility results for beads 
prepared using Pn6B PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.25 0.26 0.22 0.21 0.21 0.23 0.23 0.02 9.12 % 
13-Plex 05 0.37 0.44 0.39 0.30 0.37 0.48 0.39 0.06 15.94 % 
13-Plex 08 4.04 5.05 4.38 3.93 4.20 4.26 4.31 0.40 9.19 % 
13-Plex 10 3.28 3.16 3.24 3.06 3.01 3.58 3.22 0.20 6.31 % 
13-Plex 11 2.87 2.66 4.00 3.49 3.8 3.25 3.35 0.52 15.60 % 
13-Plex 18 1.10 1.50 1.29 1.38 1.48 1.62 1.40 0.18 13.11 % 
13-Plex 20 0.34 0.55 0.42 0.38 0.37 0.40 0.41 0.07 17.99 % 
13-Plex 21 1.23 1.51 1.74 1.49 1.70 1.63 1.55 0.19 11.99 % 
13-Plex 28 1.04 1.12 1.38 1.09 1.23 1.29 1.19 0.13 10.95 % 
13-Plex 31 6.47 10.33 7.68 7.73 6.70 6.18 7.52 1.52 20.21 % 
13-Plex 42 0.44 0.64 0.37 0.27 0.39 0.41 0.42 0.12 29.12 % 
13-Plex 44 0.24 0.29 0.30 0.26 0.27 0.34 0.28 0.04 12.36 % 
13-Plex 46 0.69 0.86 0.73 0.68 0.68 0.95 0.77 0.11 14.85 % 
13-Plex 50 1.35 1.53 1.59 1.44 1.65 1.71 1.55 0.13 8.66 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.22 0.27 0.26 0.19 0.24 0.26 0.24 0.03 12.64 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.13 0.05 0.05 0.05 0.05 0.06 0.03 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-29: Inter operator reproducibility results for beads 
prepared using Pn9V PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.28 0.31 0.31 0.30 0.32 0.34 0.31 0.02 6.45 % 
13-Plex 05 1.09 1.07 1.10 1.06 0.99 1.25 1.09 0.09 7.86 % 
13-Plex 06 0.52 0.56 0.46 0.45 0.48 0.45 0.49 0.04 9.16 % 
13-Plex 08 2.89 2.96 2.79 2.61 3.18 2.83 2.88 0.19 6.59 % 
13-Plex 10 4.23 5.26 3.70 3.33 3.61 4.09 4.04 0.68 16.92 % 
13-Plex 11 1.18 1.18 1.14 1.48 1.02 0.93 1.16 0.19 16.24 % 
13-Plex 16 0.66 0.55 0.61 0.74 0.53 0.59 0.61 0.08 12.57 % 
13-Plex 20 3.02 2.55 2.80 3.05 2.80 2.73 2.83 0.19 6.61 % 
13-Plex 28 0.70 0.63 0.58 0.71 0.76 0.75 0.69 0.07 10.21 % 
13-Plex 31 0.44 0.41 0.37 0.44 0.33 0.36 0.39 0.05 11.58 % 
13-Plex 42 1.42 1.01 1.40 1.29 1.65 1.60 1.40 0.23 16.56 % 
13-Plex 46 0.58 0.51 0.56 0.57 0.50 0.72 0.57 0.08 13.76 % 
13-Plex 50 0.75 0.67 0.65 0.70 0.82 0.82 0.74 0.07 10.06 % 
13-Plex 51 0.21 0.19 0.16 0.18 0.18 0.22 0.19 0.02 11.53 % 
13-Plex 52 0.18 0.18 0.12 0.13 0.17 0.18 0.16 0.03 17.23 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.10 0.10 0.10 0.00 0.00 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.12 0.06 0.03 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 16 
Number of samples with % CV of less than or equal to 25.00 16 





Appendix IV-30: Inter operator reproducibility results for beads 
prepared using Pn14 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.89 0.81 0.92 0.98 0.83 0.88 0.89 0.06 6.96 %  
13-Plex 08 4.39 4.67 4.73 6.74 4.88 5.05 5.08 0.84 16.63 % 
13-Plex 10 5.50 6.10 4.49 3.75 3.95 4.62 4.74 0.91 19.14 % 
13-Plex 11 0.82 0.65 0.56 0.42 0.55 0.52 0.59 0.14 23.21 % 
13-Plex 12 2.96 3.63 2.79 2.50 2.77 2.50 2.86 0.42 14.64 % 
13-Plex 16 1.37 1.27 0.92 0.72 0.91 0.88 1.01 0.25 24.86 % 
13-Plex 18 1.08 0.99 1.07 1.04 1.23 1.21 1.10 0.10 8.69 % 
13-Plex 25 0.40 0.27 0.21 0.18 0.25 0.21 0.25 0.08 31.05 % 
13-Plex 28 8.05 8.59 7.63 6.93 6.77 7.35 7.55 0.69 9.12 % 
13-Plex 31 0.95 0.92 0.88 0.74 0.91 0.87 0.88 0.07 8.38 %  
13-Plex 32 0.58 0.44 0.40 0.33 0.41 0.43 0.43 0.08 19.07 % 
13-Plex 42 2.03 2.09 1.29 0.91 1.32 1.36 1.50 0.46 30.89 % 
13-Plex 44 1.83 1.86 1.33 1.33 1.34 1.30 1.50 0.27 17.96 % 
13-Plex 51 1.16 1.11 0.81 0.62 0.77 0.82 0.88 0.21 23.76 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.38 0.27 0.20 0.19 0.25 0.24 0.26 0.07 26.80 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 12 





Appendix IV-31: Inter operator reproducibility results for beads 
prepared using Pn19A PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 1.17 1.31 1.23 1.14 1.12 1.28 1.21 0.08 6.40 % 
13-Plex 05 7.51 9.34 9.81 8.55 7.66 9.49 8.73 0.98 11.21 % 
13-Plex 06 0.46 0.31 0.49 0.44 0.41 0.45 0.43 0.06 14.72 % 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 10 21.55 17.54 19.76 17.89 17.13 19.14 18.84 1.66 8.82 % 
13-Plex 11 6.26 6.81 8.10 6.44 6.57 5.29 6.58 0.91 13.85 % 
13-Plex 16 4.26 3.66 5.45 5.37 4.71 4.47 4.65 0.68 14.66 % 
13-Plex 17 1.31 1.19 1.09 0.96 1.09 0.97 1.10 0.13 12.10 % 
13-Plex 18 10.93 7.86 10.64 10.84 11.53 11.53 10.56 1.37 12.99 % 
13-Plex 21 0.65 0.59 0.66 0.54 0.66 0.71 0.64 0.06 9.49 % 
13-Plex 25 1.25 1.15 1.30 1.24 1.31 1.09 1.22 0.09 7.08 % 
13-Plex 32 0.65 0.65 0.74 0.61 0.74 0.79 0.70 0.07 10.01 % 
13-Plex 33 0.54 0.31 0.58 0.52 0.54 0.56 0.51 0.10 19.53 % 
13-Plex 34 1.07 0.71 1.02 0.99 1.05 1.23 1.01 0.17 16.78 % 
13-Plex 46 2.49 2.54 2.98 2.91 2.96 3.58 2.91 0.39 13.48 % 
13-Plex 51 0.23 0.20 0.25 0.18 0.23 0.30 0.23 0.04 17.99 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.10 0.06 0.02 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-32: Inter operator reproducibility results for beads 
prepared using Pn23F PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 05 2.63 2.70 2.57 2.79 2.72 2.43 2.64 0.13 4.84 % 
13-Plex 10 6.29 6.96 5.27 4.68 5.82 5.84 5.81 0.79 13.60 % 
13-Plex 11 5.57 5.58 5.64 2.45 4.84 5.14 4.87 1.23 25.18 % 
13-Plex 12 2.63 3.87 3.29 1.82 2.96 3.17 2.96 0.69 23.38 % 
13-Plex 16 0.23 0.20 0.20 0.40 0.18 0.20 0.24 0.08 35.06 % 
13-Plex 18 1.90 2.49 1.91 1.81 2.34 2.01 2.08 0.27 13.18 % 
13-Plex 20 2.14 2.57 2.24 1.51 1.91 1.76 2.02 0.38 18.57 % 
13-Plex 21 3.73 4.21 4.21 1.59 4.02 3.68 3.57 1.00 27.93 % 
13-Plex 28 0.52 0.52 0.58 0.32 0.52 0.51 0.50 0.09 18.06 % 
13-Plex 34 0.48 0.47 0.44 0.28 0.49 0.44 0.43 0.08 17.97 % 
13-Plex 42 0.78 0.91 0.75 0.82 0.76 0.75 0.80 0.06 7.83 % 
13-Plex 46 0.70 0.74 0.62 0.52 0.67 0.71 0.66 0.08 12.08 % 
13-Plex 50 1.55 2.13 1.64 1.39 1.70 1.73 1.69 0.25 14.67 % 
13-Plex 59 0.36 0.34 0.37 0.24 0.37 0.32 0.33 0.05 14.90 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 11 





Appendix IV-33: Inter operator reproducibility results for beads 
prepared using Pn1 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.15 0.15 0.17 0.16 0.17 0.21 0.17 0.02 13.24% 
13-Plex 08 23.02 25.16 31.40 28.56 31.77 27.61 27.92 3.44 12.31% 
13-Plex 10 0.11 0.05 0.27 0.25 0.29 0.30 0.24 0.08 31.69% 
13-Plex 11 4.53 5.5 5.34 5.36 5.17 4.91 5.14 0.36 6.99% 
13-Plex 12 4.76 3.62 6.81 6.75 6.91 7.49 6.06 1.51 24.98% 
13-Plex 16 5.51 4.83 5.50 6.04 5.74 4.92 5.42 0.47 8.65% 
13-Plex 18 0.33 0.31 0.43 0.44 0.52 0.51 0.42 0.09 20.79% 
13-Plex 20 0.12 0.12 0.18 0.16 0.18 0.19 0.16 0.03 19.74% 
13-Plex 21 0.16 0.16 0.21 0.17 0.22 0.27 0.20 0.04 21.96% 
13-Plex 28 0.14 0.10 0.19 0.13 0.18 0.20 0.16 0.04 25.10% 
13-Plex 31 0.87 1.79 1.26 1.19 1.19 1.10 1.23 0.30 24.70% 
13-Plex 32 0.68 0.72 0.60 0.60 0.67 0.71 0.66 0.05 7.90% 
13-Plex 34 0.05 0.05 0.11 0.05 0.10 0.10 0.10 0.01 5.59% 
13-Plex 42 1.91 1.92 2.06 2.33 2.17 2.45 2.14 0.22 10.25% 
13-Plex 50 0.79 0.65 0.79 0.77 0.84 0.89 0.79 0.08 10.22% 
13-Plex 62 0.05 0.05 0.12 0.11 0.13 0.13 0.12 0.01 7.82% 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 16 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-34: Inter operator reproducibility results for beads 
prepared using Pn3 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 10 1.04 1.03 0.97 0.97 0.94 0.95 0.98 0.04 4.25 % 
13-Plex 11 1.02 1.3 0.80 0.68 0.76 0.84 0.90 0.23 25.14 % 
13-Plex 12 4.39 5.02 4.45 5.43 4.05 4.23 4.60 0.52 11.40 % 
13-Plex 16 0.71 0.69 0.87 1.00 0.77 0.83 0.81 0.11 14.16 % 
13-Plex 18 3.56 3.91 3.07 3.76 3.27 3.16 3.46 0.34 9.86 % 
13-Plex 20 1.69 2.12 1.77 1.98 1.40 1.47 1.74 0.28 16.15 % 
13-Plex 21 3.86 5.33 3.44 4.29 2.83 3.09 3.81 0.91 23.96 % 
13-Plex 28 0.23 0.20 0.32 0.20 0.39 0.28 0.27 0.08 27.91 % 
13-Plex 32 0.34 0.53 0.30 0.38 0.25 0.30 0.35 0.10 28.11 % 
13-Plex 34 1.70 1.51 1.45 1.27 1.63 1.32 1.48 0.17 11.40 % 
13-Plex 44 0.60 0.57 0.66 0.64 0.59 0.56 0.60 0.04 6.52 % 
13-Plex 46 7.41 11.19 6.63 7.32 5.76 6.00 7.39 1.98 26.82 % 
13-Plex 51 0.60 0.77 0.59 0.60 0.47 0.55 0.60 0.10 16.48 % 
13-Plex 52 0.38 0.45 0.35 0.37 0.33 0.30 0.36 0.05 14.11 % 
13-Plex 59 0.23 0.28 0.25 0.21 0.25 0.22 0.24 0.03 10.54 % 
13-Plex 62 0.05 0.04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.02 0.05 0.05 0.05 0.05 0.05 0.01 - 
13-Plex 69 0.05 0.04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.02 0.05 0.05 0.05 0.05 0.05 0.01 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 11 





Appendix IV-35: Inter operator reproducibility results for beads 
prepared using Pn5 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 06 0.34 0.31 0.45 0.39 0.38 0.39 0.38 0.05 12.75 % 
13-Plex 08 4.19 4.95 5.50 6.30 5.65 6.03 5.44 0.77 14.10 % 
13-Plex 10 0.21 0.25 0.25 0.26 0.25 0.29 0.25 0.03 10.18 % 
13-Plex 11 2.85 2.74 3.44 3.29 3.49 3.70 3.25 0.38 11.65 % 
13-Plex 12 3.08 2.87 3.16 3.31 3.20 3.34 3.16 0.17 5.43 % 
13-Plex 18 1.78 1.84 2.25 2.39 2.54 2.19 2.17 0.30 13.90 % 
13-Plex 20 1.13 1.37 1.60 1.68 1.53 1.58 1.48 0.20 13.55 % 
13-Plex 28 0.25 0.27 0.42 0.33 0.40 0.40 0.35 0.07 21.12 % 
13-Plex 31 0.19 0.17 0.30 0.36 0.40 0.38 0.30 0.10 33.00 % 
13-Plex 33 0.15 0.17 0.22 0.22 0.23 0.18 0.20 0.03 16.77 % 
13-Plex 44 1.28 1.40 1.48 1.35 1.41 1.39 1.39 0.07 4.81 % 
13-Plex 46 0.76 0.84 0.90 0.95 0.98 1.14 0.93 0.13 14.04 % 
13-Plex 50 6.45 9.27 7.23 7.88 7.92 7.58 7.72 0.93 12.07 % 
13-Plex 51 0.51 0.41 0.38 0.27 0.37 0.34 0.38 0.08 20.92 % 
13-Plex 59 0.05 0.05 0.10 0.05 0.11 0.05 0.11 0.01 6.73 % 
13-Plex 62 1.20 1.24 1.24 1.21 1.28 1.24 1.24 0.03 2.28 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.12 0.11 0.11 0.12 0.12 0.01 5.02 % 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 17 
Number of samples with % CV of less than or equal to 25.00 16 





Appendix IV-36: Inter operator reproducibility results for beads 
prepared using Pn6A PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.27 0.31 0.32 0.29 0.28 0.30 0.30 0.02 6.34 % 
13-Plex 05 1.35 1.67 1.75 1.75 1.60 1.49 1.60 0.16 9.85 % 
13-Plex 08 6.25 6.62 6.73 7.99 6.98 6.36 6.82 0.63 9.22 % 
13-Plex 10 4.35 3.71 3.62 3.91 3.36 3.79 3.79 0.33 8.74 % 
13-Plex 11 4.02 4.58 4.23 4.08 4.1 3.54 4.09 0.34 8.23 % 
13-Plex 17 0.19 0.19 0.28 0.21 0.24 0.20 0.22 0.04 16.24 % 
13-Plex 18 1.70 1.78 1.50 1.69 1.77 1.53 1.66 0.12 7.20 % 
13-Plex 21 1.75 2.18 2.54 2.52 2.60 2.07 2.28 0.34 14.73 % 
13-Plex 31 1.41 1.66 1.18 1.20 1.21 1.01 1.28 0.23 17.68 % 
13-Plex 34 0.17 0.19 0.19 0.18 0.18 0.21 0.19 0.01 7.32 % 
13-Plex 42 1.73 2.18 1.73 1.72 1.69 1.56 1.77 0.21 11.98 % 
13-Plex 46 1.90 1.73 1.98 2.07 1.99 1.96 1.94 0.12 5.98 % 
13-Plex 50 4.12 5.47 4.12 4.83 4.53 4.01 4.51 0.56 12.45 % 
13-Plex 51 0.41 0.52 0.68 0.57 0.67 0.66 0.59 0.11 18.24 % 
13-Plex 52 0.11 0.14 0.16 0.14 0.17 0.13 0.14 0.02 15.08 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 






Appendix IV-37: Inter operator reproducibility results for beads 
prepared using Pn7F PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 05 1.29 1.18 1.68 1.63 1.58 1.20 1.43 0.23 15.98 % 
13-Plex 08 4.56 4.93 7.12 8.62 7.59 6.67 6.58 1.57 23.82 % 
13-Plex 12 0.72 0.50 1.03 0.97 1.04 1.07 0.89 0.23 25.76 % 
13-Plex 16 1.47 1.49 2.62 2.57 2.80 2.20 2.19 0.58 26.68 % 
13-Plex 17 0.89 0.59 1.00 0.92 1.01 1.05 0.91 0.17 18.43 % 
13-Plex 18 0.92 0.99 1.23 1.38 1.47 1.32 1.22 0.22 18.02 % 
13-Plex 20 0.46 0.47 0.68 0.64 0.68 0.65 0.60 0.10 17.31 % 
13-Plex 28 6.33 5.88 15.69 11.13 12.27 8.23 9.92 3.80 38.34 % 
13-Plex 31 0.89 1.00 0.99 1.01 1.03 1.04 0.99 0.05 5.43 % 
13-Plex 34 3.93 3.68 5.71 5.64 5.43 4.44 4.81 0.90 18.78 % 
13-Plex 42 3.16 3.03 4.27 4.28 4.38 4.29 3.90 0.63 16.08 % 
13-Plex 44 0.23 0.24 0.38 0.34 0.39 0.38 0.33 0.07 22.38 % 
13-Plex 46 1.79 1.50 2.02 1.96 1.98 2.50 1.96 0.33 16.72 % 
13-Plex 51 0.24 0.21 0.22 0.19 0.22 0.26 0.22 0.02 10.85 % 
13-Plex 52 0.14 0.10 0.18 0.15 0.18 0.18 0.16 0.03 20.71 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.10 0.05 0.06 0.02 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 12 





Appendix IV-38: Inter operator reproducibility results for beads 
prepared using Pn18C PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.18 0.18 0.18 0.16 0.17 0.18 0.18 0.01 4.78 % 
13-Plex 05 2.37 2.91 2.85 2.85 2.45 2.36 2.63 0.26 10.03 % 
13-Plex 06 1.11 1.28 1.20 1.18 1.04 0.96 1.13 0.12 10.28 % 
13-Plex 10 0.60 0.76 0.52 0.56 0.53 0.57 0.59 0.09 14.93 % 
13-Plex 16 2.01 2.45 2.43 2.30 2.38 2.04 2.27 0.20 8.63 % 
13-Plex 17 0.47 0.54 0.56 0.58 0.63 0.43 0.54 0.07 13.72 % 
13-Plex 18 0.65 0.83 0.71 0.75 0.82 0.76 0.75 0.07 8.99 % 
13-Plex 21 3.14 3.30 2.82 2.44 2.91 2.81 2.90 0.30 10.26 % 
13-Plex 25 0.22 0.29 0.25 0.26 0.28 0.23 0.26 0.03 10.74 % 
13-Plex 28 4.24 4.34 5.10 4.17 4.58 3.79 4.37 0.44 10.09 % 
13-Plex 31 0.48 0.57 0.64 0.59 0.68 0.56 0.59 0.07 11.79 % 
13-Plex 34 4.69 5.43 5.80 6.36 5.58 5.43 5.55 0.55 9.83 % 
13-Plex 46 1.72 2.09 1.67 1.75 1.75 1.70 1.78 0.15 8.70 % 
13-Plex 50 1.41 1.86 1.50 1.59 1.70 1.55 1.60 0.16 9.92 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.44 0.47 0.41 0.39 0.44 0.38 0.42 0.03 8.13 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-39: Inter operator reproducibility results for beads 
prepared using Pn19F PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 9.36 10.37 10.24 8.99 8.30 8.38 9.27 0.89 9.61 % 
13-Plex 05 2.83 3.39 3.66 3.60 3.37 2.90 3.29 0.35 10.64 % 
13-Plex 08 4.64 5.48 5.86 6.57 6.18 5.59 5.72 0.66 11.58 % 
13-Plex 10 9.15 11.47 8.74 8.75 7.80 8.50 9.07 1.26 13.87 % 
13-Plex 11 6.84 7.35 4.75 4.41 4.86 3.99 5.37 1.38 25.75 % 
13-Plex 12 1.01 0.85 0.95 0.85 1.01 0.95 0.94 0.07 7.72 % 
13-Plex 16 1.45 1.62 1.89 1.74 1.93 1.57 1.70 0.19 11.05 % 
13-Plex 18 5.38 7.10 7.14 7.73 8.23 6.85 7.07 0.97 13.70 % 
13-Plex 20 2.09 2.52 2.61 2.72 2.53 2.02 2.42 0.29 11.96 % 
13-Plex 25 0.16 0.20 0.22 0.18 0.21 0.18 0.19 0.02 11.63 % 
13-Plex 28 0.74 0.79 0.72 0.54 0.69 0.58 0.68 0.10 14.32 % 
13-Plex 32 0.58 0.47 0.44 0.40 0.49 0.44 0.47 0.06 13.18 % 
13-Plex 44 0.89 1.04 1.14 1.06 1.12 0.92 1.03 0.10 10.00 % 
13-Plex 50 3.62 5.05 4.43 4.67 5.12 4.42 4.55 0.55 11.98 % 
13-Plex 51 0.32 0.25 0.27 0.20 0.27 0.29 0.27 0.04 15.12 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 






Appendix IV-40: Inter operator analyte reproducibility results for beads 
prepared using Pn4 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 05 0.66 0.62 0.70 0.66 0.04 6.06 % 
13-Plex 06 0.19 0.24 0.18 0.20 0.03 15.81 % 
13-Plex 08 1.44 1.27 1.51 1.41 0.12 8.77 % 
13-Plex 12 0.26 0.37 0.32 0.32 0.06 17.39 % 
13-Plex 17 0.10 0.10 0.05 0.10 0.00 0.00 % 
13-Plex 18 0.38 0.40 0.47 0.42 0.05 11.34 % 
13-Plex 20 0.61 0.75 0.66 0.67 0.07 10.54 % 
13-Plex 21 0.34 0.48 0.42 0.41 0.07 16.99 % 
13-Plex 28 0.76 0.99 0.80 0.85 0.12 14.46 % 
13-Plex 31 0.49 0.33 0.59 0.47 0.13 27.90 % 
13-Plex 32 0.22 0.16 0.23 0.20 0.04 18.62 % 
13-Plex 42 1.03 0.93 1.32 1.09 0.20 18.53 % 
13-Plex 46 0.51 0.27 0.66 0.48 0.20 40.98 % 
13-Plex 59 0.10 0.05 0.11 0.11 0.01 6.73 % 
13-Plex 60 0.24 0.29 0.27 0.27 0.03 9.44 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 13 





Appendix IV-41: Inter operator analyte reproducibility results for beads 
prepared using Pn6B PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.16 0.16 0.15 0.16 0.01 3.69 % 
13-Plex 05 0.34 0.33 0.33 0.33 0.01 1.73 % 
13-Plex 08 3.09 3.23 3.29 3.20 0.10 3.20 % 
13-Plex 10 2.64 2.75 2.82 2.74 0.09 3.32 % 
13-Plex 18 1.01 0.99 1.12 1.04 0.07 6.73 % 
13-Plex 20 0.34 0.34 0.35 0.34 0.01 1.68 % 
13-Plex 21 1.34 1.37 1.43 1.38 0.05 3.32 % 
13-Plex 22 3.45 4.00 4.08 3.84 0.34 8.92 % 
13-Plex 25 0.23 0.26 0.21 0.23 0.03 10.79 % 
13-Plex 28 1.09 0.87 1.15 1.04 0.15 14.22 % 
13-Plex 31 7.01 7.74 8.06 7.60 0.54 7.08 % 
13-Plex 42 0.28 0.24 0.26 0.26 0.02 7.69 % 
13-Plex 46 0.61 0.63 0.65 0.63 0.02 3.17 % 
13-Plex 50 1.19 1.30 1.29 1.26 0.06 4.83 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.22 0.20 0.21 0.21 0.01 4.76 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 







Appendix IV-42: Inter operator analyte reproducibility results for beads 
prepared using Pn9V PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.27 0.29 0.33 0.30 0.03 10.30 % 
13-Plex 05 0.84 0.97 0.93 0.91 0.07 7.29 % 
13-Plex 06 0.43 0.50 0.51 0.48 0.04 9.08 % 
13-Plex 08 2.26 2.54 2.54 2.45 0.16 6.61 % 
13-Plex 10 3.34 4.35 3.69 3.79 0.51 13.52 % 
13-Plex 16 0.44 0.44 0.53 0.47 0.05 11.06 % 
13-Plex 20 2.33 2.77 2.76 2.62 0.25 9.59 % 
13-Plex 28 0.71 0.62 0.50 0.61 0.11 17.27 % 
13-Plex 31 0.53 0.29 0.28 0.37 0.14 38.60 % 
13-Plex 34 0.99 1.26 1.18 1.14 0.14 12.13 % 
13-Plex 42 1.14 1.23 1.37 1.25 0.12 9.30 % 
13-Plex 46 0.46 0.38 0.66 0.50 0.14 28.84 % 
13-Plex 50 0.49 0.62 0.58 0.56 0.07 11.82 % 
13-Plex 51 0.16 0.13 0.13 0.14 0.02 12.37 % 
13-Plex 52 0.11 0.11 0.12 0.11 0.01 5.09 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 13 





Appendix IV-43: Inter operator analyte reproducibility results for beads 
prepared using Pn14 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 1.12 1.05 1.11 1.09 0.04 3.46 % 
13-Plex 05 3.65 3.57 3.38 3.53 0.14 3.93 % 
13-Plex 08 4.82 4.44 4.46 4.57 0.21 4.68 % 
13-Plex 10 4.39 4.19 3.86 4.15 0.27 6.45 % 
13-Plex 12 2.76 2.81 2.46 2.68 0.19 7.07 % 
13-Plex 16 0.73 0.69 0.64 0.69 0.05 6.57 % 
13-Plex 18 0.97 0.91 0.87 0.92 0.05 5.49 % 
13-Plex 25 0.20 0.20 0.19 0.20 0.01 2.94 % 
13-Plex 28 6.80 6.51 5.30 6.20 0.80 12.83 % 
13-Plex 31 0.71 0.63 0.45 0.60 0.13 22.32 % 
13-Plex 32 0.31 0.29 0.20 0.27 0.06 21.97 % 
13-Plex 42 0.62 0.68 0.70 0.67 0.04 6.24 % 
13-Plex 44 1.27 1.16 1.21 1.21 0.06 4.54 % 
13-Plex 51 0.74 0.67 0.65 0.69 0.05 6.88 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.20 0.20 0.17 0.19 0.02 9.12 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-44: Inter operator analyte reproducibility results for beads 
prepared using Pn19A PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.80 0.67 0.69 0.72 0.07 9.72% 
13-Plex 05 10.11 9.55 7.57 9.08 1.33 14.70% 
13-Plex 06 0.46 0.43 0.45 0.45 0.02 3.42% 
13-Plex 07 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 10 12.38 18.50 22.24 17.71 4.98 28.11% 
13-Plex 16 4.21 4.63 4.29 4.38 0.22 5.10% 
13-Plex 17 0.95 0.92 0.97 0.95 0.03 2.66% 
13-Plex 18 11.66 7.94 7.54 9.05 2.27 25.11% 
13-Plex 21 0.51 0.45 0.48 0.48 0.03 6.25% 
13-Plex 25 1.36 1.04 1.17 1.19 0.16 13.52% 
13-Plex 32 0.38 0.49 0.34 0.40 0.08 19.26% 
13-Plex 33 0.49 0.45 0.46 0.47 0.02 4.46% 
13-Plex 34 0.94 0.75 0.79 0.83 0.10 12.12% 
13-Plex 46 2.02 2.05 1.68 1.92 0.21 10.72% 
13-Plex 50 2.36 2.00 1.88 2.08 0.25 12.01% 
13-Plex 51 0.15 0.15 0.10 0.13 0.03 21.65% 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 13 






Appendix IV-45: Inter operator analyte reproducibility results for beads 
prepared using Pn23F PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 05 2.48 2.88 2.22 2.53 0.33 13.16 % 
13-Plex 10 4.69 4.88 4.70 4.76 0.11 2.25 % 
13-Plex 12 2.57 2.43 2.73 2.58 0.15 5.83 % 
13-Plex 16 0.22 0.31 0.17 0.23 0.07 30.41 % 
13-Plex 18 1.88 2.22 1.95 2.02 0.18 8.90 % 
13-Plex 20 1.96 1.89 2.01 1.95 0.06 3.09 % 
13-Plex 21 2.24 1.76 2.96 2.32 0.60 26.03 % 
13-Plex 22 4.60 5.44 4.61 4.88 0.48 9.87 % 
13-Plex 28 0.45 0.35 0.47 0.42 0.06 15.19 % 
13-Plex 34 0.38 0.33 0.37 0.36 0.03 7.35 % 
13-Plex 42 0.71 0.79 0.73 0.74 0.04 5.60 % 
13-Plex 46 0.51 0.59 0.51 0.54 0.05 8.61 % 
13-Plex 50 1.57 1.67 1.32 1.52 0.18 11.86 % 
13-Plex 59 0.29 0.26 0.31 0.29 0.03 8.78 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 12 





Appendix IV-46: Inter operator analyte reproducibility results for beads 
prepared using Pn1 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.12 0.14 0.14 0.13 0.01 8.66 % 
13-Plex 05 1.60 1.54 1.67 1.60 0.07 4.06 % 
13-Plex 08 30.58 21.80 29.24 27.21 4.73 17.39 % 
13-Plex 10 0.10 0.17 0.10 0.12 0.04 32.77 % 
13-Plex 12 10.58 3.21 8.17 7.32 3.76 51.34 % 
13-Plex 16 5.19 4.35 4.56 4.70 0.44 9.30 % 
13-Plex 18 0.31 0.21 0.25 0.26 0.05 19.61 % 
13-Plex 20 0.14 0.16 0.14 0.15 0.01 7.87 % 
13-Plex 21 0.12 0.18 0.14 0.15 0.03 20.83 % 
13-Plex 28 0.18 0.18 0.17 0.18 0.01 3.27 % 
13-Plex 31 1.35 0.52 0.60 0.82 0.46 55.61 % 
13-Plex 32 0.49 0.74 0.56 0.60 0.13 21.62 % 
13-Plex 34 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.93 1.29 1.90 1.71 0.36 21.16 % 
13-Plex 50 0.80 0.54 0.76 0.70 0.14 20.00 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 11 





Appendix IV-47: Inter operator analyte reproducibility results for beads 
prepared using Pn3 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 08 3.49 2.86 2.73 3.03 0.41 13.43 % 
13-Plex 10 0.76 0.88 0.89 0.84 0.07 8.58 % 
13-Plex 12 4.03 3.82 4.24 4.03 0.21 5.21 % 
13-Plex 16 0.77 0.68 0.58 0.68 0.10 14.05 % 
13-Plex 18 3.26 3.39 3.35 3.33 0.07 2.00 % 
13-Plex 20 1.91 1.87 1.7 1.83 0.11 6.10 % 
13-Plex 21 4.04 3.44 3.51 3.66 0.33 8.96 % 
13-Plex 28 0.19 0.2 0.2 0.20 0.01 2.94 % 
13-Plex 32 0.33 0.23 0.22 0.26 0.06 23.40 % 
13-Plex 34 1.13 1.37 1.33 1.28 0.13 10.07 % 
13-Plex 44 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 46 11.23 6.63 5.76 7.87 2.94 37.33 % 
13-Plex 51 0.7 0.6 0.53 0.61 0.09 14.01 % 
13-Plex 52 0.35 0.3 0.27 0.31 0.04 13.18 % 
13-Plex 59 0.19 0.2 0.18 0.19 0.01 5.26 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 13 





Appendix IV-48: Inter operator analyte reproducibility results for beads 
prepared using Pn5 PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 08 3.87 4.73 3.81 4.14 0.51 12.44 % 
13-Plex 10 0.21 0.21 0.21 0.21 0.00 0.00 % 
13-Plex 12 2.65 2.74 2.65 2.68 0.05 1.94 % 
13-Plex 18 1.48 2.00 1.41 1.63 0.32 19.78 % 
13-Plex 20 1.21 1.50 1.14 1.28 0.19 14.87 % 
13-Plex 28 0.29 0.34 0.26 0.30 0.04 13.62 % 
13-Plex 31 0.14 0.19 0.17 0.17 0.03 15.10 % 
13-Plex 33 0.14 0.16 0.14 0.15 0.01 7.87 % 
13-Plex 42 0.85 1.02 0.83 0.90 0.10 11.60 % 
13-Plex 44 1.07 1.13 1.00 1.07 0.07 6.10 % 
13-Plex 46 0.82 0.71 0.60 0.71 0.11 15.49 % 
13-Plex 50 7.00 7.98 6.07 7.02 0.96 13.61 % 
13-Plex 51 0.36 0.26 0.32 0.31 0.05 16.06 % 
13-Plex 59 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.16 0.13 0.13 0.14 0.02 12.37 % 
13-Plex 62 1.05 0.99 0.91 0.98 0.07 7.14 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-49: Inter operator analyte reproducibility results for beads 
prepared using Pn6A PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.26 0.25 0.26 0.26 0.01 2.25 % 
13-Plex 05 1.47 1.51 1.43 1.47 0.04 2.72 % 
13-Plex 08 5.65 6.21 6.17 6.01 0.31 5.20 % 
13-Plex 10 3.21 3.80 3.67 3.56 0.31 8.71 % 
13-Plex 17 0.24 0.25 0.26 0.25 0.01 4.00 % 
13-Plex 18 1.18 1.24 1.33 1.25 0.08 6.04 % 
13-Plex 21 2.18 2.00 2.27 2.15 0.14 6.39 % 
13-Plex 22 4.74 4.58 4.65 4.66 0.08 1.72 % 
13-Plex 31 0.96 1.01 1.08 1.02 0.06 5.93 % 
13-Plex 34 0.17 0.18 0.19 0.18 0.01 5.56 % 
13-Plex 42 1.20 1.30 1.31 1.27 0.06 4.79 % 
13-Plex 46 1.73 1.68 1.67 1.69 0.03 1.90 % 
13-Plex 50 3.41 3.67 3.63 3.57 0.14 3.92 % 
13-Plex 51 0.59 0.57 0.59 0.58 0.01 1.98 % 
13-Plex 52 0.13 0.16 0.15 0.15 0.02 10.41 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-50: Inter operator analyte reproducibility results for beads 
prepared using Pn7F PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 05 1.70 1.85 1.66 1.74 0.10 5.77 % 
13-Plex 08 7.40 7.56 7.84 7.60 0.22 2.93 % 
13-Plex 12 0.90 0.80 0.89 0.86 0.06 6.38 % 
13-Plex 16 2.42 2.27 2.25 2.31 0.09 4.02 % 
13-Plex 17 0.39 0.32 0.37 0.36 0.04 10.02 % 
13-Plex 18 1.32 1.37 1.33 1.34 0.03 1.97 % 
13-Plex 20 0.65 0.65 0.67 0.66 0.01 1.76 % 
13-Plex 21 1.68 1.49 1.67 1.61 0.11 6.63 % 
13-Plex 28 13.16 11.17 12.37 12.23 1.00 8.19 % 
13-Plex 31 0.70 0.88 0.74 0.77 0.09 12.22 % 
13-Plex 34 5.65 6.19 6.23 6.02 0.32 5.38 % 
13-Plex 42 3.87 4.36 4.22 4.15 0.25 6.08 % 
13-Plex 46 2.72 3.35 2.40 2.82 0.48 17.12 % 
13-Plex 51 0.24 0.24 0.23 0.24 0.01 2.44 % 
13-Plex 52 0.16 0.16 0.15 0.16 0.01 3.69 % 
13-Plex 60 0.10 0.05 0.05 0.07 0.03 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-51: Inter operator analyte reproducibility results for beads 
prepared using Pn18C PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 0.14 0.14 0.14 0.14 0.00 0.00 % 
13-Plex 05 2.37 2.85 2.36 2.53 0.28 11.08 % 
13-Plex 06 1.18 1.24 1.11 1.18 0.07 5.53 % 
13-Plex 10 0.56 0.67 0.60 0.61 0.06 9.13 % 
13-Plex 16 2.36 2.45 2.14 2.32 0.16 6.88 % 
13-Plex 17 0.43 0.47 0.45 0.45 0.02 4.44 % 
13-Plex 18 0.66 0.75 0.70 0.70 0.05 6.41 % 
13-Plex 21 2.32 2.15 2.48 2.32 0.17 7.12 % 
13-Plex 22 0.96 1.00 0.94 0.97 0.03 3.16 % 
13-Plex 28 4.00 4.20 3.94 4.05 0.14 3.36 % 
13-Plex 34 4.59 5.14 4.73 4.82 0.29 5.93 % 
13-Plex 46 1.65 1.72 1.61 1.66 0.06 3.35 % 
13-Plex 50 1.50 1.59 1.51 1.53 0.05 3.22 % 
13-Plex 52 0.20 0.20 0.21 0.20 0.01 2.84 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.44 0.42 0.43 0.43 0.01 2.33 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-52: Inter operator analyte reproducibility results for beads 
prepared using Pn19F PS. 
 
Sample Operator 1 Operator 2 Operator 3 Mean SD % CV 
13-Plex 03 9.95 11.37 9.23 10.18 1.09 10.69 % 
13-Plex 05 3.01 3.62 2.84 3.16 0.41 12.99 % 
13-Plex 08 5.29 5.80 5.39 5.49 0.27 4.92 % 
13-Plex 10 8.94 11.59 10.13 10.22 1.33 12.99 % 
13-Plex 12 1.07 0.94 1.10 1.04 0.09 8.20 % 
13-Plex 16 1.43 1.45 1.30 1.39 0.08 5.85 % 
13-Plex 18 5.72 6.42 5.49 5.88 0.48 8.24 % 
13-Plex 20 2.58 2.93 2.42 2.64 0.26 9.87 % 
13-Plex 22 5.92 5.89 5.30 5.70 0.35 6.13 % 
13-Plex 25 0.27 0.23 0.28 0.26 0.03 10.18 % 
13-Plex 28 0.79 0.89 0.84 0.84 0.05 5.95 % 
13-Plex 32 0.10 0.05 0.05 0.07 0.03 - 
13-Plex 44 1.02 1.08 1.03 1.04 0.03 3.08 % 
13-Plex 50 4.58 5.38 4.39 4.78 0.53 10.98 % 
13-Plex 51 0.21 0.19 0.22 0.21 0.02 7.39 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-53: Intra operator analyte reproducibility results for beads 
prepared using Pn4 PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 05 0.77 0.81 0.77 0.72 0.77 0.04 4.80 % 
13-Plex 06 0.25 0.25 0.28 0.30 0.27 0.02 9.07 % 
13-Plex 08 1.92 2.08 1.86 1.72 1.90 0.15 7.87 % 
13-Plex 11 4.69 4.54 4.70 5.04 4.74 0.21 4.46 % 
13-Plex 12 0.46 0.46 0.45 0.50 0.47 0.02 4.74 % 
13-Plex 17 0.05 0.05 0.05 0.13 0.07 0.04 - 
13-Plex 18 0.56 0.53 0.65 0.59 0.58 0.05 8.80 % 
13-Plex 20 0.87 0.80 0.98 0.94 0.90 0.08 8.84 % 
13-Plex 21 0.55 0.52 0.62 0.59 0.57 0.04 7.71 % 
13-Plex 28 0.89 0.83 0.86 0.98 0.89 0.06 7.28 % 
13-Plex 32 0.28 0.29 0.25 0.29 0.28 0.02 6.82 % 
13-Plex 42 1.55 1.59 1.62 1.66 1.61 0.05 2.90 % 
13-Plex 46 0.47 0.47 0.45 0.45 0.46 0.01 2.51 % 
13-Plex 59 0.14 0.14 0.15 0.16 0.15 0.01 6.49 % 
13-Plex 60 0.37 0.39 0.42 0.49 0.42 0.05 12.58 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.13 0.13 0.16 0.19 0.15 0.03 18.83 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-54: Intra operator analyte reproducibility results for beads 
prepared using Pn6B PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 0.19 0.18 0.19 0.20 0.19 0.01 4.30 % 
13-Plex 05 0.39 0.40 0.42 0.40 0.40 0.01 3.13 % 
13-Plex 08 3.36 3.22 3.31 3.03 3.23 0.15 4.50 % 
13-Plex 10 3.72 3.35 3.67 4.09 3.71 0.30 8.18 % 
13-Plex 11 3.33 3.46 3.15 3.47 3.35 0.15 4.45 % 
13-Plex 18 1.08 0.88 1.23 1.04 1.06 0.14 13.60 % 
13-Plex 20 0.36 0.32 0.43 0.37 0.37 0.05 12.29 % 
13-Plex 21 1.72 1.67 1.99 1.78 1.79 0.14 7.86 % 
13-Plex 28 1.18 1.09 1.17 1.19 1.16 0.05 3.95 % 
13-Plex 31 7.58 6.67 6.54 6.58 6.84 0.49 7.23 % 
13-Plex 42 3.12 2.69 3.00 2.82 2.91 0.19 6.55 % 
13-Plex 44 0.27 0.26 0.29 0.29 0.28 0.02 5.41 % 
13-Plex 46 0.82 0.69 0.71 0.70 0.73 0.06 8.29 % 
13-Plex 50 1.00 1.22 1.37 1.29 1.22 0.16 13.03 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.22 0.21 0.24 0.25 0.23 0.02 7.94 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-55: Intra operator analyte reproducibility results for beads 
prepared using Pn9V PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 0.29 0.25 0.29 0.24 0.27 0.03 9.83% 
13-Plex 05 1.42 1.43 1.50 1.29 1.41 0.09 6.21% 
13-Plex 06 0.59 0.60 0.64 0.50 0.58 0.06 10.14% 
13-Plex 08 2.59 2.62 3.00 2.30 2.63 0.29 10.93% 
13-Plex 10 4.55 4.39 4.79 4.00 4.43 0.33 7.49% 
13-Plex 16 0.69 0.65 0.75 0.60 0.67 0.06 9.43% 
13-Plex 20 3.10 3.21 3.51 3.14 3.24 0.19 5.73% 
13-Plex 28 0.63 0.55 0.58 0.51 0.57 0.05 8.91% 
13-Plex 31 0.45 0.38 0.45 0.37 0.41 0.04 10.54% 
13-Plex 34 1.27 1.31 1.36 1.20 1.29 0.07 5.26% 
13-Plex 42 1.29 1.21 1.40 1.16 1.27 0.10 8.28% 
13-Plex 46 0.58 0.53 0.57 0.50 0.55 0.04 6.78% 
13-Plex 50 0.72 0.70 0.79 0.64 0.71 0.06 8.68% 
13-Plex 51 0.24 0.20 0.22 0.21 0.22 0.02 7.85% 
13-Plex 52 0.19 0.16 0.18 0.16 0.17 0.01 8.70% 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.10 0.05 0.05 0.10 0.10 0.00 0.00% 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 16 
Number of samples with % CV of less than or equal to 25.00 16 





Appendix IV-56: Intra operator analyte reproducibility results for beads 
prepared using Pn14 PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 0.70 0.66 0.72 0.73 0.70 0.03 4.41 % 
13-Plex 08 3.72 3.73 3.61 3.68 3.69 0.05 1.48 % 
13-Plex 10 5.58 5.16 5.11 5.65 5.38 0.28 5.20 % 
13-Plex 11 0.45 0.44 0.46 0.45 0.45 0.01 1.81 % 
13-Plex 12 3.10 2.70 2.72 2.64 2.79 0.21 7.51 % 
13-Plex 16 1.09 1.19 1.04 1.05 1.09 0.07 6.27 % 
13-Plex 18 0.76 0.68 0.90 0.82 0.79 0.09 11.78 % 
13-Plex 25 0.27 0.26 0.29 0.28 0.28 0.01 4.69 % 
13-Plex 28 8.07 7.21 7.28 7.61 7.54 0.39 5.20 % 
13-Plex 31 0.73 0.68 0.71 0.71 0.71 0.02 2.91 % 
13-Plex 32 0.36 0.34 0.36 0.33 0.35 0.02 4.32 % 
13-Plex 42 1.62 1.60 1.64 1.71 1.64 0.05 2.91 % 
13-Plex 44 1.52 1.49 1.51 1.46 1.50 0.03 1.77 % 
13-Plex 51 0.82 0.44 0.84 0.85 0.74 0.20 26.95 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.26 0.25 0.28 0.27 0.27 0.01 4.87 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-57: Intra operator analyte reproducibility results for beads 
prepared using Pn19A PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 1.38 1.17 1.22 1.22 1.25 0.09 7.33 % 
13-Plex 05 7.75 8.54 7.65 7.49 7.86 0.47 5.95 % 
13-Plex 06 0.46 0.45 0.48 0.45 0.46 0.01 3.07 % 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 10 19.79 19.73 19.02 19.30 19.46 0.37 1.88 % 
13-Plex 11 6.65 5.77 5.13 3.80 5.34 1.20 22.47 % 
13-Plex 16 4.66 4.88 4.04 4.61 4.55 0.36 7.87 % 
13-Plex 17 1.38 1.51 1.46 1.22 1.39 0.13 9.11 % 
13-Plex 18 7.37 6.78 9.20 7.87 7.81 1.03 13.21 % 
13-Plex 21 0.76 0.69 0.88 0.68 0.75 0.09 12.25 % 
13-Plex 25 1.32 1.34 1.38 1.52 1.39 0.09 6.49 % 
13-Plex 32 0.37 0.39 0.32 0.21 0.32 0.08 24.98 % 
13-Plex 33 0.58 0.55 0.58 0.61 0.58 0.02 4.22 % 
13-Plex 34 1.06 0.94 0.90 1.05 0.99 0.08 8.07 % 
13-Plex 46 2.59 2.39 2.33 2.13 2.36 0.19 8.02 % 
13-Plex 51 0.33 0.17 0.29 0.22 0.25 0.07 28.26 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-58: Intra operator analyte reproducibility results for beads 
prepared using Pn23F PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 05 2.80 2.48 3 2.74 2.76 0.21 7.78% 
13-Plex 10 6.24 6.08 5.53 5.25 5.78 0.46 8.03% 
13-Plex 12 3.16 2.84 2.66 2.8 2.87 0.21 7.37% 
13-Plex 16 0.19 0.16 0.22 0.16 0.18 0.03 15.74% 
13-Plex 18 2.02 1.69 1.88 1.88 1.87 0.14 7.26% 
13-Plex 20 2.34 2.09 1.88 2.18 2.12 0.19 9.04% 
13-Plex 21 2.99 3.72 2.47 3.55 3.18 0.57 17.86% 
13-Plex 28 0.46 0.42 0.45 0.48 0.45 0.02 5.52% 
13-Plex 33 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 34 0.41 0.37 0.39 0.42 0.40 0.02 5.58% 
13-Plex 42 0.77 0.74 0.72 0.67 0.73 0.04 5.80% 
13-Plex 44 3.87 3.38 3.29 4.01 3.64 0.36 9.78% 
13-Plex 46 0.50 0.41 0.45 0.48 0.46 0.04 8.51% 
13-Plex 50 1.21 1.57 1.48 1.54 1.45 0.16 11.33% 
13-Plex 59 0.33 0.31 0.31 0.33 0.32 0.01 3.61% 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-59: Intra operator analyte reproducibility results for beads 
prepared using Pn1 PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 0.27 0.18 0.27 0.23 0.24 0.04 17.99 % 
13-Plex 05 1.25 1.50 1.47 1.56 1.45 0.14 9.36 % 
13-Plex 08 19.85 21.99 18.30 18.57 19.68 1.68 8.55 % 
13-Plex 10 0.23 0.19 0.17 0.27 0.22 0.04 20.63 % 
13-Plex 12 14.15 10.59 7.07 8.24 10.01 3.12 31.19 % 
13-Plex 16 3.37 4.13 4.68 4.06 4.06 0.54 13.23 % 
13-Plex 18 0.26 0.22 0.32 0.24 0.26 0.04 16.62 % 
13-Plex 20 0.21 0.15 0.16 0.22 0.19 0.04 18.98 % 
13-Plex 21 0.26 0.25 0.24 0.32 0.27 0.04 13.44 % 
13-Plex 28 0.30 0.22 0.23 0.32 0.27 0.05 18.66 % 
13-Plex 31 0.69 0.89 1.87 0.60 1.01 0.58 57.72 % 
13-Plex 32 0.51 0.79 0.72 0.82 0.71 0.14 19.68 % 
13-Plex 34 0.23 0.20 0.24 0.26 0.23 0.02 10.75 % 
13-Plex 42 0.05 0.05 0.11 0.05 0.07 0.03 - 
13-Plex 50 0.61 0.70 0.82 0.63 0.69 0.09 13.75 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 12 





Appendix IV-60: Intra operator analyte reproducibility results for beads 
prepared using Pn3 PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 08 2.74 2.76 1.51 1.52 2.13 0.71 33.44% 
13-Plex 10 1.02 0.93 0.83 0.89 0.92 0.08 8.69% 
13-Plex 12 4.27 3.96 3.63 3.58 3.86 0.32 8.32% 
13-Plex 16 0.57 0.60 0.43 0.67 0.57 0.10 17.76% 
13-Plex 18 2.94 2.87 2.26 1.97 2.51 0.47 18.81% 
13-Plex 20 1.84 1.83 1.29 1.20 1.54 0.34 22.25% 
13-Plex 21 3.39 3.66 2.41 2.67 3.03 0.59 19.42% 
13-Plex 28 0.22 0.19 0.26 0.41 0.27 0.10 36.16% 
13-Plex 32 0.29 0.32 0.55 0.12 0.32 0.18 55.26% 
13-Plex 34 1.26 1.17 1.33 2.20 1.49 0.48 32.07% 
13-Plex 44 0.64 0.58 0.50 0.50 0.56 0.07 12.26% 
13-Plex 46 5.60 5.18 4.54 5.16 5.12 0.44 8.53% 
13-Plex 51 0.31 0.28 0.26 0.35 0.30 0.04 13.05% 
13-Plex 52 5.38 5.87 3.51 0.29 3.76 2.53 67.20% 
13-Plex 59 0.22 0.18 0.18 0.22 0.20 0.02 11.55% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 10 





Appendix IV-61: Intra operator analyte reproducibility results for beads 
prepared using Pn5 PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 08 5.33 5.19 4.70 3.47 4.67 0.85 18.10% 
13-Plex 10 0.31 0.26 0.32 0.21 0.28 0.05 18.42% 
13-Plex 12 4.28 3.73 3.59 2.74 3.59 0.64 17.77% 
13-Plex 18 2.08 2.10 2.18 1.46 1.96 0.33 17.02% 
13-Plex 20 1.60 1.53 1.63 1.13 1.47 0.23 15.77% 
13-Plex 28 0.35 0.34 0.39 0.34 0.36 0.02 6.71% 
13-Plex 31 0.23 0.17 0.26 0.20 0.22 0.04 18.01% 
13-Plex 33 0.24 0.20 0.26 0.14 0.21 0.05 25.20% 
13-Plex 42 1.08 1.13 1.24 0.07 0.88 0.54 61.83% 
13-Plex 44 1.69 1.72 1.72 1.38 1.63 0.17 10.18% 
13-Plex 46 0.82 0.85 0.91 0.78 0.84 0.05 6.52% 
13-Plex 50 11.06 10.51 9.47 6.22 9.32 2.17 23.25% 
13-Plex 51 0.05 0.05 0.05 0.45 0.15 0.20 - 
13-Plex 59 0.11 0.07 0.10 0.08 0.09 0.02 20.29% 
13-Plex 60 0.21 0.20 0.22 0.20 0.21 0.01 4.61% 
13-Plex 62 1.38 1.47 1.47 1.27 1.40 0.09 6.80% 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.11 0.10 0.12 0.10 0.11 0.01 8.91% 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 16 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-62: Intra operator analyte reproducibility results for beads 
prepared using Pn6A PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 0.29 0.27 0.30 0.30 0.29 0.01 4.88 % 
13-Plex 05 1.20 1.30 1.24 1.47 1.30 0.12 9.14 % 
13-Plex 08 4.30 4.28 4.17 4.56 4.33 0.17 3.82 % 
13-Plex 10 4.68 4.04 4.62 4.23 4.39 0.31 7.02 % 
13-Plex 12 0.12 0.12 0.12 0.13 0.12 0.01 4.08 % 
13-Plex 17 0.39 0.35 0.39 0.38 0.38 0.02 5.01 % 
13-Plex 18 1.00 0.98 0.92 1.05 0.99 0.05 5.45 % 
13-Plex 21 2.44 2.49 2.52 2.54 2.50 0.04 1.74 % 
13-Plex 31 0.84 0.82 0.82 0.95 0.86 0.06 7.28 % 
13-Plex 34 0.29 0.28 0.28 0.30 0.29 0.01 3.33 % 
13-Plex 42 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 46 2.12 2.25 2.14 2.29 2.20 0.08 3.77 % 
13-Plex 50 2.89 3.16 2.99 3.19 3.06 0.14 4.65 % 
13-Plex 51 0.65 0.65 0.66 0.70 0.67 0.02 3.58 % 
13-Plex 52 0.17 0.16 0.16 0.19 0.17 0.01 8.32 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 14 






Appendix IV-63: Intra operator analyte reproducibility results for beads 
prepared using Pn7F PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 05 1.40 1.49 1.50 1.69 1.52 0.12 8.02 % 
13-Plex 08 4.76 5.27 5.14 5.63 5.20 0.36 6.91 % 
13-Plex 12 0.79 0.94 0.90 1.04 0.92 0.10 11.27 % 
13-Plex 16 1.56 2.24 2.39 2.70 2.22 0.48 21.66 % 
13-Plex 17 0.66 0.57 0.67 0.70 0.65 0.06 8.61 % 
13-Plex 18 1.01 1.04 1.06 1.14 1.06 0.06 5.23 % 
13-Plex 20 0.56 0.65 0.66 0.77 0.66 0.09 13.03 % 
13-Plex 21 1.77 2.53 2.90 3.07 2.57 0.58 22.49 % 
13-Plex 28 7.25 10.55 11.42 10.90 10.03 1.89 18.82 % 
13-Plex 31 1.42 0.67 0.66 0.57 0.83 0.40 47.70 % 
13-Plex 34 4.39 5.41 5.63 5.53 5.24 0.57 10.95 % 
13-Plex 42 0.28 0.29 0.30 0.34 0.30 0.03 8.69 % 
13-Plex 46 3.42 2.11 2.06 2.08 2.42 0.67 27.66 % 
13-Plex 51 0.22 0.20 0.20 0.19 0.20 0.01 6.21 % 
13-Plex 52 0.15 0.18 0.21 0.23 0.19 0.04 18.18 % 
13-Plex 60 0.05 0.12 0.13 0.15 0.13 0.02 11.46 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 16 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-64: Intra operator analyte reproducibility results for beads 
prepared using Pn18C PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 0.17 0.17 0.15 0.17 0.17 0.01 6.06 % 
13-Plex 05 2.59 2.63 2.83 2.72 2.69 0.11 3.96 % 
13-Plex 06 1.28 1.43 1.49 1.32 1.38 0.10 7.03 % 
13-Plex 10 0.75 0.66 0.68 0.63 0.68 0.05 7.50 % 
13-Plex 16 1.98 2.35 2.47 2.36 2.29 0.21 9.33 % 
13-Plex 17 0.67 0.59 0.63 0.59 0.62 0.04 6.18 % 
13-Plex 18 0.84 0.66 0.72 0.68 0.73 0.08 11.12 % 
13-Plex 21 1.57 2.26 2.50 2.45 2.20 0.43 19.56 % 
13-Plex 28 3.18 3.95 3.80 4.08 3.75 0.40 10.62 % 
13-Plex 34 5.39 5.63 4.99 5.06 5.27 0.30 5.66 % 
13-Plex 42 1.37 1.20 1.20 1.21 1.25 0.08 6.70 % 
13-Plex 46 1.33 1.67 1.58 1.48 1.52 0.15 9.62 % 
13-Plex 50 1.65 2.00 1.97 1.72 1.84 0.18 9.59 % 
13-Plex 52 1.05 0.86 0.87 0.84 0.91 0.10 10.77 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.41 0.40 0.41 0.42 0.41 0.01 1.99 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-65: Intra operator analyte reproducibility results for beads 
prepared using Pn19F PS. 
 
Sample Batch 1 Batch 2 Batch 3 Batch 4 Mean SD % CV 
13-Plex 03 11.46 13.30 12.21 12.52 12.37 0.76 6.16 % 
13-Plex 05 3.33 3.13 3.11 2.91 3.12 0.17 5.50 % 
13-Plex 08 5.32 5.02 5.19 4.66 5.05 0.29 5.67 % 
13-Plex 10 11.43 12.98 12.27 13.15 12.46 0.78 6.29 % 
13-Plex 12 1.30 1.13 1.26 1.26 1.24 0.07 5.99 % 
13-Plex 16 1.62 1.60 1.57 1.61 1.60 0.02 1.35 % 
13-Plex 18 6.36 5.65 5.34 5.32 5.67 0.49 8.57 % 
13-Plex 20 2.91 2.61 2.84 2.65 2.75 0.15 5.28 % 
13-Plex 25 0.21 0.23 0.22 0.25 0.23 0.02 7.51 % 
13-Plex 28 0.73 0.71 0.84 0.87 0.79 0.08 10.07 % 
13-Plex 32 0.14 0.15 0.26 0.30 0.21 0.08 37.52 % 
13-Plex 44 1.22 1.19 1.23 1.28 1.23 0.04 3.04 % 
13-Plex 46 3.80 3.88 4.29 3.87 3.96 0.22 5.63 % 
13-Plex 50 5.85 5.45 5.79 5.26 5.59 0.28 5.02 % 
13-Plex 51 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.12 0.07 0.04 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-66: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.38 0.37 0.44 0.41 0.38 0.40 0.03 7.28 % 
13-Plex 05 0.65 0.78 0.82 0.73 0.74 0.74 0.06 8.53 % 
13-Plex 06 0.26 0.26 0.28 0.18 0.19 0.23 0.05 19.49 % 
13-Plex 10 0.34 0.44 0.49 0.38 0.37 0.40 0.06 14.91 % 
13-Plex 12 0.47 0.36 0.50 0.40 0.44 0.43 0.06 12.79 % 
13-Plex 20 0.80 0.82 0.92 0.72 0.65 0.78 0.10 13.12 % 
13-Plex 21 0.55 0.55 0.60 0.45 0.43 0.52 0.07 14.08 % 
13-Plex 28 0.86 0.99 0.88 0.85 0.84 0.88 0.06 6.91 % 
13-Plex 31 0.25 0.49 0.55 0.46 0.46 0.44 0.11 25.67 % 
13-Plex 32 0.20 0.29 0.27 0.26 0.25 0.25 0.03 13.23 % 
13-Plex 50 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 51 0.21 0.23 0.26 0.20 0.21 0.22 0.02 10.75 % 
13-Plex 59 0.11 0.15 0.16 0.13 0.11 0.13 0.02 17.28 % 
13-Plex 60 0.44 0.40 0.47 0.41 0.35 0.41 0.05 10.88 % 
13-Plex 69 0.16 0.15 0.15 0.13 0.13 0.14 0.01 9.32 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 13 





Appendix IV-67: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.25 0.26 0.20 0.20 0.18 0.22 0.03 16.02 % 
13-Plex 05 0.37 0.44 0.28 0.27 0.29 0.33 0.07 22.16 % 
13-Plex 16 0.14 0.22 0.15 0.13 0.13 0.15 0.04 24.56 % 
13-Plex 18 1.10 1.50 1.85 1.23 1.29 1.39 0.29 21.02 % 
13-Plex 20 0.34 0.55 0.49 0.37 0.35 0.42 0.09 22.46 % 
13-Plex 21 1.23 1.51 1.61 1.03 1.06 1.29 0.26 20.35 % 
13-Plex 25 0.20 0.29 0.19 0.20 0.18 0.21 0.04 20.94 % 
13-Plex 28 1.04 1.12 1.16 1.04 1.02 1.08 0.06 5.64 % 
13-Plex 34 0.13 0.19 0.14 0.10 0.11 0.13 0.04 26.17 % 
13-Plex 42 0.44 0.64 0.58 0.43 0.45 0.51 0.10 18.85 % 
13-Plex 44 0.24 0.29 0.21 0.19 0.19 0.22 0.04 18.83 % 
13-Plex 46 0.69 0.86 0.91 0.70 0.74 0.78 0.10 12.72 % 
13-Plex 50 1.35 1.53 2.11 1.34 1.43 1.55 0.32 20.69 % 
13-Plex 51 1.34 1.44 1.70 1.30 1.40 1.44 0.16 10.94 % 
13-Plex 59 0.22 0.27 0.19 0.19 0.18 0.21 0.04 17.50 % 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 12 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-68: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.28 0.31 0.27 0.38 0.23 0.29 0.06 19.03% 
13-Plex 06 0.52 0.56 0.58 0.55 0.49 0.54 0.04 6.55% 
13-Plex 12 0.54 0.49 0.65 0.60 0.52 0.56 0.06 11.50% 
13-Plex 16 0.66 0.55 0.64 0.60 0.53 0.60 0.06 9.39% 
13-Plex 17 0.17 0.15 0.15 0.16 0.16 0.16 0.01 5.30% 
13-Plex 18 0.78 0.70 0.80 0.70 0.60 0.72 0.08 11.07% 
13-Plex 28 0.70 0.63 0.72 0.70 0.63 0.68 0.04 6.33% 
13-Plex 31 0.44 0.41 0.54 0.50 0.46 0.47 0.05 10.85% 
13-Plex 32 0.46 0.48 0.55 0.55 0.53 0.51 0.04 8.09% 
13-Plex 44 0.14 0.15 0.15 0.15 0.11 0.14 0.02 12.37% 
13-Plex 46 0.58 0.51 0.60 0.58 0.50 0.55 0.05 8.23% 
13-Plex 50 0.75 0.67 0.77 0.79 0.69 0.73 0.05 7.05% 
13-Plex 51 0.21 0.19 0.24 0.23 0.18 0.21 0.03 12.14% 
13-Plex 52 0.18 0.18 0.18 0.15 0.12 0.16 0.03 16.56% 
13-Plex 59 0.11 0.16 0.14 0.11 0.05 0.13 0.02 18.84% 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-69: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.89 0.81 0.72 0.66 0.90 0.80 0.11 13.19% 
13-Plex 11 0.82 0.65 0.68 0.60 0.71 0.69 0.08 11.89% 
13-Plex 17 0.19 0.13 0.14 0.13 0.12 0.14 0.03 19.54% 
13-Plex 18 1.08 0.99 0.76 0.83 0.95 0.92 0.13 13.83% 
13-Plex 25 0.40 0.27 0.23 0.34 0.23 0.29 0.07 25.29% 
13-Plex 31 0.95 0.92 0.77 0.83 0.70 0.83 0.10 12.42% 
13-Plex 32 0.58 0.44 0.43 0.37 0.42 0.45 0.08 17.53% 
13-Plex 38 0.25 0.25 0.25 0.21 0.29 0.25 0.03 11.31% 
13-Plex 48 0.85 0.91 0.86 0.84 0.63 0.82 0.11 13.26% 
13-Plex 49 0.31 0.25 0.30 0.23 0.19 0.26 0.05 19.45% 
13-Plex 51 1.16 1.11 0.97 1.01 1.03 1.06 0.08 7.32% 
13-Plex 56 0.95 3.30 0.96 0.86 0.80 1.37 1.08 78.51% 
13-Plex 59 0.28 0.19 0.16 0.27 0.17 0.21 0.06 26.56% 
13-Plex 60 0.38 0.27 0.26 0.23 0.28 0.28 0.06 20.01% 
13-Plex 62 1.26 1.05 0.85 1.00 1.02 1.04 0.15 14.20% 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 12 





Appendix IV-70: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 1.17 1.05 0.88 1.42 0.82 1.07 0.24 22.52% 
13-Plex 06 0.46 0.41 0.38 0.59 0.34 0.44 0.10 22.15% 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 17 1.31 1.15 0.94 1.41 1.01 1.16 0.20 16.96% 
13-Plex 20 1.07 1.13 0.90 0.87 0.84 0.96 0.13 13.46% 
13-Plex 21 0.65 0.56 0.47 0.78 0.47 0.59 0.13 22.46% 
13-Plex 25 1.25 1.18 0.94 1.41 1.02 1.16 0.19 16.07% 
13-Plex 28 0.70 0.45 0.40 0.42 0.55 0.50 0.12 24.57% 
13-Plex 31 0.44 0.88 0.72 0.85 0.86 0.75 0.18 24.59% 
13-Plex 32 0.65 0.63 0.47 0.33 0.35 0.49 0.15 30.99% 
13-Plex 33 0.54 0.42 0.33 0.48 0.45 0.44 0.08 17.49% 
13-Plex 34 1.07 0.86 0.71 1.13 0.80 0.91 0.18 19.61% 
13-Plex 44 0.44 0.34 0.26 0.44 0.26 0.35 0.09 25.89% 
13-Plex 51 0.23 0.16 0.15 0.32 0.23 0.22 0.07 31.35% 
13-Plex 52 0.18 0.33 0.25 0.36 0.27 0.28 0.07 25.36% 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 14 
Number of samples with % CV of less than or equal to 25.00 10 





Appendix IV-71: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 08 0.44 0.46 0.45 0.45 0.41 0.44 0.02 4.35% 
13-Plex 16 0.23 0.20 0.20 0.18 0.17 0.20 0.02 11.75% 
13-Plex 25 0.25 0.18 0.18 0.17 0.21 0.20 0.03 16.52% 
13-Plex 28 0.52 0.52 0.45 0.46 0.53 0.50 0.04 7.62% 
13-Plex 29 1.07 0.83 1.00 0.98 0.69 0.91 0.15 16.71% 
13-Plex 31 0.39 0.39 0.29 0.32 0.33 0.34 0.04 12.94% 
13-Plex 34 0.48 0.47 0.40 0.38 0.43 0.43 0.04 10.01% 
13-Plex 38 0.27 0.23 0.28 0.24 0.19 0.24 0.04 14.73% 
13-Plex 42 0.78 0.91 0.71 0.71 0.62 0.75 0.11 14.46% 
13-Plex 46 0.70 0.74 0.60 0.65 0.69 0.68 0.05 7.87% 
13-Plex 48 0.66 0.61 0.59 0.67 0.46 0.60 0.08 14.06% 
13-Plex 49 0.61 0.51 0.61 0.50 0.49 0.54 0.06 11.15% 
13-Plex 51 0.45 0.48 0.38 0.39 0.41 0.42 0.04 9.97% 
13-Plex 52 0.26 0.20 0.20 0.18 0.25 0.22 0.03 16.02% 
13-Plex 59 0.36 0.34 0.31 0.31 0.45 0.35 0.06 16.30% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-72: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.15 0.15 0.15 0.18 0.15 0.16 0.01 8.60 % 
13-Plex 10 0.11 0.05 0.11 0.05 0.05 0.11 0.00 0.00 % 
13-Plex 20 0.12 0.12 0.05 0.05 0.05 0.12 0.00 0.00 % 
13-Plex 21 0.16 0.16 0.13 0.12 0.13 0.14 0.02 13.36 % 
13-Plex 28 0.14 0.10 0.10 0.05 0.05 0.11 0.02 20.38 % 
13-Plex 29 0.13 0.27 0.32 0.23 0.18 0.23 0.07 32.90 % 
13-Plex 31 0.87 1.79 1.61 1.35 1.27 1.38 0.35 25.50 % 
13-Plex 32 0.68 0.72 0.71 0.49 0.56 0.63 0.10 16.11 % 
13-Plex 34 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 48 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 49 0.18 0.17 0.20 0.15 0.18 0.18 0.02 10.32 % 
13-Plex 50 0.79 0.65 0.70 0.63 0.59 0.67 0.08 11.45 % 
13-Plex 58 0.17 0.19 0.21 0.17 0.18 0.18 0.02 9.09 % 
13-Plex 59 0.11 0.10 0.05 0.05 0.05 0.11 0.01 6.73 % 
13-Plex 60 0.11 0.12 0.13 0.05 0.05 0.12 0.01 8.33 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 13 
Number of samples with % CV of less than or equal to 25.00 11 





Appendix IV-73: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.27 0.31 0.27 0.30 0.37 0.30 0.04 13.48% 
13-Plex 06 0.13 0.18 0.19 0.11 0.18 0.16 0.04 22.56% 
13-Plex 15 0.34 0.37 0.33 0.41 0.43 0.38 0.04 11.53% 
13-Plex 16 0.71 0.69 0.67 0.78 0.95 0.76 0.11 15.00% 
13-Plex 27 0.76 1.02 0.70 0.76 0.59 0.81 0.14 20.63% 
13-Plex 28 0.23 0.20 0.27 0.14 0.14 0.20 0.06 29.00% 
13-Plex 29 0.45 0.94 0.63 0.64 0.57 0.65 0.18 28.01% 
13-Plex 32 0.34 0.53 0.51 0.43 0.73 0.51 0.14 28.54% 
13-Plex 44 0.60 0.57 0.72 0.49 0.64 0.60 0.09 14.08% 
13-Plex 49 0.26 0.39 0.24 0.30 0.28 0.29 0.06 19.77% 
13-Plex 51 0.60 0.77 0.77 0.71 0.96 0.76 0.13 17.15% 
13-Plex 52 0.38 0.45 0.40 0.36 0.40 0.40 0.03 8.41% 
13-Plex 56 0.50 1.82 1.20 0.73 0.83 1.02 0.52 50.74% 
13-Plex 59 0.23 0.28 0.32 0.17 0.19 0.24 0.06 26.14% 
13-Plex 60 0.58 0.13 0.18 0.10 0.14 0.23 0.20 88.47% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 9 






Appendix IV-74: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 06 0.34 0.31 0.42 0.28 0.28 0.33 0.06 17.83 % 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 09 0.61 0.63 0.67 0.50 0.58 0.60 0.06 10.67 % 
13-Plex 10 0.21 0.25 0.22 0.20 0.21 0.22 0.02 8.82 % 
13-Plex 20 1.13 1.37 1.51 1.12 1.21 1.27 0.17 13.27 % 
13-Plex 28 0.25 0.27 0.34 0.24 0.24 0.27 0.04 15.70 % 
13-Plex 31 0.19 0.17 0.26 0.15 0.19 0.19 0.04 21.60 % 
13-Plex 32 0.27 0.21 0.26 0.19 0.23 0.23 0.03 14.43 % 
13-Plex 33 0.15 0.17 0.26 0.16 0.18 0.18 0.04 23.88 % 
13-Plex 34 0.27 0.26 0.33 0.23 0.23 0.26 0.04 15.53 % 
13-Plex 42 1.13 1.12 1.43 1.01 1.10 1.16 0.16 13.75 % 
13-Plex 44 1.28 1.40 1.62 1.25 1.40 1.39 0.15 10.47 % 
13-Plex 46 0.76 0.84 1.13 0.72 0.80 0.85 0.16 19.15 % 
13-Plex 51 0.51 0.41 0.57 0.41 0.46 0.47 0.07 14.56 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.20 0.19 0.25 0.18 0.18 0.20 0.03 14.58 % 
13-Plex 62 1.20 1.24 1.41 1.12 1.22 1.24 0.11 8.59 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-75: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.27 0.31 0.26 0.29 0.30 0.29 0.02 7.25 % 
13-Plex 05 1.35 1.67 1.76 1.31 1.71 1.56 0.21 13.64 % 
13-Plex 12 0.13 0.16 0.19 0.13 0.10 0.14 0.03 24.09 % 
13-Plex 17 0.19 0.19 0.19 0.18 0.14 0.18 0.02 12.18 % 
13-Plex 18 1.70 1.78 1.88 1.60 1.68 1.73 0.11 6.16 % 
13-Plex 20 0.08 0.11 0.14 0.08 0.10 0.10 0.02 24.41 % 
13-Plex 21 1.75 2.18 1.83 1.66 1.83 1.85 0.20 10.67 % 
13-Plex 28 0.12 0.12 0.16 0.13 0.10 0.13 0.02 17.39 % 
13-Plex 31 1.41 1.66 1.58 1.26 1.75 1.53 0.20 12.85 % 
13-Plex 32 0.18 0.22 0.22 0.17 0.25 0.21 0.03 15.73 % 
13-Plex 34 0.17 0.19 0.28 0.13 0.19 0.19 0.05 28.62 % 
13-Plex 42 1.73 2.18 2.07 1.60 2.03 1.92 0.25 12.76 % 
13-Plex 46 1.90 1.73 1.86 1.62 1.51 1.72 0.16 9.45 % 
13-Plex 51 0.41 0.52 0.63 0.43 0.43 0.48 0.09 19.03 % 
13-Plex 52 0.11 0.14 0.14 0.11 0.11 0.12 0.02 13.47 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-76: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.13 0.11 0.16 0.13 0.11 0.13 0.02 16.01 % 
13-Plex 06 0.09 0.09 0.12 0.07 0.07 0.09 0.02 23.29 % 
13-Plex 07 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 12 0.72 0.50 0.75 0.55 0.60 0.62 0.11 17.28 % 
13-Plex 17 0.89 0.59 0.74 0.65 0.79 0.73 0.12 16.06 % 
13-Plex 18 0.92 0.99 1.08 0.77 0.83 0.92 0.12 13.46 % 
13-Plex 20 0.46 0.47 0.51 0.36 0.42 0.44 0.06 12.80 % 
13-Plex 21 1.17 0.96 1.13 0.81 0.88 0.99 0.16 15.76 % 
13-Plex 31 0.89 1.00 1.21 0.93 1.07 1.02 0.13 12.40 % 
13-Plex 32 1.17 0.97 1.09 0.92 1.16 1.06 0.11 10.60 % 
13-Plex 33 0.63 0.31 0.55 0.43 0.50 0.48 0.12 25.12 % 
13-Plex 44 0.23 0.24 0.33 0.19 0.21 0.24 0.05 22.44 % 
13-Plex 51 0.24 0.21 0.30 0.18 0.20 0.23 0.05 20.66 % 
13-Plex 52 0.14 0.10 0.15 0.10 0.10 0.12 0.02 21.10 % 
13-Plex 59 0.11 0.12 0.17 0.10 0.10 0.12 0.03 24.30 % 
13-Plex 62 0.41 0.28 0.40 0.26 0.30 0.33 0.07 21.21 % 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 14 





Appendix IV-77: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 03 0.18 0.18 0.23 0.20 0.18 0.19 0.02 11.29% 
13-Plex 06 1.11 1.28 1.31 1.11 1.09 1.18 0.11 8.97% 
13-Plex 10 0.60 0.76 0.57 0.60 0.64 0.63 0.07 11.78% 
13-Plex 15 0.23 0.23 0.22 0.23 0.21 0.22 0.01 3.99% 
13-Plex 17 0.47 0.54 0.63 0.53 0.58 0.55 0.06 10.83% 
13-Plex 18 0.65 0.83 0.88 0.67 0.72 0.75 0.10 13.43% 
13-Plex 25 0.22 0.29 0.33 0.27 0.24 0.27 0.04 15.93% 
13-Plex 31 0.48 0.57 0.72 0.53 0.55 0.57 0.09 15.84% 
13-Plex 38 0.65 0.79 0.61 0.67 0.74 0.69 0.07 10.44% 
13-Plex 44 1.00 1.33 1.38 1.00 1.22 1.19 0.18 15.13% 
13-Plex 48 0.39 0.40 0.34 0.36 0.37 0.37 0.02 6.42% 
13-Plex 52 0.24 0.24 0.28 0.21 0.23 0.24 0.03 10.62% 
13-Plex 58 0.46 0.48 0.39 0.45 0.52 0.46 0.05 10.31% 
13-Plex 59 0.46 0.51 0.60 0.48 0.46 0.50 0.06 11.65% 
13-Plex 62 0.44 0.47 0.53 0.43 0.45 0.46 0.04 8.57% 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 15 





Appendix IV-78: Low end reproducibility results for beads prepared 













Mean SD % CV 
13-Plex 12 1.01 0.85 1.26 0.90 1.01 1.01 0.16 15.73% 
13-Plex 16 1.45 1.62 1.87 1.40 1.54 1.58 0.18 11.72% 
13-Plex 17 0.36 0.27 0.36 0.29 0.34 0.32 0.04 12.84% 
13-Plex 21 0.63 0.90 0.88 0.58 0.63 0.72 0.15 21.14% 
13-Plex 25 0.16 0.20 0.25 0.19 0.17 0.19 0.04 18.08% 
13-Plex 28 0.74 0.79 0.99 0.80 0.75 0.81 0.10 12.49% 
13-Plex 31 0.62 0.72 0.93 0.55 0.67 0.70 0.14 20.65% 
13-Plex 32 0.58 0.47 0.50 0.43 0.54 0.50 0.06 11.62% 
13-Plex 33 0.12 0.14 0.23 0.13 0.17 0.16 0.04 28.09% 
13-Plex 34 0.60 0.62 0.75 0.54 0.58 0.62 0.08 12.86% 
13-Plex 44 0.89 1.04 1.29 0.84 1.00 1.01 0.18 17.31% 
13-Plex 49 0.32 0.43 0.27 0.32 0.20 0.31 0.08 27.30% 
13-Plex 51 0.32 0.25 0.35 0.23 0.26 0.28 0.05 17.98% 
13-Plex 52 0.11 0.10 0.12 0.08 0.09 0.10 0.02 15.81% 
13-Plex 59 0.12 0.12 0.17 0.10 0.10 0.12 0.03 23.47% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 66 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 69 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 73 0.05 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples tested (not including negative samples) 15 
Number of samples with % CV of less than or equal to 25.00 13 






Appendix V. Assay Validation: Linearity 
 
Appendix V-1: Linearity results using beads prepared from all panel A 
serotypes 
 




Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 0.69 0.48 0.90 0.79 0.98 
13-Plex 08 2.37 1.66 3.08 2.23 2.24 
13-Plex 11 5.42 3.79 7.05 3.69 3.52 
13-Plex 12 0.36 0.25 0.47 0.33 0.32 
13-Plex 18 0.55 0.39 0.72 0.58 0.63 
13-Plex 20 0.76 0.53 0.99 0.74 0.76 
13-Plex 22 1.67 1.17 2.17 1.76 1.61 
13-Plex 42 1.75 1.23 2.28 1.36 1.40 
13-Plex 46 0.60 0.42 0.78 0.48 0.44 
13-Plex 53 0.31 0.22 0.40 0.18 N/A 
Total number of samples included in analysis 19 
Number of samples with adjusted result within ± 30 % 15 
Percentage of results within acceptance criteria 78.95 % 
Pn6B 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 08 5.26 3.68 6.84 5.22 5.53 
13-Plex 11 3.09 2.16 4.02 2.49 2.04 
13-Plex 12 0.05 0.04 0.07 N/A N/A 
13-Plex 18 1.60 1.12 2.08 1.66 1.81 
13-Plex 20 0.42 0.29 0.55 0.42 N/A 
13-Plex 22 5.41 3.79 7.03 5.30 4.99 
13-Plex 31 9.20 6.44 11.96 8.09 8.47 
13-Plex 42 0.60 0.42 0.78 0.46 N/A 
13-Plex 46 0.84 0.59 1.09 0.66 0.65 
13-Plex 50 1.49 1.04 1.94 1.70 1.45 
Total number of samples included in analysis 16 
Number of samples with adjusted result within ± 30 % 15 
Percentage of results within acceptance criteria 93.75% 
Pn9V 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 1.14 0.80 1.48 1.37 1.43 
13-Plex 08 2.79 1.95 3.63 2.97 2.95 
13-Plex 11 1.34 0.94 1.74 1.09 0.94 
13-Plex 12 0.51 0.36 0.66 0.42 0.35 
13-Plex 18 0.70 0.49 0.91 0.67 0.68 
13-Plex 20 2.98 2.09 3.87 2.75 2.51 
13-Plex 22 2.00 1.40 2.60 1.97 1.73 
13-Plex 42 1.63 1.14 2.12 1.48 1.49 
13-Plex 46 0.58 0.41 0.75 0.47 0.47 
13-Plex 50 0.66 0.46 0.86 0.80 0.64 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30  % 19 





Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 3.37 2.36 4.38 3.48 3.54 
13-Plex 08 4.20 2.94 5.46 4.28 4.41 
13-Plex 11 0.73 0.51 0.95 0.55 0.44 
13-Plex 12 2.96 2.07 3.85 2.65 2.56 
13-Plex 18 0.86 0.60 1.12 0.93 0.97 
13-Plex 20 3.76 2.63 4.89 3.51 3.16 
13-Plex 22 3.17 2.22 4.12 3.44 3.08 
13-Plex 42 2.10 1.47 2.73 1.65 1.56 
13-Plex 46 1.74 1.22 2.26 1.47 1.56 
13-Plex 50 0.88 0.62 1.14 1.00 0.75 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30 % 19 
Percentage of results within acceptance criteria 95.00% 
Pn19A 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 9.71 6.80 12.62 7.46 8.15 
13-Plex 11 5.22 3.65 6.79 4.00 3.70 
13-Plex 18 9.26 6.48 12.04 6.63 7.11 
13-Plex 20 1.04 0.73 1.35 1.07 0.94 
13-Plex 22 2.71 1.90 3.52 2.78 2.54 
13-Plex 31 0.99 0.69 1.29 0.82 4.36 
13-Plex 42 0.87 0.61 1.13 0.69 N/A 
13-Plex 46 2.96 2.07 3.85 2.47 2.57 
13-Plex 50 2.67 1.87 3.47 3.14 2.71 
13-Plex 53 8.74 6.12 11.36 7.98 7.74 
Total number of samples included in analysis 19 
Number of samples with adjusted result within ± 30 % 18 
Percentage of results within acceptance criteria 94.74% 
Pn23F 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 2.61 1.83 3.39 3.08 3.31 
13-Plex 11 4.74 3.32 6.16 4.04 3.86 
13-Plex 12 2.80 1.96 3.64 2.46 2.55 
13-Plex 18 1.99 1.39 2.59 1.94 2.07 
13-Plex 20 2.11 1.48 2.74 1.93 1.89 
13-Plex 22 5.08 3.56 6.60 5.36 4.29 
13-Plex 42 0.78 0.55 1.01 0.73 0.70 
13-Plex 46 0.69 0.48 0.90 0.59 0.58 
13-Plex 50 1.62 1.13 2.11 1.87 1.62 
13-Plex 53 0.39 0.27 0.51 N/A N/A 
Total number of samples included in analysis 18 
Number of samples with adjusted result within ± 30 % 18 
Percentage of results within acceptance criteria 100.00% 
cxii 
 




Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 1.99 1.39 2.59 1.60 1.62 
13-Plex 08 31.88 22.32 41.44 27.61 25.44 
13-Plex 11 5.27 3.69 6.85 3.89 3.83 
13-Plex 18 0.41 0.29 0.53 0.30 0.27 
13-Plex 22 3.07 2.15 3.99 3.25 2.82 
13-Plex 31 1.92 1.34 2.50 0.87 0.72 
13-Plex 42 3.30 2.31 4.29 2.52 2.51 
13-Plex 46 3.98 2.79 5.17 4.60 4.64 
13-Plex 50 0.90 0.63 1.17 0.89 0.65 
13-Plex 53 1.68 1.18 2.18 0.80 0.72 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30 % 15 
Percentage of results within acceptance criteria 75.00% 
Pn3 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 8.43 5.90 10.96 6.29 6.35 
13-Plex 12 4.40 3.08 5.72 3.24 2.96 
13-Plex 18 4.76 3.33 6.19 3.61 3.66 
13-Plex 20 2.46 1.72 3.20 2.12 1.94 
13-Plex 22 8.58 6.01 11.15 7.15 6.16 
13-Plex 31 4.92 3.44 6.40 1.98 3.27 
13-Plex 42 8.76 6.13 11.39 4.19 3.70 
13-Plex 46 4.09 2.86 5.32 4.17 4.72 
13-Plex 50 9.77 6.84 12.70 7.13 10.71 
13-Plex 53 8.84 6.19 11.49 4.67 4.79 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30 % 16 
Percentage of results within acceptance criteria 80.00% 
Pn5 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 08 4.90 3.43 6.37 5.70 5.68 
13-Plex 11 3.01 2.11 3.91 2.31 2.05 
13-Plex 12 3.14 2.20 4.08 3.01 2.91 
13-Plex 18 1.99 1.39 2.59 2.07 2.21 
13-Plex 20 1.34 0.94 1.74 1.35 1.31 
13-Plex 22 1.06 0.74 1.38 1.31 1.24 
13-Plex 42 1.35 0.95 1.76 1.32 1.37 
13-Plex 46 0.90 0.63 1.17 0.83 0.83 
13-Plex 50 7.55 5.29 9.82 6.62 7.12 
13-Plex 53 0.54 0.38 0.70 0.50 0.52 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30 % 19 






Appendix V-2: Linearity results using beads prepared from all panel B 
serotypes (continued) 
 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 2.00 1.40 2.60 1.89 1.97 
13-Plex 08 7.20 5.04 9.36 7.90 7.73 
13-Plex 11 4.79 3.35 6.23 3.68 3.46 
13-Plex 18 2.02 1.41 2.63 1.88 1.94 
13-Plex 20 0.05 0.04 0.07 - - 
13-Plex 22 6.04 4.23 7.85 6.61 6.76 
13-Plex 31 2.11 1.48 2.74 1.36 2.23 
13-Plex 42 2.80 1.96 3.64 2.45 2.48 
13-Plex 46 2.18 1.53 2.83 1.88 1.81 
13-Plex 50 4.92 3.44 6.40 5.75 5.32 
Total number of samples included in analysis 18 
Number of samples with adjusted result within ± 30 % 18 
Percentage of results within acceptance criteria 100.00% 
Pn7F 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 1.06 0.74 1.38 1.31 1.32 
13-Plex 08 3.85 2.70 5.01 4.75 5.21 
13-Plex 11 4.73 3.31 6.15 3.39 3.06 
13-Plex 12 0.57 0.40 0.74 0.49 0.39 
13-Plex 18 0.84 0.59 1.09 0.90 0.94 
13-Plex 22 2.99 2.09 3.89 3.40 3.75 
13-Plex 42 2.97 2.08 3.86 3.26 3.31 
13-Plex 46 1.84 1.29 2.39 1.55 1.39 
13-Plex 50 0.94 0.66 1.22 1.36 1.09 
13-Plex 53 0.94 0.66 1.22 0.72 0.77 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30 % 16 
Percentage of results within acceptance criteria 80.00% 
Pn18C 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 3.27 2.29 4.25 2.78 3.12 
13-Plex 08 2.97 2.08 3.86 2.99 2.90 
13-Plex 11 5.88 4.12 7.64 3.76 3.71 
13-Plex 12 2.05 1.44 2.67 1.95 2.01 
13-Plex 18 0.81 0.57 1.05 0.77 0.87 
13-Plex 22 1.06 0.74 1.38 1.14 1.18 
13-Plex 42 1.59 1.11 2.07 1.39 1.60 
13-Plex 46 2.02 1.41 2.63 1.56 1.66 
13-Plex 50 1.46 1.02 1.90 1.48 1.44 
13-Plex 53 0.84 0.59 1.09 0.90 1.02 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30 % 20 






Appendix VI-2: Linearity results using beads prepared from all panel B 
serotypes (continued) 
Positive Sample Result Result -30% Result + 30% 
Spiked result adjusted 
for dilution factor 
1/4 1/8 
13-Plex 05 3.50 2.45 4.55 3.68 3.90 
13-Plex 08 5.25 3.68 6.83 5.61 5.42 
13-Plex 11 6.94 4.86 9.02 5.67 5.43 
13-Plex 12 0.96 0.67 1.25 0.93 0.78 
13-Plex 18 6.42 4.49 8.35 6.16 6.38 
13-Plex 20 2.33 1.63 3.03 2.21 2.09 
13-Plex 22 5.63 3.94 7.32 6.48 6.62 
13-Plex 42 3.26 2.28 4.24 3.04 3.37 
13-Plex 46 4.24 2.97 5.51 3.91 4.06 
13-Plex 53 1.72 1.20 2.24 1.65 1.74 
Total number of samples included in analysis 20 
Number of samples with adjusted result within ± 30 % 20 






Appendix VI. Assay Validation: Stability 
 
Appendix VI-1: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn4 PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 0.36 0.36 0.34 0.30 0.34 0.03 8.32 % 
13-Plex 06 0.22 0.20 0.24 0.23 0.22 0.02 7.68 % 
13-Plex 08 1.75 1.78 1.66 1.62 1.70 0.07 4.41 % 
13-Plex 10 0.37 0.34 0.32 0.37 0.35 0.02 7.00 % 
13-Plex 11 5.70 5.32 5.00 5.19 5.30 0.30 5.58 % 
13-Plex 12 0.38 0.39 0.45 0.44 0.42 0.04 8.46 % 
13-Plex 18 0.65 0.44 0.52 0.51 0.53 0.09 16.52 % 
13-Plex 19 1.99 2.13 1.99 2.34 2.11 0.17 7.83 % 
13-Plex 20 0.60 0.65 0.68 0.74 0.67 0.06 8.77 % 
13-Plex 21 0.35 0.43 0.40 0.38 0.39 0.03 8.63 % 
13-Plex 28 0.72 0.66 0.82 0.75 0.74 0.07 9.02 % 
13-Plex 31 0.37 0.39 0.39 0.41 0.39 0.02 4.19 % 
13-Plex 39 2.00 2.45 2.68 2.26 2.35 0.29 12.28 % 
13-Plex 41 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 2.01 2.07 2.19 1.94 2.05 0.11 5.16 % 
13-Plex 44 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.27 0.32 0.31 0.26 0.29 0.03 10.15 % 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 15 
Number of samples with % CV ≤ 25 % 15 





Appendix VI-2: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn6B PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 05 0.35 0.35 0.33 0.32 0.34 0.02 4.44 % 
13-Plex 08 3.65 3.83 3.83 3.51 3.71 0.16 4.19 % 
13-Plex 10 2.74 2.51 2.41 2.64 2.58 0.14 5.62 % 
13-Plex 11 3.35 3.08 3.00 3.07 3.13 0.15 4.93 % 
13-Plex 17 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 18 1.67 1.12 1.32 1.35 1.37 0.23 16.67 % 
13-Plex 19 2.98 2.81 2.65 3.13 2.89 0.21 7.19 % 
13-Plex 21 1.31 1.60 1.35 1.39 1.41 0.13 9.15 % 
13-Plex 25 0.22 0.16 0.18 0.21 0.19 0.03 14.31 % 
13-Plex 28 0.99 0.86 1.03 1.02 0.98 0.08 8.05 % 
13-Plex 31 7.38 7.54 7.09 8.49 7.63 0.61 7.95 % 
13-Plex 33 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 34 0.05 0.05 0.05 0.10 0.06 0.03 - 
13-Plex 39 1.18 1.37 1.44 1.21 1.30 0.13 9.63 % 
13-Plex 41 0.44 0.45 0.54 0.37 0.45 0.07 15.50 % 
13-Plex 50 1.26 1.68 1.53 2.67 1.79 0.62 34.46 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.20 0.21 0.20 0.16 0.19 0.02 11.52 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 14 
Number of samples with % CV ≤ 25 % 13 





Appendix VI-3: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn9V PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 0.28 0.31 0.27 0.25 0.28 0.02 9.01 % 
13-Plex 05 0.92 0.99 0.89 0.93 0.93 0.04 4.50 % 
13-Plex 08 2.56 2.53 2.56 2.38 2.51 0.09 3.44 % 
13-Plex 10 3.64 3.35 2.98 3.65 3.41 0.32 9.27 % 
13-Plex 11 1.01 0.98 0.89 0.90 0.95 0.06 6.26 % 
13-Plex 12 0.58 0.57 0.67 0.65 0.62 0.05 8.08 % 
13-Plex 18 0.79 0.54 0.65 0.65 0.66 0.10 15.58 % 
13-Plex 19 4.38 4.51 4.03 4.75 4.42 0.30 6.80 % 
13-Plex 20 2.26 2.50 2.44 2.78 2.50 0.22 8.64 % 
13-Plex 28 0.50 0.45 0.53 0.51 0.50 0.03 6.84 % 
13-Plex 31 0.28 0.29 0.30 0.31 0.30 0.01 4.38 % 
13-Plex 33 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 34 1.01 0.96 0.95 1.23 1.04 0.13 12.63 % 
13-Plex 39 0.66 0.77 0.82 0.65 0.73 0.08 11.51 % 
13-Plex 42 1.49 1.83 1.65 1.97 1.74 0.21 12.07 % 
13-Plex 52 0.13 0.16 0.14 0.14 0.14 0.01 8.83 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 15 
Number of samples with % CV ≤ 25 % 15 





Appendix VI-4: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn14 PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 0.85 0.89 0.80 0.72 0.82 0.07 8.99 % 
13-Plex 08 4.14 4.35 4.28 3.95 4.18 0.18 4.22 % 
13-Plex 10 3.25 3.28 3.10 3.43 3.27 0.14 4.14 % 
13-Plex 12 2.32 2.42 2.69 2.78 2.55 0.22 8.53 % 
13-Plex 16 0.65 0.55 0.61 0.61 0.61 0.04 6.82 % 
13-Plex 17 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 18 1.28 0.88 1.04 1.06 1.07 0.16 15.44 % 
13-Plex 19 1.98 1.96 1.89 2.13 1.99 0.10 5.08 % 
13-Plex 21 3.85 4.38 3.71 3.95 3.97 0.29 7.27 % 
13-Plex 28 5.34 4.99 5.56 5.62 5.38 0.28 5.30 % 
13-Plex 33 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 39 3.86 3.32 3.44 3.44 3.52 0.24 6.74 % 
13-Plex 41 0.22 0.21 0.27 0.19 0.22 0.03 15.30 % 
13-Plex 42 1.64 1.69 1.69 1.55 1.64 0.07 4.02 % 
13-Plex 50 0.61 0.82 0.77 1.38 0.90 0.34 37.49 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.23 0.18 0.19 0.20 0.20 0.02 10.80 % 
13-Plex 62 1.01 0.88 1.14 0.94 0.99 0.11 11.26 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 15 
Number of samples with % CV ≤ 25 % 13 





Appendix VI-5: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn19A PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 0.91 0.89 0.85 0.75 0.85 0.07 8.37 % 
13-Plex 04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 05 7.40 8.71 7.70 7.97 7.95 0.56 7.06 % 
13-Plex 06 0.46 0.44 0.48 0.46 0.46 0.02 3.55 % 
13-Plex 10 13.04 12.67 12.61 12.61 12.73 0.21 1.63 % 
13-Plex 18 11.66 7.98 10.20 10.15 10.00 1.52 15.17 % 
13-Plex 19 1.71 1.75 1.58 1.86 1.73 0.12 6.70 % 
13-Plex 20 0.78 0.85 0.83 0.93 0.85 0.06 7.36 % 
13-Plex 21 0.48 0.60 0.51 0.51 0.53 0.05 9.90 % 
13-Plex 25 1.48 1.11 1.19 1.39 1.29 0.17 13.29 % 
13-Plex 33 0.57 0.44 0.46 0.49 0.49 0.06 11.66 % 
13-Plex 34 0.65 0.65 0.64 0.83 0.69 0.09 13.25 % 
13-Plex 39 4.06 3.43 3.63 3.62 3.69 0.27 7.23 % 
13-Plex 41 0.14 0.10 0.11 0.05 0.12 0.02 17.84 % 
13-Plex 47 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 50 2.44 3.16 2.91 6.08 3.65 1.65 45.21 % 
13-Plex 51 0.30 0.31 0.29 0.37 0.32 0.04 11.32 % 
13-Plex 62 6.15 4.91 7.58 5.61 6.06 1.13 18.67 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 16 
Number of samples with % CV ≤ 25 % 15 





Appendix VI-6: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn23F PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 4.30 4.64 4.06 3.63 4.16 0.42 10.21 % 
13-Plex 08 0.31 0.33 0.33 0.30 0.32 0.02 4.72 % 
13-Plex 11 3.92 3.59 3.36 3.52 3.60 0.24 6.55 % 
13-Plex 12 2.27 2.28 2.57 2.49 2.40 0.15 6.28 % 
13-Plex 16 0.25 0.21 0.22 0.23 0.23 0.02 7.51 % 
13-Plex 18 2.60 1.82 2.17 2.18 2.19 0.32 14.55 % 
13-Plex 19 6.26 6.40 5.96 6.83 6.36 0.36 5.68 % 
13-Plex 20 1.50 1.64 1.51 1.78 1.61 0.13 8.18 % 
13-Plex 28 0.33 0.33 0.36 0.36 0.35 0.02 5.02 % 
13-Plex 31 0.60 0.63 0.60 0.64 0.62 0.02 3.34 % 
13-Plex 33 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 34 0.23 0.26 0.24 0.31 0.26 0.04 13.69 % 
13-Plex 39 1.50 1.85 1.91 1.58 1.71 0.20 11.73 % 
13-Plex 41 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 0.88 1.05 0.95 1.14 1.01 0.11 11.33 % 
13-Plex 44 2.90 4.03 2.92 2.11 2.99 0.79 26.40 % 
13-Plex 52 0.18 0.22 0.19 0.18 0.19 0.02 9.83 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 15 
Number of samples with % CV ≤ 25 % 15 





Appendix VI-7: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn1 PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 0.14 0.12 0.14 0.14 0.14 0.01 7.41 % 
13-Plex 05 1.38 1.14 1.58 1.38 1.37 0.18 13.14 % 
13-Plex 08 28.28 27.65 26.52 26.98 27.36 0.77 2.82 % 
13-Plex 10 0.10 0.13 0.10 0.12 0.11 0.01 13.33 % 
13-Plex 11 7.48 7.43 7.95 6.21 7.27 0.74 10.22 % 
13-Plex 12 16.12 17.88 19.08 20.71 18.45 1.94 10.50 % 
13-Plex 16 3.95 4.99 4.06 4.00 4.25 0.50 11.66 % 
13-Plex 18 0.71 0.30 0.19 0.29 0.37 0.23 61.86 % 
13-Plex 19 3.30 3.26 2.43 3.53 3.13 0.48 15.39 % 
13-Plex 20 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 21 0.11 0.14 0.05 0.10 0.12 0.02 17.84 % 
13-Plex 31 1.65 1.80 1.56 1.02 1.51 0.34 22.54 % 
13-Plex 34 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.75 1.77 1.68 1.39 1.65 0.18 10.68 % 
13-Plex 44 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 50 0.37 0.70 0.76 0.71 0.64 0.18 28.13 % 
13-Plex 51 0.05 0.05 0.05 0.15 0.08 0.05 - 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 13 
Number of samples with % CV ≤ 25 % 11 




Appendix VI-8: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn3 PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 0.29 0.25 0.30 0.29 0.28 0.02 7.85% 
13-Plex 05 6.90 5.22 7.86 6.95 6.73 1.10 16.35% 
13-Plex 10 0.64 0.93 0.73 0.75 0.76 0.12 15.93% 
13-Plex 16 0.66 0.85 0.70 0.68 0.72 0.09 11.98% 
13-Plex 18 9.40 3.79 2.46 3.89 4.89 3.08 63.05% 
13-Plex 19 2.82 2.89 2.01 2.94 2.67 0.44 16.49% 
13-Plex 20 1.81 2.16 1.38 2.14 1.87 0.37 19.52% 
13-Plex 21 5.73 7.54 4.26 6.10 5.91 1.35 22.81% 
13-Plex 28 0.12 0.13 0.12 0.12 0.12 0.01 4.08% 
13-Plex 33 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 34 0.73 0.95 0.83 1.05 0.89 0.14 15.68% 
13-Plex 39 7.09 10.11 11.66 10.93 9.95 2.01 20.18% 
13-Plex 41 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 44 0.50 0.56 0.47 0.52 0.51 0.04 7.37% 
13-Plex 50 10.98 10.37 13.08 11.22 11.41 1.17 10.23% 
13-Plex 51 0.55 0.68 0.66 1.08 0.74 0.23 31.27% 
13-Plex 59 0.17 0.15 0.16 0.16 0.16 0.01 5.10% 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 04 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 15 
Number of samples with % CV ≤ 25 % 13 





Appendix VI-9: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn5 PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 10 0.17 0.21 0.18 0.19 0.19 0.02 9.11 % 
13-Plex 11 3.38 3.50 3.51 3.39 3.45 0.07 2.02 % 
13-Plex 12 2.92 3.21 3.84 3.42 3.35 0.39 11.56 % 
13-Plex 18 3.05 1.71 0.85 1.68 1.82 0.91 49.94 % 
13-Plex 19 4.48 4.55 3.20 4.84 4.27 0.73 17.07 % 
13-Plex 20 0.97 1.22 0.75 1.24 1.05 0.23 22.19 % 
13-Plex 28 0.21 0.21 0.22 0.21 0.21 0.01 2.35 % 
13-Plex 31 0.12 0.13 0.12 0.05 0.12 0.01 4.68 % 
13-Plex 33 0.14 0.16 0.13 0.16 0.15 0.01 10.17 % 
13-Plex 39 1.64 1.84 1.75 1.82 1.76 0.09 5.12 % 
13-Plex 41 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.15 1.09 1.07 0.91 1.06 0.10 9.71 % 
13-Plex 44 1.10 1.32 1.11 1.12 1.16 0.11 9.06 % 
13-Plex 50 3.32 6.23 7.46 6.58 5.90 1.79 30.43 % 
13-Plex 51 0.34 0.41 0.38 0.66 0.45 0.14 32.30 % 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.88 0.98 0.86 0.99 0.93 0.07 7.23 % 
13-Plex 71 0.10 0.10 0.05 0.05 0.10 0.00 0.00 % 
Total number of samples included in analysis 16 
Number of samples with %CV ≤ 25 % 14 





Appendix VI-10: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn6A PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 03 0.22 0.19 0.22 0.23 0.22 0.02 8.06 % 
13-Plex 05 1.60 1.37 1.90 1.70 1.64 0.22 13.42 % 
13-Plex 08 7.56 7.22 7.00 6.94 7.18 0.28 3.91 % 
13-Plex 10 4.09 5.08 4.64 4.89 4.68 0.43 9.19 % 
13-Plex 11 4.24 4.43 4.63 4.12 4.36 0.22 5.13 % 
13-Plex 12 0.05 0.05 0.10 0.05 0.05 0.00 - 
13-Plex 18 3.67 1.57 0.81 1.54 1.90 1.23 64.97 % 
13-Plex 19 11.44 12.21 8.45 13.14 11.31 2.03 17.94 % 
13-Plex 21 2.09 2.85 1.74 2.29 2.24 0.46 20.71 % 
13-Plex 31 1.00 1.11 0.98 0.62 0.93 0.21 22.95 % 
13-Plex 34 0.05 0.13 0.11 0.15 0.13 0.02 15.38 % 
13-Plex 39 1.64 1.74 1.83 1.78 1.75 0.08 4.61 % 
13-Plex 41 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.68 1.54 1.54 1.28 1.51 0.17 11.06 % 
13-Plex 50 2.30 4.01 4.67 4.39 3.84 1.06 27.67 % 
13-Plex 51 0.45 0.56 0.51 0.86 0.60 0.18 30.64 % 
13-Plex 59 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 14 
Number of samples with % CV ≤ 25 % 11 




Appendix VI-11: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn7F PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 08 6.43 5.94 5.69 5.47 5.88 0.41 7.01 % 
13-Plex 10 1.87 2.36 1.97 2.21 2.10 0.22 10.62 % 
13-Plex 12 0.74 0.80 0.89 0.87 0.83 0.07 8.31 % 
13-Plex 17 1.20 1.14 1.17 1.26 1.19 0.05 4.30 % 
13-Plex 18 2.08 1.25 0.79 1.22 1.34 0.54 40.40 % 
13-Plex 21 1.93 2.43 1.67 2.16 2.05 0.32 15.83 % 
13-Plex 28 15.73 16.55 16.45 15.96 16.17 0.39 2.42 % 
13-Plex 31 0.64 0.71 0.62 0.40 0.59 0.13 22.62 % 
13-Plex 39 1.72 1.89 1.96 1.89 1.87 0.10 5.48 % 
13-Plex 41 0.87 0.81 0.92 0.83 0.86 0.05 5.66 % 
13-Plex 42 3.43 3.47 3.54 2.66 3.28 0.41 12.60 % 
13-Plex 44 0.30 0.35 0.27 0.28 0.30 0.04 11.86 % 
13-Plex 50 1.01 1.51 1.85 1.71 1.52 0.37 24.18 % 
13-Plex 51 0.24 0.29 0.28 0.46 0.32 0.10 30.69 % 
13-Plex 52 0.15 0.16 0.14 0.15 0.15 0.01 5.44 % 
13-Plex 59 0.12 0.12 0.11 0.11 0.12 0.01 5.02 % 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 16 
Number of samples with % CV ≤ 25 % 13 





Appendix VI-12: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn18C PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD % CV 
1 5 10 15 
13-Plex 04 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 06 1.17 1.25 1.36 1.06 1.21 0.13 10.48 % 
13-Plex 08 3.07 2.94 2.62 2.64 2.82 0.22 7.92 % 
13-Plex 10 0.45 0.56 0.49 0.53 0.51 0.05 9.43 % 
13-Plex 11 9.58 8.72 9.15 7.98 8.86 0.68 7.70 % 
13-Plex 16 2.01 2.25 1.96 1.96 2.05 0.14 6.78 % 
13-Plex 17 0.69 0.63 0.66 0.67 0.66 0.03 3.77 % 
13-Plex 19 3.29 3.37 2.42 3.59 3.17 0.51 16.23 % 
13-Plex 21 2.43 2.98 1.90 2.52 2.46 0.44 18.02 % 
13-Plex 25 0.24 0.27 0.17 0.27 0.24 0.05 19.86 % 
13-Plex 31 0.56 0.62 0.54 0.31 0.51 0.14 26.79 % 
13-Plex 33 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 34 3.69 4.89 4.28 5.41 4.57 0.75 16.32 % 
13-Plex 39 1.08 1.11 1.20 1.14 1.13 0.05 4.52 % 
13-Plex 44 0.95 1.14 1.01 0.98 1.02 0.08 8.20 % 
13-Plex 50 0.76 1.29 1.55 1.42 1.26 0.35 27.62 % 
13-Plex 51 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.33 0.38 0.32 0.37 0.35 0.03 8.41 % 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 15 
Number of samples with % CV ≤ 25 % 13 





Appendix VI-13: Stability results after different numbers of freeze/thaw 
cycles for beads prepared using Pn19F PS. 
 
Sample ID 
Number of Freeze Thaw Cycles 
Mean SD %CV 
1 5 10 15 
13-Plex 05 3.14 2.66 3.65 3.19 3.16 0.40 12.81% 
13-Plex 10 8.91 11.29 9.65 10.81 10.17 1.08 10.66% 
13-Plex 11 3.11 3.17 3.33 2.83 3.11 0.21 6.70% 
13-Plex 12 0.93 1.04 1.20 1.09 1.07 0.11 10.53% 
13-Plex 16 1.32 1.51 1.32 1.34 1.37 0.09 6.71% 
13-Plex 18 14.62 6.63 3.18 6.50 7.73 4.86 62.87% 
13-Plex 19 7.01 7.48 5.16 7.61 6.82 1.13 16.63% 
13-Plex 20 2.17 2.76 1.72 2.70 2.34 0.49 20.95% 
13-Plex 21 0.69 0.92 0.52 0.76 0.72 0.17 22.95% 
13-Plex 25 0.17 0.17 0.11 0.19 0.16 0.03 21.65% 
13-Plex 34 0.40 0.50 0.43 0.54 0.47 0.06 13.68% 
13-Plex 39 2.06 2.23 2.22 2.23 2.19 0.08 3.82% 
13-Plex 42 2.58 2.50 2.37 2.00 2.36 0.26 10.87% 
13-Plex 50 2.47 4.28 4.94 4.61 4.08 1.10 27.08% 
13-Plex 51 0.19 0.25 0.23 0.40 0.27 0.09 34.31% 
13-Plex 52 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.10 0.10 0.05 0.05 0.10 0.00 0.00% 
13-Plex 60 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.05 0.05 0.00 - 
Total number of samples included in analysis 16 
Number of samples with %CV ≤ 25% 12 









Sample ID <1 Hour 5 Hours Mean SD % CV 
13-Plex 03 0.30 0.35 0.33 0.04 10.88% 
13-Plex 06 0.22 0.22 0.22 0.00 0.00% 
13-Plex 08 2.23 2.13 2.18 0.07 3.24% 
13-Plex 10 0.32 0.28 0.30 0.03 9.43% 
13-Plex 11 7.09 6.93 7.01 0.11 1.61% 
13-Plex 12 0.30 0.22 0.26 0.06 21.76% 
13-Plex 18 0.41 0.53 0.47 0.08 18.05% 
13-Plex 19 2.19 2.34 2.27 0.11 4.68% 
13-Plex 20 0.50 0.71 0.61 0.15 24.54% 
13-Plex 21 0.35 0.34 0.35 0.01 2.05% 
13-Plex 28 0.73 0.84 0.79 0.08 9.91% 
13-Plex 31 0.48 0.46 0.47 0.01 3.01% 
13-Plex 39 6.81 9.69 8.25 2.04 24.68% 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 42 2.94 3.04 2.99 0.07 2.36% 
13-Plex 44 0.05 0.05 0.05 0.00 - 
13-Plex 52 0.10 0.05 0.08 0.04 - 
13-Plex 60 0.23 0.16 0.20 0.05 25.38% 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 93.33% 
Pn 6B 
Sample ID <1 Hour 5 Hours Mean SD % CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 05 0.38 0.38 0.38 0.00 0.00% 
13-Plex 08 3.75 3.68 3.72 0.05 1.33% 
13-Plex 10 3.38 2.86 3.12 0.37 11.79% 
13-Plex 11 3.65 3.41 3.53 0.17 4.81% 
13-Plex 17 0.05 0.05 0.05 0.00 - 
13-Plex 18 0.81 1.02 0.92 0.15 16.23% 
13-Plex 19 2.45 2.62 2.54 0.12 4.74% 
13-Plex 21 1.36 1.26 1.31 0.07 5.40% 
13-Plex 25 0.19 0.19 0.19 0.00 0.00% 
13-Plex 28 0.95 1.11 1.03 0.11 10.98% 
13-Plex 31 5.52 5.38 5.45 0.10 1.82% 
13-Plex 33 0.05 0.10 0.08 0.04 - 
13-Plex 34 0.12 0.05 0.09 0.05 58.23% 
13-Plex 39 1.49 1.96 1.73 0.33 19.27% 
13-Plex 41 0.54 0.69 0.62 0.11 17.25% 
13-Plex 50 1.39 1.44 1.42 0.04 2.50% 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.16 0.20 0.18 0.03 15.71% 
13-Plex 71 0.05 0.05 0.05 0.00 - 




Appendix VI-14: Short term temperature stability results for Panel A 
serotype (continued)   
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 93.33% 
Pn 9V 
Sample ID <1 Hour 5 Hours Mean SD % CV 
13-Plex 03 0.23 0.28 0.26 0.04 13.86% 
13-Plex 05 1.12 1.08 1.10 0.03 2.57% 
13-Plex 08 3.28 3.01 3.15 0.19 6.07% 
13-Plex 10 4.49 3.78 4.14 0.50 12.14% 
13-Plex 11 0.89 0.89 0.89 0.00 0.00% 
13-Plex 12 0.55 0.43 0.49 0.08 17.32% 
13-Plex 18 0.47 0.58 0.53 0.08 14.82% 
13-Plex 19 4.11 4.32 4.22 0.15 3.52% 
13-Plex 20 2.03 2.69 2.36 0.47 19.78% 
13-Plex 28 0.57 0.67 0.62 0.07 11.40% 
13-Plex 31 0.25 0.25 0.25 0.00 0.00% 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 34 1.23 0.97 1.10 0.18 16.71% 
13-Plex 39 0.90 1.12 1.01 0.16 15.40% 
13-Plex 42 1.97 2.01 1.99 0.03 1.42% 
13-Plex 52 0.17 0.14 0.16 0.02 13.69% 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 100.00% 
Pn 14 
Sample ID <1 Hour 5 Hours Mean SD % CV 
13-Plex 03 0.76 0.89 0.83 0.09 11.14% 
13-Plex 08 5.07 5.02 5.05 0.04 0.70% 
13-Plex 10 3.61 3.17 3.39 0.31 9.18% 
13-Plex 12 2.06 1.67 1.87 0.28 14.79% 
13-Plex 16 0.45 0.51 0.48 0.04 8.84% 
13-Plex 17 0.05 0.05 0.05 0.00 - 
13-Plex 18 0.78 0.98 0.88 0.14 16.07% 
13-Plex 19 1.77 1.86 1.82 0.06 3.51% 
13-Plex 21 3.84 3.58 3.71 0.18 4.96% 
13-Plex 28 5.19 5.86 5.53 0.47 8.57% 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 39 2.31 3.00 2.66 0.49 18.38% 
13-Plex 41 0.23 0.30 0.27 0.05 18.68% 
13-Plex 42 1.95 1.93 1.94 0.01 0.73% 
13-Plex 50 0.73 0.76 0.75 0.02 2.85% 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.15 0.19 0.17 0.03 16.64% 
cxxx 
 
Appendix VI-14: Short term temperature stability results for Panel A 
serotype (continued)   
13-Plex 62 1.06 1.30 1.18 0.17 14.38% 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 100.00% 
Pn 19A 
Sample ID <1 Hour 5 Hours Mean SD % CV 
13-Plex 03 0.73 0.84 0.79 0.08 9.91% 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 05 10.40 6.29 8.35 2.91 34.83% 
13-Plex 06 0.43 0.42 0.43 0.01 1.66% 
13-Plex 10 12.84 14.17 13.51 0.94 6.96% 
13-Plex 18 11.22 10.02 10.62 0.85 7.99% 
13-Plex 19 1.72 1.65 1.69 0.05 2.94% 
13-Plex 20 0.83 0.87 0.85 0.03 3.33% 
13-Plex 21 0.59 0.59 0.59 0.00 0.00% 
13-Plex 25 1.25 1.05 1.15 0.14 12.30% 
13-Plex 33 0.49 0.63 0.56 0.10 17.68% 
13-Plex 34 0.79 0.61 0.70 0.13 18.18% 
13-Plex 39 2.79 3.80 3.30 0.71 21.67% 
13-Plex 41 0.05 0.10 0.08 0.04 - 
13-Plex 47 0.05 0.05 0.05 0.00 - 
13-Plex 50 2.45 2.56 2.51 0.08 3.11% 
13-Plex 51 0.21 0.32 0.27 0.08 29.35% 
13-Plex 62 8.61 12.27 10.44 2.59 24.79% 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 13 
Percentage of positive sample with % CV ≤ 25 % 86.67% 
Pn 23F 
Sample ID <1 Hour 5 Hours Mean SD % CV 
13-Plex 03 3.99 4.73 4.36 0.52 12.00% 
13-Plex 08 0.43 0.40 0.42 0.02 5.11% 
13-Plex 11 4.70 4.23 4.47 0.33 7.44% 
13-Plex 12 2.56 1.87 2.22 0.49 22.03% 
13-Plex 16 0.13 0.14 0.14 0.01 5.24% 
13-Plex 18 1.66 2.12 1.89 0.33 17.21% 
13-Plex 19 5.78 5.83 5.81 0.04 0.61% 
13-Plex 20 1.42 1.86 1.64 0.31 18.97% 
13-Plex 28 0.38 0.45 0.42 0.05 11.93% 
13-Plex 31 0.31 0.30 0.31 0.01 2.32% 
13-Plex 33 0.05 0.10 0.08 0.04 - 
13-Plex 34 0.29 0.24 0.27 0.04 13.34% 
13-Plex 39 1.55 1.93 1.74 0.27 15.44% 
13-Plex 41 0.05 0.13 0.09 0.06 - 
cxxxi 
 











13-Plex 42 1.21 1.13 1.17 0.06 4.83% 
13-Plex 44 2.18 2.97 2.58 0.56 21.69% 
13-Plex 52 0.24 0.20 0.22 0.03 12.86% 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 100.00% 
cxxxii 
 




Sample ID <1 Hour 5 Hours Mean SD %CV 
13-Plex 03 0.19 0.22 0.21 0.02 10.35% 
13-Plex 05 1.70 1.53 1.62 0.12 7.44% 
13-Plex 08 28.43 29.50 28.97 0.76 2.61% 
13-Plex 10 0.05 0.05 0.05 0.00 - 
13-Plex 11 5.30 5.02 5.16 0.20 3.84% 
13-Plex 12 6.27 4.94 5.61 0.94 16.78% 
13-Plex 16 4.99 5.55 5.27 0.40 7.51% 
13-Plex 18 0.31 0.40 0.36 0.06 17.93% 
13-Plex 19 3.55 3.25 3.40 0.21 6.24% 
13-Plex 20 0.05 0.12 0.09 0.05 58.23% 
13-Plex 21 0.13 0.12 0.13 0.01 5.66% 
13-Plex 31 1.86 1.73 1.80 0.09 5.12% 
13-Plex 34 0.05 0.05 0.05 0.00 - 
13-Plex 42 4.45 3.62 4.04 0.59 14.55% 
13-Plex 44 0.05 0.05 0.05 0.00 - 
13-Plex 50 1.25 0.97 1.11 0.20 17.84% 
13-Plex 51 0.10 0.10 0.10 0.00 0.00% 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 14 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 100.00% 
Pn 3 
Sample ID <1 Hour 5 Hours Mean SD %CV 
13-Plex 03 0.25 0.29 0.27 0.03 10.48% 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 05 7.89 6.79 7.34 0.78 10.60% 
13-Plex 10 0.73 0.62 0.68 0.08 11.52% 
13-Plex 12 3.56 2.33 2.95 0.87 29.53% 
13-Plex 16 0.55 0.60 0.58 0.04 6.15% 
13-Plex 18 3.36 4.35 3.86 0.70 18.16% 
13-Plex 19 2.66 2.69 2.68 0.02 0.79% 
13-Plex 20 1.46 2.22 1.84 0.54 29.21% 
13-Plex 21 6.17 6.14 6.16 0.02 0.34% 
13-Plex 28 0.13 0.14 0.14 0.01 5.24% 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 39 10.12 12.99 11.56 2.03 17.56% 
13-Plex 41 0.05 0.12 0.09 0.05 - 
13-Plex 44 0.65 0.50 0.58 0.11 18.45% 
13-Plex 50 9.40 9.60 9.43 0.04 0.45% 
13-Plex 51 0.88 0.87 0.88 0.01 0.81% 
13-Plex 59 0.19 0.20 0.20 0.01 3.63% 
13-Plex 62 0.05 0.05 0.05 0.00 - 









Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 13 
Percentage of positive sample with % CV ≤ 25 % 86.67 % 
Pn 5 
Sample ID <1 Hour 5 Hours Mean SD %CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 10 0.24 0.21 0.23 0.02 9.43% 
13-Plex 11 3.46 3.55 3.51 0.06 1.82% 
13-Plex 12 2.71 1.89 2.30 0.58 25.21% 
13-Plex 18 1.69 2.08 1.89 0.28 14.63% 
13-Plex 19 4.45 4.21 4.33 0.17 3.92% 
13-Plex 20 0.93 1.12 1.03 0.13 13.11% 
13-Plex 28 0.20 0.29 0.25 0.06 25.98% 
13-Plex 31 0.34 0.26 0.30 0.06 18.86% 
13-Plex 33 0.17 0.20 0.19 0.02 11.47% 
13-Plex 39 1.83 1.90 1.87 0.05 2.65% 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.34 1.23 1.29 0.08 6.05% 
13-Plex 44 1.23 1.10 1.17 0.09 7.89% 
13-Plex 50 11.61 8.49 10.05 2.21 21.95% 
13-Plex 51 0.45 0.45 0.45 0.00 0.00% 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.05 0.10 0.08 0.04 - 
13-Plex 62 1.15 1.07 1.11 0.06 5.10% 
13-Plex 71 0.05 0.10 0.08 0.04 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 13 
Percentage of positive sample with % CV ≤ 25 % 86.67% 
Pn 6A 
Sample ID <1 Hour 5 Hours Mean SD %CV 
13-Plex 03 0.20 0.22 0.21 0.01 6.73% 
13-Plex 05 1.87 1.62 1.75 0.18 10.13% 
13-Plex 08 7.49 7.52 7.51 0.02 0.28% 
13-Plex 10 4.47 3.94 4.21 0.37 8.91% 
13-Plex 11 4.19 4.37 4.28 0.13 2.97% 
13-Plex 12 0.10 0.05 0.08 0.04 47.14% 
13-Plex 18 1.30 1.60 1.45 0.21 14.63% 
13-Plex 19 12.15 11.32 11.74 0.59 5.00% 
13-Plex 21 1.75 1.79 1.77 0.03 1.60% 
13-Plex 31 1.04 0.99 1.02 0.04 3.48% 
13-Plex 34 0.16 0.13 0.15 0.02 14.63% 
13-Plex 39 1.70 1.75 1.73 0.04 2.05% 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.87 1.49 1.68 0.27 15.99% 
13-Plex 50 5.91 4.70 5.31 0.86 16.13% 

























Appendix VI-15: Short term temperature stability results for Panel B 
serotype (continued) 









13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 93.33% 
Pn 7F 
Sample ID <1 Hour 5 Hours Mean SD %CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 08 7.04 6.84 6.94 0.14 2.04% 
13-Plex 10 1.96 1.71 1.84 0.18 9.63% 
13-Plex 12 0.74 0.62 0.68 0.08 12.48% 
13-Plex 17 0.92 0.90 0.91 0.01 1.55% 
13-Plex 18 0.96 1.22 1.09 0.18 16.87% 
13-Plex 21 1.44 1.33 1.39 0.08 5.62% 
13-Plex 28 7.73 11.50 9.62 2.67 27.73% 
13-Plex 31 1.03 0.97 1.00 0.04 4.24% 
13-Plex 39 2.13 2.13 2.13 0.00 0.00% 
13-Plex 41 0.75 0.75 0.75 0.00 0.00% 
13-Plex 42 5.02 3.86 4.44 0.82 18.47% 
13-Plex 44 0.35 0.29 0.32 0.04 13.26% 
13-Plex 50 2.49 2.10 2.30 0.28 12.02% 
13-Plex 51 0.36 0.34 0.35 0.01 4.04% 
13-Plex 52 0.10 0.15 0.13 0.04 28.28% 
13-Plex 59 0.12 0.14 0.13 0.01 10.88% 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 16 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 87.50% 
Pn 18C 
Sample ID <1 Hour 5 Hours Mean SD %CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 06 1.36 1.22 1.29 0.10 7.67% 
13-Plex 08 3.05 3.06 3.06 0.01 0.23% 
13-Plex 10 0.61 0.56 0.59 0.04 6.04% 
13-Plex 11 5.08 5.12 5.10 0.03 0.55% 
13-Plex 16 1.95 2.47 2.21 0.37 16.64% 
13-Plex 17 0.63 0.59 0.61 0.03 4.64% 
13-Plex 19 3.29 3.18 3.24 0.08 2.40% 
13-Plex 21 2.32 2.37 2.35 0.04 1.51% 
13-Plex 25 0.28 0.27 0.28 0.01 2.57% 
13-Plex 31 0.60 0.57 0.59 0.02 3.63% 
























Appendix VI-15: Short term temperature stability results for Panel B 
serotype (continued) 
13-Plex 34 4.47 3.85 4.16 0.44 10.54% 
13-Plex 39 1.14 1.14 1.14 0.00 0.00% 
13-Plex 44 1.24 1.08 1.16 0.11 9.75% 
13-Plex 50 2.22 1.73 1.98 0.35 17.54% 
13-Plex 51 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.42 0.40 0.41 0.01 3.45% 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 
cxxxvii 
 
Percentage of positive sample with % CV ≤ 25 % 100.00% 
Pn 19F 
Sample ID <1 Hour 5 Hours Mean SD %CV 
13-Plex 05 4.07 3.50 3.79 0.40 10.65% 
13-Plex 10 10.83 9.53 10.18 0.92 9.03% 
13-Plex 11 2.54 2.53 2.54 0.01 0.28% 
13-Plex 12 1.00 0.73 0.87 0.19 22.07% 
13-Plex 16 1.35 1.59 1.47 0.17 11.54% 
13-Plex 18 5.88 7.38 6.63 1.06 16.00% 
13-Plex 19 7.52 7.11 7.32 0.29 3.96% 
13-Plex 20 2.00 2.53 2.27 0.37 16.55% 
13-Plex 21 0.72 0.74 0.73 0.01 1.94% 
13-Plex 25 0.21 0.21 0.21 0.00 - 
13-Plex 34 0.55 0.47 0.51 0.06 11.09% 
13-Plex 39 2.75 2.69 2.72 0.04 1.56% 
13-Plex 42 3.91 3.33 3.62 0.41 11.33% 
13-Plex 50 7.36 6.02 6.69 0.95 14.16% 
13-Plex 51 0.24 0.23 0.24 0.01 3.01% 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.09 0.11 0.10 0.01 14.14% 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 





Appendix VI-16: Post preparative temperature stability results for 
Panel A serotypes 
 
Pn 4 
Sample ID <1 Hour 6 Hours Mean SD % CV 
13-Plex 03 0.32 0.30 0.31 0.01 4.56 % 
13-Plex 06 0.05 0.05 0.05 0.00 - 
13-Plex 08 1.44 1.29 1.37 0.11 7.77 % 
13-Plex 10 0.26 0.28 0.27 0.01 5.24 % 
13-Plex 11 6.43 7.07 6.75 0.45 6.70 % 
13-Plex 12 0.23 0.18 0.21 0.04 17.25 % 
13-Plex 18 0.42 0.39 0.41 0.02 5.24 %  
13-Plex 19 0.96 1.30 1.13 0.24 21.28 % 
13-Plex 20 0.22 0.28 0.25 0.04 16.97 % 
13-Plex 21 0.23 0.22 0.23 0.01 3.14 %  
13-Plex 28 0.23 0.23 0.23 0.00 0.00 % 
13-Plex 31 1.40 1.12 1.26 0.20 15.71 % 
13-Plex 39 5.89 4.10 5.00 1.27 25.34 % 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 42 2.09 1.70 1.90 0.28 14.55 % 
13-Plex 44 0.05 0.05 0.05 0.00 - 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.17 0.19 0.18 0.01 7.86 % 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 14 
Number of positive samples with % CV ≤ 25 % 13 
Percentage of positive sample with % CV ≤ 25 % 92.86% 
Pn 6B 
Sample ID <1 Hour 6 Hours Mean SD % CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 05 0.31 0.29 0.30 0.01 4.71 % 
13-Plex 08 4.18 3.88 4.03 0.21 5.26 % 
13-Plex 10 2.80 3.31 3.06 0.36 11.80 % 
13-Plex 11 2.93 2.54 2.74 0.28 10.08 % 
13-Plex 17 0.05 0.05 0.05 0.00 - 
13-Plex 18 1.28 1.15 1.22 0.09 7.57 %  
13-Plex 19 1.86 2.44 2.15 0.41 19.08 % 
13-Plex 21 1.30 1.21 1.26 0.06 5.07 % 
13-Plex 25 0.18 0.18 0.18 0.00 0.00 % 
13-Plex 28 0.81 0.91 0.86 0.07 8.22 % 
13-Plex 31 8.54 8.06 8.30 0.34 4.09 % 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 34 0.13 0.11 0.12 0.01 11.79 % 
13-Plex 39 1.66 1.52 1.59 0.10 6.23 % 
13-Plex 41 0.54 0.54 0.54 0.00 0.00 % 




Appendix VI-16: Post preparative temperature stability results for 
Panel A serotypes (continued) 
  
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.18 0.20 0.19 0.01 7.44 % 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 100.00 % 
Pn 9V 
Sample ID <1 Hour 6 Hours Mean SD % CV 
13-Plex 03 0.25 0.27 0.26 0.01 5.44 % 
13-Plex 05 0.95 0.91 0.93 0.03 3.04 % 
13-Plex 08 2.44 2.60 2.52 0.11 4.49 % 
13-Plex 10 3.64 3.65 3.65 0.01 0.19 % 
13-Plex 11 0.75 0.78 0.77 0.02 2.77 % 
13-Plex 12 0.51 0.49 0.50 0.01 2.83 % 
13-Plex 18 0.47 0.46 0.47 0.01 1.52 % 
13-Plex 19 3.03 3.33 3.18 0.21 6.67 % 
13-Plex 20 2.54 2.30 2.42 0.17 7.01 % 
13-Plex 28 0.46 0.49 0.48 0.02 4.47 % 
13-Plex 31 0.22 0.23 0.23 0.01 3.14 % 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 34 1.17 1.02 1.10 0.11 9.69 % 
13-Plex 39 1.01 0.93 0.97 0.06 5.83 % 
13-Plex 42 1.58 1.55 1.57 0.02 1.36 % 
13-Plex 52 0.11 0.11 0.11 0.00 0.00 % 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 100.00 % 
Pn 14 
Sample ID <1 Hour 6 Hours Mean SD % CV 
13-Plex 03 0.70 0.73 0.72 0.02 2.97 % 
13-Plex 08 4.66 4.28 4.47 0.27 6.01 % 
13-Plex 10 4.04 4.51 4.28 0.33 7.77 % 
13-Plex 12 2.91 2.33 2.62 0.41 15.65 % 
13-Plex 16 0.66 0.79 0.73 0.09 12.68 % 
13-Plex 17 0.05 0.05 0.05 0.00 - 
13-Plex 18 0.90 0.27 0.59 0.45 76.15 % 
13-Plex 19 1.28 1.23 1.26 0.04 2.82 % 
13-Plex 21 5.48 4.29 4.89 0.84 17.23 % 
13-Plex 28 5.80 6.11 5.96 0.22 3.68 % 
13-Plex 33 0.05 0.05 0.05 0.00 - 
cxl 
 
Appendix VI-16: Post preparative temperature stability results for 
Panel A serotypes (continued) 
 
13-Plex 39 2.85 2.98 2.92 0.09 3.15 % 
13-Plex 41 0.23 0.22 0.23 0.01 3.14 % 
13-Plex 42 1.47 1.54 1.51 0.05 3.29 % 
13-Plex 50 0.82 0.92 0.87 0.07 8.13 % 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.16 0.18 0.17 0.01 8.32 % 
13-Plex 62 0.90 1.02 0.96 0.08 8.84 % 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 93.33 % 
Pn 19A 
Sample ID <1 Hour 6 Hours Mean SD % CV 
13-Plex 03 0.95 1.03 0.99 0.06 5.71 % 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 05 8.79 7.93 8.36 0.61 7.27 % 
13-Plex 06 0.65 0.69 0.67 0.03 4.22 % 
13-Plex 10 13.52 14.04 13.78 0.37 2.67 % 
13-Plex 18 9.40 5.94 7.67 2.45 31.90 % 
13-Plex 19 1.60 1.80 1.70 0.14 8.32 % 
13-Plex 20 1.08 1.09 1.09 0.01 0.65 % 
13-Plex 21 0.69 0.71 0.70 0.01 2.02 % 
13-Plex 25 1.44 1.43 1.44 0.01 0.49 % 
13-Plex 33 0.52 0.55 0.54 0.02 3.97 % 
13-Plex 34 0.72 0.68 0.70 0.03 4.04 % 
13-Plex 39 3.35 3.03 3.19 0.23 7.09 % 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 47 0.05 0.05 0.05 0.00 - 
13-Plex 50 2.42 2.46 2.44 0.03 1.16 % 
13-Plex 51 0.25 0.18 0.22 0.05 23.02 % 
13-Plex 62 6.99 7.48 7.24 0.35 4.79 % 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 93.33 % 
Pn 23F 
Sample ID <1 Hour 6 Hours Mean SD % CV 
13-Plex 03 7.94 8.56 8.25 0.44 5.31 % 
13-Plex 08 0.72 0.66 0.69 0.04 6.15 % 
13-Plex 11 2.70 3.43 3.07 0.52 16.84 % 
13-Plex 12 1.74 1.99 1.87 0.18 9.48 % 




Appendix VI-16: Post preparative temperature stability results for 




13-Plex 18 2.39 2.23 2.31 0.11 4.90 % 
13-Plex 19 8.47 10.23 9.35 1.24 13.31 % 
13-Plex 20 1.42 1.45 1.44 0.02 1.48 % 
13-Plex 28 0.46 0.31 0.39 0.11 27.55 % 
13-Plex 31 1.68 1.76 1.72 0.06 3.29 % 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 34 0.36 0.36 0.36 0.00 0.00 % 
13-Plex 39 3.00 2.82 2.91 0.13 4.37 % 
13-Plex 41 0.19 0.15 0.17 0.03 16.64 % 
13-Plex 42 1.48 1.19 1.34 0.21 15.36 % 
13-Plex 44 2.52 2.37 2.45 0.11 4.34 %  
13-Plex 52 0.28 0.25 0.27 0.02 8.00 % 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 16 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 93.75 % 
cxlii 
 
Appendix VI-17: Post preparative temperature stability results for 
Panel B serotypes 
 
Pn 1 
Sample ID <1 Hour 6 Hours Mean SD %CV 
13-Plex 03 0.13 0.11 0.12 0.01 11.79% 
13-Plex 05 1.22 1.29 1.26 0.05 3.94% 
13-Plex 08 29.57 28.90 29.24 0.47 1.62% 
13-Plex 10 0.05 0.05 0.05 0.00 - 
13-Plex 11 4.83 5.11 4.97 0.20 3.98% 
13-Plex 12 8.26 5.99 7.13 1.61 22.53% 
13-Plex 16 3.52 4.02 3.77 0.35 9.38% 
13-Plex 18 0.28 0.26 0.27 0.01 5.24% 
13-Plex 19 2.02 2.70 2.36 0.48 20.37% 
13-Plex 20 0.05 0.11 0.08 0.04 - 
13-Plex 21 0.12 0.11 0.12 0.01 6.15% 
13-Plex 31 0.91 0.61 0.76 0.21 27.91% 
13-Plex 34 0.06 0.05 0.06 0.01 - 
13-Plex 42 2.66 2.07 2.37 0.42 17.64% 
13-Plex 44 0.05 0.05 0.05 0.00 - 
13-Plex 50 0.76 0.73 0.75 0.02 2.85% 
13-Plex 51 0.05 0.05 0.05 0.00 - 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 12 
Number of positive samples with % CV ≤ 25 % 11 
Percentage of positive sample with % CV ≤ 25 % 91.67% 
Pn 3 
Sample ID <1 Hour 6 Hours Mean SD %CV 
13-Plex 03 0.21 0.20 0.21 0.01 3.45% 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 05 3.72 6.43 5.08 1.92 37.76% 
13-Plex 10 0.90 0.96 0.93 0.04 4.56% 
13-Plex 12 5.23 6.93 6.08 1.20 19.77% 
13-Plex 16 0.71 0.69 0.70 0.01 2.02% 
13-Plex 18 4.51 2.99 3.75 1.07 28.66% 
13-Plex 19 2.88 3.24 3.06 0.25 8.32% 
13-Plex 20 2.09 2.74 2.42 0.46 19.03% 
13-Plex 21 5.15 5.15 5.15 0.00 0.00% 
13-Plex 28 0.18 0.12 0.15 0.04 28.28% 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 39 11.75 2.48 7.12 6.55 92.13% 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 44 0.62 0.62 0.62 0.00 0.00% 
13-Plex 50 10.39 10.27 10.33 0.08 0.82% 
13-Plex 51 0.80 0.80 0.80 0.00 0.00% 




Appendix VI-17: Post preparative temperature stability results for 
Panel B serotypes (continued) 
 
  
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 11 
Percentage of positive sample with % CV ≤ 25 % 73.33 % 
Pn 5 
Sample ID <1 Hour 6 Hours Mean SD %CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 10 0.24 0.26 0.25 0.01 5.66% 
13-Plex 11 3.14 3.94 3.54 0.57 15.98% 
13-Plex 12 2.80 3.55 3.18 0.53 16.70% 
13-Plex 18 2.43 1.78 2.11 0.46 21.83% 
13-Plex 19 3.56 4.26 3.91 0.49 12.66% 
13-Plex 20 1.50 1.34 1.42 0.11 7.97% 
13-Plex 28 0.39 0.26 0.33 0.09 28.28% 
13-Plex 31 0.34 0.33 0.34 0.01 2.11% 
13-Plex 33 0.21 0.25 0.23 0.03 12.30% 
13-Plex 39 2.08 2.00 2.04 0.06 2.77% 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.35 1.37 1.36 0.01 1.04% 
13-Plex 44 1.11 1.31 1.21 0.14 11.69% 
13-Plex 50 8.86 8.60 8.73 0.18 2.11% 
13-Plex 51 0.31 0.26 0.29 0.04 12.41% 
13-Plex 52 0.05 0.05 0.05 0.00 - 
13-Plex 59 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.89 1.06 0.98 0.12 12.33% 
13-Plex 71 0.05 0.10 0.08 0.04 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 93.33% 
Pn 6A 
Sample ID <1 Hour 6 Hours Mean SD %CV 
13-Plex 03 0.22 0.26 0.24 0.03 11.79% 
13-Plex 05 1.23 1.74 1.49 0.36 24.28% 
13-Plex 08 7.62 5.30 6.46 1.64 25.39% 
13-Plex 10 4.03 4.83 4.43 0.57 12.77% 
13-Plex 11 3.27 3.74 3.51 0.33 9.48% 
13-Plex 12 0.11 0.13 0.12 0.01 11.79% 
13-Plex 18 1.77 1.34 1.56 0.30 19.55% 
13-Plex 19 9.74 12.15 10.95 1.70 15.57% 
13-Plex 21 1.96 2.03 2.00 0.05 2.48% 
13-Plex 31 1.60 1.57 1.59 0.02 1.34% 
13-Plex 34 0.14 0.11 0.13 0.02 16.97% 
13-Plex 39 1.17 1.28 1.23 0.08 6.35% 
13-Plex 41 0.05 0.05 0.05 0.00 - 
13-Plex 42 1.45 1.30 1.38 0.11 7.71% 
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Appendix VI-17: Post preparative temperature stability results for 
Panel B serotypes (continued) 
 
  
13-Plex 50 3.89 3.72 3.81 0.12 3.16% 
13-Plex 51 0.59 0.59 0.59 0.00 0.00% 
13-Plex 59 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 14 
Percentage of positive sample with % CV ≤ 25 % 93.33% 
Pn 7F 
Sample ID <1 Hour 6 Hours Mean SD %CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 08 5.81 4.16 4.99 1.17 23.40% 
13-Plex 10 1.86 1.96 1.91 0.07 3.70% 
13-Plex 12 0.79 0.86 0.83 0.05 6.00% 
13-Plex 17 0.75 0.90 0.83 0.11 12.86% 
13-Plex 18 1.11 0.81 0.96 0.21 22.10% 
13-Plex 21 1.22 1.20 1.21 0.01 1.17% 
13-Plex 28 8.18 5.59 6.89 1.83 26.60% 
13-Plex 31 1.53 1.39 1.46 0.10 6.78% 
13-Plex 39 1.99 1.83 1.91 0.11 5.92% 
13-Plex 41 0.80 0.90 0.85 0.07 8.32% 
13-Plex 42 3.25 3.36 3.31 0.08 2.35% 
13-Plex 44 0.26 0.27 0.27 0.01 2.67% 
13-Plex 50 1.48 1.64 1.56 0.11 7.25% 
13-Plex 51 0.35 0.25 0.30 0.07 23.57% 
13-Plex 52 0.13 0.11 0.12 0.01 11.79% 
13-Plex 59 0.13 0.12 0.13 0.01 5.66% 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
13-Plex 77 0.05 0.05 0.05 0.00 - 
Total number of positive samples 16 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 93.75% 
Pn 18C 
Sample ID <1 Hour 6 Hours Mean SD %CV 
13-Plex 04 0.05 0.05 0.05 0.00 - 
13-Plex 06 0.85 1.06 0.96 0.15 15.55% 
13-Plex 08 2.96 2.14 2.55 0.58 22.74% 
13-Plex 10 0.59 0.63 0.61 0.03 4.64% 
13-Plex 11 5.09 5.59 5.34 0.35 6.62% 
13-Plex 16 1.76 1.85 1.81 0.06 3.53% 
13-Plex 17 0.54 0.67 0.61 0.09 15.19% 
13-Plex 19 2.81 3.27 3.04 0.33 10.70% 
13-Plex 21 1.43 1.58 1.51 0.11 7.05% 
13-Plex 25 0.23 0.21 0.22 0.01 6.43% 
cxlv 
 
Appendix VI-17: Post preparative temperature stability results for 
Panel B serotypes (continued) 
 
 
13-Plex 31 0.83 0.86 0.85 0.02 2.51% 
13-Plex 33 0.05 0.05 0.05 0.00 - 
13-Plex 34 3.91 3.95 3.93 0.03 0.72% 
13-Plex 39 1.82 1.42 1.62 0.28 17.46% 
13-Plex 44 0.72 0.85 0.79 0.09 11.71% 
13-Plex 50 1.27 1.28 1.28 0.01 0.55% 
13-Plex 51 0.05 0.05 0.05 0.00 - 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.28 0.32 0.30 0.03 9.43% 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 15 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 100.00% 
Pn 19F 
Sample ID <1 Hour 6 Hours Mean SD %CV 
13-Plex 05 2.38 3.51 2.95 0.80 27.13% 
13-Plex 10 10.33 12.07 11.20 1.23 10.99% 
13-Plex 11 2.25 2.67 2.46 0.30 12.07% 
13-Plex 12 1.03 1.33 1.18 0.21 17.98% 
13-Plex 16 1.62 1.63 1.63 0.01 0.44% 
13-Plex 18 6.78 5.04 5.91 1.23 20.82% 
13-Plex 19 5.94 7.31 6.63 0.97 14.62% 
13-Plex 20 2.49 2.16 2.33 0.23 10.04% 
13-Plex 21 0.78 0.83 0.81 0.04 4.39% 
13-Plex 25 0.24 0.21 0.23 0.02 9.43% 
13-Plex 34 0.57 0.58 0.58 0.01 1.23% 
13-Plex 39 2.48 2.48 2.48 0.00 0.00% 
13-Plex 42 2.90 2.94 2.92 0.03 0.97% 
13-Plex 50 4.75 5.07 4.91 0.23 4.61% 
13-Plex 51 0.25 0.21 0.23 0.03 12.30% 
13-Plex 52 0.10 0.05 0.08 0.04 - 
13-Plex 59 0.11 0.12 0.12 0.01 6.15% 
13-Plex 60 0.05 0.05 0.05 0.00 - 
13-Plex 62 0.05 0.05 0.05 0.00 - 
13-Plex 71 0.05 0.05 0.05 0.00 - 
Total number of positive samples 16 
Number of positive samples with % CV ≤ 25 % 15 
Percentage of positive sample with % CV ≤ 25 % 93.75% 
 
 
